Compositions and systems for RNA programmable cell editing and methods of making and using same

CellREADR addresses the limitations of existing genetic approaches by using RNA-based targeting with ADAR enzymes to achieve precise and scalable manipulation of cell types, overcoming inefficiencies and ethical issues in current methods.

JP2024541983AInactive Publication Date: 2024-11-13DUKE UNIV +1
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
JP2024525343
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-19
Filing Date
2022-10-31
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current genetic approaches for manipulating cell types are inherently unwieldy, slow, difficult to scale, and raise ethical concerns, particularly in primates and humans, while somatic cell manipulation using CRISPR/Cas9 technology has low efficiency and frequent unintended off-target effects, and viral vector-based transcriptional enhancers are difficult to identify and validate, making them unsuitable for scalable and user-friendly cell type targeting.

Method used

A novel RNA-based technology, CellREADR, which utilizes endogenous ADAR enzymes to directly engage RNA and target specific cell types through Watson-Crick base pairing, enabling precise and scalable manipulation by introducing modular RNA molecules that form RNA duplexes with cellular RNA, allowing ADAR-mediated editing of stop codons for protein translation.

Benefits of technology

CellREADR provides a specific, easy-to-construct, and generalizable method for targeting and manipulating cell types across species, with high efficiency and minimal off-target effects, enabling precise control over cellular functions and therapeutic interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541983000001_ABST
    Figure 2024541983000001_ABST
Patent Text Reader

Abstract

The readrRNA (RNA sensing by endogenous ADAR) molecule is a modular RNA molecule that facilitates sensing and detection of cell type or cell state of cells, including cells of mammalian nervous system, such as neural or non-neuronal cells of mammalian central nervous system and / or peripheral nervous system, and / or facilitates delivery of effector protein to selected cells.The composition that comprises such modular RNA molecule and another nucleic acid (linked or not linked to modular RNA molecule) is CellREADR (cell access through RNA sensing by endogenous ADAR).CellREADR utilizes the RNA editing mediated by ADAR (adenosine deaminase acting on RNA) to sense the presence of selected cellular RNA in cells of mammalian nervous system through readrRNA, and combine the detection of RNA that defines the cell with the translation of one or more effector proteins in cells of mammalian nervous system.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This PCT application claims the benefit of U.S. Provisional Application No. 63 / 343,669, filed May 19, 2022, and U.S. Provisional Application No. 63 / 273,343, filed October 29, 2021, the contents of each of which are incorporated herein in their entirety.

[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This invention was made with Government support under Federal Grant Numbers U19MH114821-03 and DP1MH129954 awarded by the National Institutes of Health. The Federal Government has certain rights to this invention.

[0003] Sequence Listing This application contains a sequence listing that has been submitted via the Patent Center as a WIPO standard ST.26 XML file. The XML file, created on October 31, 2022, is named "123658-10903.xml" and is 193,913 bytes in size. The sequence listing is incorporated herein by reference. [Background technology]

[0004] background The diversity of cell types underlies the diversity of forms of life and physiological systems within individual organisms [1]. Cell types, defined by their distinct gene expression profiles, morphological and physiological properties, and tissue functions, are the medium through which genetic information shapes the phenotype and behavior of organisms. All bodily functions emerge from the interactions between cell types, and abnormal cell type physiology and function give rise to a myriad of diseases [2]. Recent high-throughput single-cell genomic approaches hold the promise of identifying all of the major molecularly defined cell types in the human body and many other organisms [3][4]. Beyond molecular profiling, it is necessary to monitor and manipulate each and every cell type across levels of biological organization to identify their specific roles in tissue structure and system function.

[0005] In the context of accessing and manipulating cell types in multicellular organisms, most, if not all, genetic approaches to date have attempted to recapitulate cell type-specific mRNA expression by manipulating DNA regulatory elements in the genome through germline or somatic cells, or by using transcriptional enhancer-based viral vectors. To date, nearly all genetic approaches to cell types have relied on DNA-based transcriptional regulatory elements to express tool genes (e.g., markers, sensors, effectors) that mimic certain cell-specific RNA expression, primarily through germline manipulation in only a handful of organisms [5–7]. All germline approaches, including CRISPR [8–10], are inherently cumbersome, slow, difficult to scale and generalize, and raise ethical concerns, especially in primates and humans [11, 12]. Recently, viral vector-based transcriptional enhancers have shown promise for targeting cell types in animals [13-19], but such enhancers are difficult to identify and validate, and often require extensive efforts due to their complex relationships with target genes and cell types

[13] . Somatic cell engineering, usually by CRISPR / Cas9 technology, is currently low-efficiency and prone to contain unintended off-targets. Enhancer viral vector approaches also have major limitations rooted in their complex relationships with gene expression and cell types, which require extensive efforts, specialized expertise, extensive validation, and are unlikely to be truly scalable, user-friendly, and generalizable across species. Therefore, although viral vectors based on transcriptional enhancers have shown promise for targeting somatic cell types in animals, such enhancers are difficult to identify and validate, and often require extensive efforts due to their complex relationships with target genes and cell types. In essence, all DNA and transcription-based approaches are indirect in their attempt to mimic and exploit cell-type specific RNA expression patterns. Summary of the Invention [Means for solving the problem]

[0006] Summary of the Invention The present disclosure is based in part on the discovery of a new class of cell-type technology that avoids DNA-based transcription processes and directly involves RNA that defines cell type. In some embodiments, this novel technology (referred to as CellREADR: Cell Access through RNA Sensing by Endogenous ADAR [Adenosine Deaminase Acting on RNA]) utilizes the RNA sensing and editing mechanism ubiquitous in all animal cells to detect the presence of cellular RNA and switch on the translation of effector proteins to monitor and manipulate cell type. The compositions and methods provided herein can be deployed as the operation of a single RNA molecule through Watson-Crick base pairing that targets a specific cell type thanks to the presence of target RNA. Thus, CellREADR is inherently specific, easy to construct and use, scalable, programmable, and general across species.

[0007] Thus, the present disclosure provides a modular RNA molecule comprising: (i) a 5' region comprising a sensor domain comprising a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA of a cell of a mammalian central nervous system, where the sensor domain comprises a stop codon editable by ADAR; and (ii) a 3' region comprising a protein coding domain, where the protein coding domain is downstream of and in frame with the sensor domain, where upon introduction of the modular RNA into a cell of a mammalian central nervous system that contains an Adar enzyme, the stretch of contiguous nucleotides of the sensor domain and the corresponding nucleotide stretch of the cellular RNA form an RNA duplex comprising a stop codon, and the stop codon comprised in the RNA duplex is edited by ADAR in the cell, thereby allowing translation of the protein.

[0008] Also disclosed herein is a modular RNA molecule comprising: (i) a 5' region comprising a sensor domain comprising a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides of a cellular RNA of a mammalian peripheral nervous system cell, the sensor domain comprising a stop codon that is editable by ADAR; and (ii) a 3' region comprising a protein-coding domain, the protein-coding domain being downstream of and in frame with the sensor domain, such that upon introduction of the modular RNA into a mammalian peripheral nervous system cell comprising an Adar enzyme, the stretch of consecutive nucleotides of the sensor domain and the corresponding stretch of nucleotides of the cellular RNA form an RNA duplex comprising a stop codon, and the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing translation of the protein. In the modular RNA molecule, the stretch of consecutive nucleotides of the sensor domain is capable of forming an RNA duplex with at least a portion of an mRNA. In the modular RNA molecule, the protein-coding region encodes an effector protein. In one embodiment of the modular RNA molecule, it further encodes a self-cleaving 2A peptide located between the sensor domain and the effector RNA region. In one embodiment of the modular RNA molecule, the self-cleaving 2A peptide is selected from the group consisting of one or more of T2A peptide, P2A peptide, E2A peptide, and F2A peptide. In one embodiment of the modular RNA molecule, the efRNA-encoded protein comprises a protein selected from the group of a marker and a transcription activator or repressor.

[0009] Also disclosed herein are compositions comprising: (i) a first nucleic acid comprising a modular RNA molecule comprising: (a) a sensor domain comprising a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA of a mammalian cell of the central nervous system, where the sensor domain comprises a stop codon editable by ADAR; and (b) a first protein coding domain encoding an effector protein, where the first protein coding region is downstream of and in frame with the sensor domain; and (ii) a second nucleic acid comprising a second protein coding domain. Also disclosed herein is a composition comprising: (i) a first nucleic acid comprising a modular RNA molecule comprising (a) a sensor domain comprising a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides of a cellular RNA of a mammalian cell of the peripheral nervous system, the sensor domain comprising a stop codon that is editable by ADAR; and (b) a first protein-coding domain that encodes an effector protein, the first protein-coding region being downstream of and in frame with the sensor domain; and (ii) a second nucleic acid comprising a second protein-coding domain. In one embodiment of the composition, the first and second nucleic acids comprise a single nucleic acid molecule. In one embodiment of the composition, the first and second nucleic acids comprise two nucleic acid molecules. In one embodiment of the composition, the first and second nucleic acids are covalently linked. In one embodiment of the composition, the second protein-coding domain is comprised within a gene that comprises a transcriptional control element, optionally a promoter. In one embodiment of the composition, the effector protein binds to the gene. In one embodiment of the composition, the expression of the second protein coding domain is modulated by an effector protein. In one embodiment of the composition, the first protein coding domain encodes a transcription activator or a transcription repressor. In one embodiment of the composition, the first protein coding domain encodes a DNA recombinase. In one embodiment of the composition, the brain cell comprises a mammalian cortical cell. In one embodiment of the composition, the brain cell comprises a mammalian Schwann cell or a mammalian satellite cell of the peripheral nervous system.In one embodiment of the composition, the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, the section of contiguous nucleotides of the sensor domain is complementary to a section of contiguous nucleotides of a selected cellular RNA of a brain cortical cell encoded by the Fezf2 gene, and the second nucleic acid comprises a second protein coding region under the transcriptional control of a TRE-3G eukaryotic inducible promoter. In one embodiment of the composition, the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, the section of contiguous nucleotides of the sensor domain is complementary to a section of contiguous nucleotides of a selected cellular RNA of a peripheral CNS cell, and the second nucleic acid comprises a second protein coding region under the transcriptional control of a TRE-3G eukaryotic inducible promoter. In one aspect of the composition, the first protein coding region encodes a cell death protein selected from the group consisting of thymidine kinase (TK) and cytosine deaminase (CD), programmed cell death proteins selected from the group consisting of CASP3, CASP9, BCL, GSDME, GSDMD, GZMA and GZMB, neural activation proteins selected from the group consisting of ChR2 and DREADD-M3Dq, immune enhancer proteins selected from the group consisting of IFNB, IFNG, TNFA, IL2, IL12, IL15 and CD40L, physiological editing proteins selected from the group consisting of NaChBac and Kir2.1, protein synthesis inhibitory proteins comprising ricin, neural inhibitory proteins selected from the group consisting of DREADD-hM4D, NpHR and GtACR1, proteins involved in neural cell fate such as NEUROD, proteins involved in cell regeneration including epidermal growth factor.

[0010] Also disclosed herein is a nucleic acid delivery vehicle that comprises the modular RNA molecule described herein, or the composition described herein, or the DNA that codes for the modular RNA molecule described herein.In one embodiment, the nucleic acid delivery vehicle can be a nanoparticle, a liposome, a vector, an exosome, a microvesicle, a gene gun, and a selective endogenous encapsulation (SEND) system for cell delivery.In one embodiment, the nucleic acid delivery vehicle comprises a viral vector, and the viral vector includes, but is not limited to, adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus, vesicular stomatitis virus.

[0011] Also disclosed herein are modular RNA molecules encoded by DNA vectors. Also disclosed herein are compositions in which modular RNA molecules are encoded by DNA vectors. Also disclosed herein are delivery vehicles comprising modular RNA molecules encoded by DNA vectors. Also disclosed herein are pharmaceutical compositions comprising modular RNA molecules as described herein, and / or compositions comprising modular RNA molecules as described herein, and / or delivery vehicles as described herein, together with pharma- ceutically acceptable carriers, excipients and / or diluents. Also disclosed herein are cells comprising modular RNA molecules as described herein, and / or compositions comprising modular RNA molecules as described herein, and / or delivery vehicles as described herein. Also disclosed herein are cells that are mammalian cells. Also disclosed herein are kits comprising modular RNA molecules as described herein, and / or compositions comprising modular RNA molecules as described herein, and / or delivery vehicles as described herein, and packaging therefor.

[0012] Also disclosed herein is a method of introducing a modular RNA, or a nucleic acid composition encoding a modular RNA, or a delivery vehicle comprising a modular RNA or a nucleic acid composition encoding a modular RNA, into a selected cell of a mammal, comprising contacting the cell of the mammal with the modular RNA molecule, the nucleic acid composition encoding a modular RNA, or a delivery vehicle comprising a modular RNA or a nucleic acid composition encoding a modular RNA, under conditions that allow the cell of the mammal to contain the delivery vehicle comprising the modular RNA or the nucleic acid composition encoding a modular RNA as described herein.

[0013] Also disclosed herein is a method of inducing ADAR editing of a stop codon in a mammalian cell comprising a selected target cellular RNA to allow expression of an in-frame downstream encoded protein, comprising the steps of introducing a modular RNA molecule into the mammalian cell under conditions in which the modular RNA is comprised in the cell, wherein the modular RNA comprises (i) a 5' region comprising a sensor domain comprising a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of the selected cellular RNA, wherein the sensor domain comprises a stop codon editable by ADAR, and (ii) a 3' region comprising a domain encoding an effector protein, wherein the protein coding region is downstream of and in frame with the sensor domain, and wherein upon introduction of the modular RNA molecule into the mammal, an RNA duplex is formed in the cell between the stretch of contiguous nucleotides of the sensor domain and the corresponding stretch of contiguous nucleotides of the cellular RNA, wherein the RNA duplex comprises an ADAR-editable stop codon, and wherein the ADAR edits the stop codon comprised in the RNA duplex, thereby allowing translation of the protein, and the protein is produced in the mammal.

[0014] Also disclosed herein is a method for treating a disease or disorder in a mammal, comprising the steps of: preparing a medicament, the medicament comprising a modular RNA molecule, a composition comprising the modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, and administering the medicament to the mammal in a therapeutically effective amount that allows translation of an effector protein in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells provides treatment for the disease or disorder in the mammal. In certain aspects of the method, the medicament comprises and is administered a composition comprising the medicament comprising the modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle as described herein, wherein a first protein coding region encoding an effector protein included in the medicament encodes a transactivator protein that activates expression of a second protein coding region, and expression of the second protein coding region in the selected cells is therapeutically effective in treating the disease or disorder.

[0015] Also disclosed herein is a method for stimulating L5b / L6 cortical descending projection neuron (CFPN) signals in the forelimb somatosensory cortex of a mouse in response to mechanical stimulation of the forepaw, as measured by photometry, comprising administering to the mouse a composition, wherein the sensor domain comprises a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA encoding Ctip2, the first protein-coding domain encodes an effector protein comprising the tetracycline-dependent transcriptional activator tTA2, and the second nucleic acid comprises a gene encoding the calcium indicator GCaMP6s under the transcriptional control of the TRE-3G eukaryotic inducible promoter.

[0016] Also disclosed herein is a method for stimulating forelimb movement in response to light stimulation of the caudal forelimb area (CFA) of a mouse, comprising administering a composition to the mouse, wherein the sensor domain comprises a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides of a cellular RNA encoding Ctip2, the first protein-encoding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2, and the second nucleic acid comprises a gene encoding the light-activated ion channel channelrhodopsin-2 under the transcriptional control of a TRE-3G eukaryotic inducible promoter. In one aspect of the method, the second gene is operably linked to the TRE-3G eukaryotic inducible promoter, and the second gene encodes enhanced yellow fluorescent protein (eYFP).

[0017] Also described herein are pharmaceutical compositions comprising modular RNA molecules, compositions comprising modular RNA molecules, and / or nucleic acid compositions, and / or delivery vehicles, all as described herein, as well as pharma- ceutical compositions comprising pharma- ceutical acceptable carriers, excipients, and / or diluents. Also described herein are cells comprising modular RNA molecules, compositions comprising modular RNA molecules, and / or nucleic acid compositions, and / or delivery vehicles, all as described herein. Also described herein are kits comprising modular RNA molecules, compositions comprising modular RNA molecules, and / or nucleic acid compositions, and / or delivery vehicles, all as described herein.

[0018] in vivo targeting of vesicular GABA transporter (vGAT) mRNA in the mammalian cortex 11. A method of identifying GABAergic neurons in the mammalian cortex in vivo, comprising administering to the S1 barrel cortex and hippocampus of a mammal a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a stretch of contiguous nucleotides of a sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by a vGAT gene, a first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding smV5, the second nucleic acid comprising a coding region for green fluorescent protein under the transcriptional control of a TRE-3G eukaryotic inducible promoter, the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter, the modular RNA molecule is upstream of the sensor domain and comprises a gene encoding mCherry under the transcriptional control of the hSyn promoter, and upon administration, a composition comprising a modular RNA molecule and / or a nucleic acid composition and / or a delivery vehicle, all as described herein, is administered to the S1 barrel cortex and hippocampus of the mammal. Also described herein is a method, comprising the step of: mRNA is co-labeled with magenta and GFP, showing the identification of GABAergic neurons in mammalian cortex.In one embodiment of the method, sesRNA targeting vGAT mRNA is complementary to the whole or part of exon 1 of vGAT mRNA.

[0019] 11. A method of identifying GABAergic neurons in the mammalian cortex in vivo comprising targeting transducin-like enhancer protein 4 (Tle4) mRNA, comprising administering to the S1 barrel cortex of the mammal a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a stretch of contiguous nucleotides of a sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of the cortical cell encoded by a Tle4 gene, the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding smFlag, the second nucleic acid comprising a coding region for green fluorescent protein under the transcriptional control of a TRE-3G eukaryotic inducible promoter, the first nucleic acid comprising the modular RNA molecule is under the transcriptional control of an hSyn promoter, the modular RNA molecule is upstream of the sensor domain and comprises a gene encoding mCherry under the transcriptional control of the hSyn promoter, and upon administration, targeting Tle4 in the S1 barrel cortex of the mammal. Also described herein is a method, comprising the step of: mRNA is co-labeled with magenta and GFP, showing the identification of TLE4 positive projection neurons in mammalian cortex.In one embodiment of the method, sesRNA targeting Tle4 mRNA is complementary to the whole or part of exon 15 of Tle4 mRNA.

[0020] A method of determining which cortical layers express human FOXP2 in an organotypic culture platform, comprising administering to the culture a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a stretch of contiguous nucleotides of a sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by the forkhead box protein P2 (FOXP2) gene, and a first protein-encoding domain is complementary to a gene encoding an effector protein comprising the tetracycline-dependent transcriptional activator tTA2 and smV5. Also described herein is a method comprising the steps of: a) encoding a second effector protein comprising a first nucleic acid that encodes a second effector protein comprising a second nucleic acid that comprises a coding region for green / yellow fluorescent protein (mNeon) under the transcriptional control of a TRE-3G eukaryotic inducible promoter; and b) encoding a first effector protein comprising a first nucleic acid that comprises a modular RNA molecule under the transcriptional control of an hSyn promoter, the modular RNA molecule being upstream of a sensor domain and comprising a gene encoding ClipF under the transcriptional control of the hSyn promoter; and c) encoding a first effector protein comprising a first nucleic acid that encodes a second effector protein comprising a second effector protein comprising a first nucleic acid that comprises a coding region for green / yellow fluorescent protein (mNeon) under the transcriptional control of a TRE-3G eukaryotic inducible promoter; and d) encoding a first effector protein comprising a first nucleic acid that comprises a modular RNA molecule under the transcriptional control of an hSyn promoter, the modular RNA molecule being upstream of a sensor domain and comprising a gene encoding ClipF under the transcriptional control of the hSyn promoter; and

[0021] 16. A method for suppressing neural activity promoting focal epileptic seizures comprising targeting a pathophysiological neural ensemble (PNE) involved in seizure activity comprising cell type targeted modulation of neural activity of the PNE, comprising: (i) providing a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a stretch of contiguous nucleotides of a sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by a human SST gene, a first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding osmFlag, the second nucleic acid comprises a coding region for green fluorescent protein (GFB) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, and a first nucleic acid comprising a modular RNA molecule encoding a cellular endothelial cell comprising a nucleoside analogue (NAA) encoding a phosphodiesterase (PHG)-dependent transcriptional activator (GIF) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, and a second nucleic acid comprising a modular RNA molecule encoding a phosphodiesterase (GIF)-dependent transcriptional activator (GIF) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, the first nucleic acid comprising a modular RNA molecule encoding a phosphodiesterase (GIF)-dependent transcriptional activator (GIF) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, the first nucleic acid comprising a modular RNA molecule encoding a phosphodiesterase (GIF)-dependent transcriptional activator (GIF) under the transcriptional control of a TRE-3G eukaryotic inducible promoter, the second ... and (ii) administering to the mammal the drug and the designer receptor gene in a therapeutically effective amount that enables translation of the effector protein upon administration of an oral dose of olanzapine or clozapine-n-oxide, which activates the DREADD, or an oral dose of varenicline, which activates the PSAM, in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells provides treatment of epilepsy in the mammal.

[0022] 1. A method for suppressing neural activity promoting focal epileptic seizures comprising targeting a pathophysiological neural ensemble (PNE) involved in seizure activity comprising cell type targeted modulation of neural activity of the PNE, the method comprising: (i) providing an agent, the agent comprising a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a stretch of contiguous nucleotides of a sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by the human mid-early growth cfos gene, the first protein coding domain encodes an effector protein comprising a tetracycline-dependent transcriptional activator tTA2 and a second effector protein comprising a gene encoding osmFlag, the second nucleic acid comprises a coding region for green fluorescent protein (GFB) under the transcriptional control of the TRE-3G eukaryotic inducible promoter, and the first nucleic acid comprising the modular RNA molecule encodes a gene encoding the hSyn promoter. Also described herein is a method comprising the steps of: (i) providing a modular RNA molecule under the transcriptional control of a hSyn promoter, the modular RNA molecule being upstream of the sensor domain and including a gene encoding mCherry under the transcriptional control of the hSyn promoter; (ii) further providing a gene encoding a designer receptor exclusively activated by designer drugs (DREADD) or a gene encoding a pharmacologically selective actuator module / pharmacologically selective effector molecule (PSAM); and (iii) administering to the mammal the drug and the designer receptor gene in a therapeutically effective amount that enables translation of the effector protein upon administration of an oral dose of olanzapine or clozapine-n-oxide to activate the DREADD or an oral dose of varenicline to activate the PSAM in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells provides treatment of the disease or disorder in the mammal.

[0023] A method of treating chronic pain in a mammal, comprising the steps of: (i) preparing a medicament, the medicament comprising a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a first module of the modular RNA comprises a stretch of contiguous nucleotides of a sensor domain that is complementary to a stretch of contiguous nucleotides of a selected cellular RNA encoded by either the human TRPV1 gene or the human NaV1.8 gene, a first protein coding domain encoding an effector protein comprises a tetracycline-dependent transcriptional activator tTA2, and the first module of the modular RNA molecule inhibits transcription of the hSyn promoter. Also described herein are methods comprising the steps of (i) administering to a mammal an agent in a therapeutically effective amount that enables translation of an effector protein in selected cells of the mammal, the agent being under transcriptional control of a TRE-3G eukaryotic inducible promoter and further comprising a spacer upstream of the sensor domain, the modular RNA further comprising a second module, the second module being upstream of the first module, the second module encoding an shRNA against NaV1.7 or NaV1.8 and under transcriptional control of a TRE-3G eukaryotic inducible promoter; and (ii) administering to the mammal an agent in a therapeutically effective amount that enables translation of an effector protein in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells provides treatment for chronic pain in the mammal.

[0024] 11. A method of treating Alzheimer's disease in a mammal, comprising the steps of: (i) preparing an agent, the agent comprising a composition comprising a modular RNA molecule, and / or a nucleic acid composition, and / or a delivery vehicle, all as described herein, wherein a first module of the modular RNA comprises a stretch of contiguous nucleotides of a sensor domain that is complementary to a stretch of contiguous nucleotides of a selected cellular RNA encoded by one of the group consisting of human astrocyte marker gene for aldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP) gene, excitatory amino acid transporter 1 (EAAT1) gene, and microglial genes: C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119), ionized calcium binding adaptor molecule 1 (IBA-1), and and (ii) administering to the mammal an agent in a therapeutically effective amount that enables translation of the effector protein in selected cells of the mammal, thereby producing the protein in the cells, wherein production of the protein in the cells provides treatment for Alzheimer's disease in the mammal. Also described herein are methods comprising the steps of: (i) administering to the mammal an agent in a therapeutically effective amount that enables translation of the effector protein in selected cells of the mammal, wherein a first protein coding domain encoding an effector protein comprises tetracycline-dependent transcriptional activator tTA2, and a first module of the modular RNA molecule is under transcriptional control of an hSyn promoter and further comprises a spacer upstream of the sensor domain, and the modular RNA further comprises a second module, the second module being upstream of the first module, the second module encoding an shRNA against ApoE4 and under transcriptional control of a TRE-3G eukaryotic inducible promoter. [Brief description of the drawings]

[0025] [Figure 1]CellREADR design and implementation in mammalian cells. a, CellREADR is a single modular readrRNA molecule consisting of a translationally in-frame 5'-sensor domain (sesRNA) and a 3'-effector domain (efRNA), separated by a T2a coding region. The sesRNA is complementary to cellular RNA and contains an in-frame STOP codon that prevents efRNA translation. Base pairing between the sesRNA and the target RNA recruits ADAR, which mediates A→I editing, converting the UAG STOP to a UGG Trp codon and switching on translation of the effector protein. b–d, b, CAG-tdT (top) expresses tdTomato target RNA from a CAG promoter, and READRtdT-GFP (bottom) expresses a readrRNA consisting of a BFP coding region followed by sesRNAtdT and efRNAGFP, driven by a CAG promoter. c, 293T cells transfected with both CAG-tdT and READRtdT-GFP showed robust GFP expression that colocalized with BFP and RFP (bottom). Cells transfected with only READRtdT-GFP (top) or CAG-tdT expressing a sesRNACtrl with a scrambled coding sequence containing a STOP codon and a control READRCtrl (middle) showed little GFP expression. Representative FACS analysis of GFP and RFP expression is shown on the right. d, Quantification of CellREADR efficiency by FACS. e-g, Effects of target RNA levels in CellREADR. e, Expression vectors to quantify the effects of target RNA levels in CellREADR. In rtTA-TRE-ChETA (top), BFP-ChETA fused target RNA is transcribed from the TRE, driven by constitutively expressed rtTA in a tetracycline concentration-dependent manner. READRChETA-GFP (bottom) expresses a readrRNA consisting of an mCherry coding region followed by sesRNAChETA and efRNAGFP.f, In 293T cells co-transfected with rtTA-TRE-ChETA and READRChETA-GFP, FACS analysis revealed that increasing tetracycline concentration in the medium resulted in an increased percentage of BFP+ in RFP+ cells. g, The ratio of GFP+ to RFP+ increased with increasing tetracycline concentration. CAG-ChETA constitutively expressing BFP-ChETA RNA served as a positive control, and READRChETA expressing sesRNACtrl served as a negative control. h-i, ADAR1 is required for CellREDAR function. FACS analysis (h) of wild-type or ADAR1KO 293T cells expressing sesRNAtdT only, sesRNACtrl and tdT, sesRNAtdT and tdT, or sesRNAtdT and tdT with ADAR2 overexpression. Arrows indicate the GFP+ / RFP+ population. i, Quantification of cell conversion ratio. j, Sanger sequencing electropherograms showing A to G conversion at the intended editing site in the different samples indicated. k, Bar graphs show quantification of A to G conversion rates at the targeted editing site. Error bars in d, f, g, and k are mean ± sem. n = 3, n represents the number of independent experiments performed in parallel.

[0026] [Diagram 2]Characteristics of sesRNA. a, The optimal sesRNA length is about 200-300 nt. Using READRBFP-tdT-GFP and tdT as the target RNA, sesRNAtdT with variable lengths were tested to identify the optimal length, quantified as the cell conversion ratio in a FACS assay. b, The effect of mismatches between sesRNA and target RNA base pairing. The number of mismatches (top) and the percent identity (bottom) between sesRNAtdT and tdT target RNA are shown for each case. c, The effect of sesRNA sensing of different locations and sequences within the target RNA (e.g., different ChETA and tdT coding regions) expressed from the EF1a-ChETA-tdT vector; the promoter region was used as a negative control. The efficiency of readrRNA was shown (bottom). d, To improve stringency, sesRNAtdT was designed to contain one to three STOP codons (X-TAG) in the READRtdT-Luc vector. e-f, Luminescence of 293T cells transfected with READRtdT-Luc alone (e) or co-transfected with CAG-tdT (f). g, Schematic of double and triple sensor READRChETA / tdT-GFP vectors using sesRNA arrays targeting different regions of the ChETA-tdT fusion transcript expressed from EF1a-ChETA-tdT. h, FACS analysis of 293T cells co-transfected with EF1a-ChETA-tdT and double or triple READRtdT-GFP vectors. Arrows indicate GFP+ / RFP+ populations. i, Quantification of the efficiency of the various double or triple READRtdT-GFP vectors in (h). j, Scheme for cross-targeting of cells expressing two target RNAs (ChETA and tdT) using dual-sensor READRChETA / tdT-GFP or READRChETA / tdT-Luc vectors; each sesRNA in the dual-sensor array contains an editable STOP.k, FACS analysis showed that co-transfection of 293T cells with READRChet / atdT-GFP and either CAG-ChETA or CAG-tdT resulted in little GFP translation, and only triple transfection led to GFP expression. EF1a-ChETA-tdT (expressing ChETA-tdT fusion transcript) co-transfection was used as a positive control. Quantification was shown using FACS (l) and luciferase assay (m). Error bars in a-c, e-f, i, and l-m are mean ± sem. n=3, n represents the number of independent experiments performed in parallel.

[0027] [Figure 3-1]Endogenous RNA sensing with CellREADR. a, Schematic of the genomic locus of the human EEF1A1 gene showing the exon and intron structure (not to scale), pre-mRNA (middle), and mRNA (bottom). sesRNAEEF1A1(1-7) was designed to sample across the EEF1A1 transcript including the coding sequence (CDS). b, Schematic of the READREEF1A1-GFP vector to test sesRNAEEF1A1(1-7); the BFP expression cassette labels all transfected cells. c, Quantification of the efficiency of sesRNAEEF1A1(1-7) in 293T cells. d, High sensitivity of CellREADR. Quantification of CellREADR efficiency for several endogenous cellular RNAs with different expression levels; TPM (transcripts per million) from RNAseq data was used to show the cellular RNA expression levels. One to three sesRNAs were designed for each target. e, Schematic diagram for cross-targeting of two endogenous RNAs (EEF1A1 and ACTB) using dual sensor READREEF1A1 / ACTB-GFP vector; each sesRNA in the dual sensor array contains an editable STOP. Dual sensors READRCtrl / Ctrl-GFP, READREEF1A1 / Ctrl-GFP or READRCtrl / ACTB-GFP were used as controls. Quantification of efficiency showed that only 293T cells with READRChet / atdT-GFP transfection resulted in significant GFP expression. f, CellREADR did not alter the cellular transcriptome assayed by RNA sequencing. Comparison of transcriptome between cells transfected with sesRNAEEF1A1(7) or sesRNACtrl (top) and sesRNAPCNA or sesRNACtrl (bottom). g. Volcano plot of differential gene expression analysis between sesRNAEEF1A1 or sesRNACtrl (top), sesRNAPCNA or sesRNACtrl (bottom). Genes with adjusted P-value <0.01 and log2 (fold change) >2 were defined as significantly differentially expressed genes and labeled in red.One gene, OAS2, was detected with significantly increased expression in the sesRNAEEF1A group. h, Transcriptome-wide analysis of the effect of sesRNAEEF1A1 (top) or sesRNAACTB (bottom) on A to I editing by RNA sequencing. Differential RNA editing rates were assessed using Pearson correlation coefficient analysis. Error bars in c-e are mean ± sem. n = 3, n represents the number of independent experiments performed in parallel. [Figure 3-2] Same as above. [Figure 3-3] Same as above.

[0028] [Figure 4-1]CellREADR targeting, monitoring, and manipulation of neural cell types in mice. a. Genomic structure of mouse Ctip2 gene with sesRNA3 and sesRNA8 locations indicated. b. Schematic of specific and binary AAV vectors for targeting Ctip2 neurons in brain tissue. In the specific READRCtip2-smFlag / tTA2 vector, the hSyn promoter drives expression of sequences encoding mCherry followed by sesRNACtip2, smFlag, and tTA2 effectors. In the binary vector, the reporter vector drives mNeonGreen expression from the TRE promoter in response to tTA2 from READRCtip2-smFlag / tTA2. c, Coronal section of S1 cortex injected with READRCtip2(3)-smFlag / tTA2 AAV. Immunofluorescence with FLAG (left) and CTIP2 (center) antibodies showed that READR-labeled cells (FLAG+, green) showed high colocalization with CTIP2+ PNs. d, Enlarged view of the boxed area in (c). Arrowheads indicate representative colabeled cells. e, Specificity of READRCtip2(3) delivered with specific vectors. f, In S1 cortex co-injected with binary AAV vectors, neurons were infected with READRCtip2 expressing mCherry (f1). In a subset of these neurons, sesRNACtip2(3) triggered the translation of tTA2 and activation of mNeon expression in L5b PNs (f2). The specificity of mNeon expression in Ctip2 PNs was assessed using CTIP2 immunofluorescence (f3-5). f5 is the boxed area in f4. Arrowheads indicate colabeled cells. g, Specificity of READRCtip2(3) delivered with a binary vector. h, Efficiency of binary READRCti p 2(3) calculated as GFP+ cells within mCherry- and CTIP2-expressing cells. i–l, READRCtip2(3) enabled calcium imaging of specific cortical neuron types in vivo. i–j, Schematic of stimulation of the left paw in anesthetized mice (i) and fiber photometric recordings (j).j, AAV-PTEnhancer-tTA2 or AAV-Ctip2-CellREADR-tTA2 were co-injected with AAV-TRE-GCaMP6s into the primary somatosensory cortex, upper limb region (SSp-ul). k, Heatmap of neuronal activity aligned with the onset of stimulation of the left paw. l, Average calcium signal aligned with the onset of stimulation of the left paw (left two panels). Peak Z-score of the response is shown (right panel, n = 2 mice each). Grey area indicates 1 s of stimulation. Black traces are from data aligned with shuffled onset times. Shading around the mean represents ± sem. Data are mean ± sem. m–p, READRCtip2 (3) enabled optogenetic manipulation of specific cortical neuron types in behaving mice. m–n, Schematic of optogenetic stimulation experiments in head-fixed mice (m), and viral injections (n). Two cameras were used to record the induced locomotion. The tip of the nose is the coordinate origin. The X, Y, and Z axes correspond to the medial-lateral, anterior-posterior, and dorsal-ventral axes, respectively. A reflective marker was attached to the rear of the left paw for tracking (red dot). n, AAV-PT Enhancer-tTA2 or AAV-Ctip2-CellREADR-tTA2 was co-injected with AAV-TRE-ChRger2-eYFP into the caudal forelimb area (CFA). o, Left paw speed before and after stimulation onset (n=20 trials for PT Enhancer mice; n=16 trials for Ctip2 CellREADR mice). Black traces indicate the average. The red line indicates the onset of the stimulus. The blue bar represents 500 ms of stimulation (see also Supplementary Video 1). p, Trajectory of left paw movement during optogenetic stimulation (n=20 trials for PT Enhancer mice; n=16 trials for Ctip2 CellREADR mice). Lateral (left) and frontal (right) trajectories were normalized to the starting position of the left paw. Black trajectories indicate the average. Squares indicate the position of the left paw when stimulation stopped. [Figure 4-2] Same as above. [Figure 4-3] Same as above. [Figure 4-4] Same as above.

[0029] [Figure 5-1]CellREADR-enabled targeting and recording of human cortical neuronal types. a, Schematic of binary AAV vectors for targeting neuronal types in human brain tissue. In the READR vector, the hSyn promoter drives the transcription of sequences encoding ClipF-Tag followed by sesRNAFOXP2, smV5, and tTA2. In TRE3g-mNeon, the TRE promoter drives mNeon in response to tTA from the READR virus. b, Genomic structure of the human FOXP2 gene. Two sesRNAs were designed to target FOXP2 mRNA. c, READR targeting of human FOXP2 cells. FOXP2 cells in the upper layers (mNeon, native fluorescent) were targeted with READRFOXP2(1) AAV in organotypic slices from the temporal neocortex (c1). FOXP2 cells in deeper layers were targeted with READRFOXP2(2) from the parietal neocortex (c2). Insets in c1 and c2 showed enlarged views of boxed regions. Dashed lines delineate pia and white matter. d, Immunostaining of FOXP2 in READRFOXP2(2)-labeled neurons. Arrowheads indicate neurons colabeled with mNeon native fluorescence (left) and FOXP2 immunofluorescence (middle), and arrows indicate cells labeled by mNeon only. e, Specificity of READRFOXP2(2) assayed by FOXP2 immunofluorescence. Error bars are mean ± sem. n=2 biological replicates were performed. f, Current-clamp recording traces of three mNeon-labeled neurons (top). Input-output curves of the cells show similar spiking behavior (top). g, Morphology of labeled neurons recorded in (f) (blue curves). Patched cells were filled with biocytin for post-hoc recovery and visualized in bright field and by silver staining. Brown, cyan, and purple arrowheads indicate cell bodies, axons, and dendrites, respectively. h, SesRNA designed to target exon 2 of human VGAT mRNA. i, Organotypic slices from human temporal neocortex co-infected with AAV-READRVGAT, TRE3g-mNeon, and visualized by native fluorescence 8 days after infection. j–k, Morphology of AAV-READRVGAT-labeled interneurons.l, Colocalization of mNeon native fluorescence (left) with VGAT mRNA (middle) by in situ hybridization. Arrowheads indicate co-labeled neurons and arrows indicate cells labeled only by mNeon. m, Specificity of READRVGAT assayed by VGAT mRNA in situ. Error bars are mean ± sem. n=2 biological replicates were performed. n, Current-clamp recording traces (top) of three labeled neurons filled with biocytin for post-hoc recovery. Streptavidin dye was used for visualization. Input-output curves (bottom) show distinct spiking behaviors: coordinated (blue), fast (green), delayed onset (red). o, Morphology of READRVGAT-labeled cells recorded in (n). [Figure 5-2] Same as above. [Figure 5-3] Same as above. [Figure 5-4] Same as above.

[0030] [Figure 6-1]Design and testing of singular and binary CellREADR vectors. a, Schematic of singular CellREADR vectors. Left, PGK-tdT expresses tdTomato target RNA from the PGK promoter. READRtdT-GFP expresses READR RNA consisting of sesRNAtdT and efRNAGFP, driven by a CAG promoter. Vertical dashed lines indicate the complementary base-pairing region between tdT mRNA and sesRNAtdT, and the sequence surrounding the editable STOP codon is shown on the right. At the editing site, an editable adenine (turquoise) in sesRNAtdT is mismatched with a cytosine in tdT mRNA. TdTomato is a tandem repeat of two dTomato genes, and thus the tdT RNA contains two copies of the target sequence for sesRNAtdT base pairing. b-d, Validation of READRtdT-GFP vectors. In 293T cells cotransfected with READRtdT-GFP and PGK-tdT (b), many switched on GFP translation and fluorescence (c, upper arrow). In cells cotransfected with the control empty vector, few cells showed GFP expression (c, lower). GFP expression was further assayed by Western blot (d). e, Binary vector design for CellREADR luciferase assay. READRtdT-tTA2 expresses readrRNA consisting of sesRNAtdT and efRNAtTA2, and TRE-ffLuc expresses luciferase RNA upon tTA2 activation. f, Luciferase activity was dramatically increased only in cells transfected with the three vectors in (e). Cotransfection of TRE-ffLuc and CAG-tTA2, which constitutively express tTA2, served as a positive control. g, Schematic READRtdT-GFP vector in which a spacer sequence was inserted before the sesRNAtdT coding region. h, 293T cells were transfected with READRtdT-GFP vectors encoding spacers of variable length without (gray) or with (pink) tdT target RNA expression, respectively. Quantification of conversion ratio calculated as the percentage of GFP+ cells among RFP+ cells.i, Binary vector design for CellREADR assay. j, Representative image of GFP conversion by binary vector in (i). Few GFP+ cells were observed in cells co-transfected with sesRNACtrl vector. Conversion percentages are shown on the right. Error bars in f and h are mean ± sem. n = 3 for f, n = 2 for h, n represents the number of independent experiments performed in parallel. [Figure 6-2] Same as above. [Figure 6-3] Same as above.

[0031] [Figure 7-1]CellREADR enables RNA sensing-dependent gene editing and cell ablation. a, Vector design for CellREADR-mediated and targeted RNA-dependent gene editing. In READRtdT-Cas9 / GFP, the CAG promoter drives expression of sequences encoding BFP followed by sesRNAtdT, Cas9, and eGFP effectors. In another vector, the EF1a promoter drives tdT expression, and the U6b promoter drives expression of a guide RNA (gRNA) targeting the DYRK1A gene in 293T cells. b, Quantification of READRtdT-Cas9 / GFP efficiency as a percent of GFP among cells expressing RFP and BFP with or without tdT target RNA. c, Cells transfected with both U6b-gRNADYRK1A-CAG-tdT and READRtdT-Cas9 / GFP showed robust GFP expression that colocalized with BFP and RFP (bottom). Cells transfected with READRtdT-Cas9 / GFP alone (top) showed little GFP expression. d, SURVEYOR assay showed Cas9-mediated cleavage at the human DYRK1A locus. DNA cleavage was observed in cell lysates transfected with U6b-gRNADYRK1A-CAG-tdT and READRtdT-Cas9 / GFP, but not with U6b-gRNADYRK1A and READRtdT-Cas9 / GFP lacking tdT target RNA. CAG-Cas9 and U6b-gRNADYRK1A cell lysates and 293T cell lysates without plasmid transfection were used as positive and negative controls, respectively. Arrows indicate cleavage products. e, Vector design for CellREADR-mediated and target RNA-dependent cell death induction. In READRtdT-taCasp3-TEVp, the CAG promoter drives the expression of sequences encoding BFP followed by sesRNAtdT as an effector and taCasp3-TEVp to induce cell death.f. Cell apoptosis levels, measured by luminescence, were increased in cells transfected with READRtdT-taCasp3-TEVp and EF1a-tdT compared to cells without tdT RNA. Error bars in b and f are mean values ​​± sem. n = 3, n represents the number of independent experiments performed in parallel. [Figure 7-2] Same as above.

[0032] [Figure 8] Effect of CellREADR on targeted mRNA a, Quantitative PCR showing that CellREADR-mediated sesRNA expression did not affect the expression level of targeted RNA. b, Base pairing of EEF1A1 mRNA and sesRNAEEF1A1-CDS. EEF1A1 mRNA or sesRNA is represented in blue and red, respectively. Peptides translated from EEF1A1 mRNA are highlighted in brown. Targeted regions of EEF1A1 mRNA were analyzed by RNAseq. c, The ratio of A to G changes of EEF1A1 mRNA at each adenosine position was quantified and shown in a heat map. Two adenosines (A107 and A115) showed a higher A to G editing ratio (c). Off-target editing of the two sensitive adenosines may induce potential amino acid changes (underlined in b). Error bars are mean ± sem. n=3, n represents the number of biological replicates performed.

[0033] [Figure 9-1]Design and screening of sesRNA targeting Fezf2 and Ctip2 RNA in vitro and in vivo. a-b, Genomic structure of mouse Fezf2 (a) and Ctip2 (b) genes with various sesRNA locations as indicated. c, List of sesRNA and Fezf2 and Ctip2 target gene fragments used for sesRNA screening. d, In target vector CAG-BFP-Fezf2 or CAG-BFP-Ctip2, 200bp-3000bp genomic regions of Fezf2 or Ctip2 genes containing sequences complementary to sesRNA in (a, b) were cloned downstream of BFP and T2a coding regions driven by CAG promoter. In READR vector, READRFezf2-GFP or READRCtip2-GFP express the corresponding sesRNA shown in (a, b). e-f, Quantification of the efficiency of READRFezf2-GFP (e) or READRCtip2-GFP (f) as GFP conversion ratio by FACS assay of 293T cells co-transfected with CAG-BFP-Fezf2 or CAG-BFP-Ctip2 targeting vectors, respectively. g, Schematic of binary READR AAV vector. In the READR vector, the hSyn promoter drives expression of sequences encoding mCherry followed by sesRNACtip2, smFlag and tTA2 effector. In the reporter vector, the TRE promoter drives mNeonGreen in response to tTA2 from the READR vector. h, Coronal section of mouse cortex injected with binary READRFezf2 vector. mNeonG showed READRFezf2-labeled cells. Four Fezf2 sesRNAs were screened. i, Quantification of the specificity of the four Fezf2 sesRNAs in (h).For in-vivo screening of Fezf2 sesRNA, the specificity of each sesRNA was calculated by co-labeling with READR AAV and CTIP2 antibody (due to lack of FEZF2 antibody), Ctip2 represents a subset of Fezf2+ cells (not shown), and CTIP2 antibody gives an underestimation of the specificity of Fezf2 sesRNA. SesRNA1 showed the highest specificity. j, Coronal section of mouse cortex injected with binary READRCtip2 vector. mNeonG showed binary READR labeled cells. Eight Ctip2 sesRNAs were screened. k, Quantification of the specificity of the eight sesRNAs in (j). The specificity of each sesRNA was calculated by co-labeling with binary READRCtip2AAV and CTIP2 antibody (not shown). SesRNA3 and sesRNA8 showed the highest specificity. [Figure 9-2] Same as above.

[0034] [Figure 10]CellREADR targeting of PNFezf2 and PNC tip2 types in mouse cortex with ADAR2 overexpression. a-b, Genomic structure of mouse Fezf2 (a) and Ctip2 (b) genes, respectively, with the location of sesRNAs indicated. c, Schematic of binary AAV vectors for targeting neuronal types. In READRFezf2-tTA2, the hSyn promoter drives expression of sequences encoding ADAR2 followed by sesRNAFezf2(1), T2a, and tTA2 effectors. In TRE-mRuby, the TRE promoter drives mRuby3 in response to READR virus-derived tTA2. d, Images of coronal sections from Fezf2-CreER;LoxpSTOPLoxp-H2bGFP mouse brain showing the distribution pattern of Fezf2+PNs in S1 somatosensory cortex (d1). Rodrigo Munoz-Castaneda et al. Cellular anatomy of the mouse primary motor cortex Nature volume 598, pages 159-166 (2021), Cre reporter transgenic mice were generated by crossing the "knock-in" Cre driver with reporter mice (CAG-LoxP-STOP-LoxP-H2B-GFP) previously described in Kim, Y. et al. Brain-wide maps reveal stereotyped cell-type-based cortical architecture and subcortical sexual dimorphism. Cell 171, 456-469.e422 (2017). Co-injection of AAV READRFezf2(1)-tTA2 and TRE-mRuby specifically labeled PNs at L5b and L6 (d2). Co-labeling with CellREADR AAV and H2bGFP (d3) and enlarged view of (d4). Arrows indicate co-labeled cells and arrowheads indicate neurons that were labeled by CellREADR AAV but not by Fezf2-H2bGFP (d4). e, Specificity of READRFezf2(1)-tTA2.f, Coronal section of WT brain immunostained with CTIP2 antibody showing the distribution pattern of Ctip2+ PNs in S1 cortex (f1). Co-injection of AAV READRCtip2(1) and TRE-mRuby specifically labeled PNs in L5b (f2). Co-labeling with CellREADR AAV and CTIP2 antibody (f3) and enlarged view of (f4). Arrows indicate co-labeled cells, and arrowheads indicate cells mislabeled by READRCtip2(1) (f4). g, Specificity of READRCtip2(1). h, Axonal projection patterns of AAV READRCtip2(1)-tTA2- and TRE-eYFP-infected PNs in S1 cortex. Representative images showing projections to the striatum, thalamus, midbrain, pons and medulla (arrows). i, Schematic locations of coronal sections are shown in the right panel.

[0035] [Figure 11] Expression levels and layer distribution of cortical cell type markers in mice. a, Cluster plot of selected genes in transcriptomic cell type clusters based on dataset from the Allen Institute for Brain Science, showing gene expression levels and cortical distribution. b, Gene expression levels of key cell type marker genes. Plots were generated using scRNAseq data40.

[0036] [Figure 12]CellREADR targeting of additional cortical neuronal types in mice. a, Genomic structure of mouse Satb2 gene with indicated sesRNA location. b-c, Cell labeling pattern in S1 by coinjection of binary vectors described in Fig. 4i. (b1) AAV READRSatb2 and TRE-mNeon labeled cells in both upper and deeper layers. (b2) Satb2 mRNA in-situ hybridization. (b3) Co-labeling with READRSatb2 and Satb2 mRNA. c, Enlarged view of boxed area in (b3). Arrows indicate co-labeled cells. d, Satb2 mRNA expression pattern in S1 cortex at P56 from the Allen Mouse Brain Atlas. e, Specificity of READRSatb2 measured as percent of Satb2+ cells among mNeon cells. f, Genomic structure of mouse PlxnD1 gene with indicated sesRNA location. g-h, AAV READRPlxnD1 and TRE-mNeon labeled cells in upper layers and L5a in S1 (g1). PlxnD1 mRNA in-situ hybridization (g2). Co-labeling with READRPlxnD1 AAV and PlxnD1 mRNA (g3). h, Enlarged view of boxed area in (g3). Arrows indicate co-labeled cells. i, PlxnD1 mRNA expression in P56 S1 cortex from the Allen Mouse Brain Atlas. j, Specificity of READRPlxnD1 measured as percentage of PlxnD1+ cells among mNeon cells. k, Genomic structure of mouse Rorb gene with location of sesRNA indicated. l, AAV READRRorb and TRE-mNeon labeled cells in layer 4 (l1, l3). DAPI staining showed layer structure (l2). The mNeon labeling pattern is consistent with Rorb mRNA expression in P56 S1 cortex from the Allen Mouse Brain Atlas (m), and the specificity of the Rorb sesRNA remains to be rigorously quantified due to the lack of specific antibodies to RORB and in situ probes for Rorb mRNA. n, Genomic structure of the mouse vGAT gene with the location of the sesRNA indicated.o-p, Binary READRvGAT and TRE-mNeon labeled cells (o1). vGAT mRNA in-situ hybridization (o2). Co-labeling with READRvGAT AAV and vGAT mRNA (o3). p, Enlarged view of rectangle in (o3). Arrows indicate co-labeled cells. q, vGAT mRNA expression in P56 S1 cortex from the Allen Mouse Brain Atlas. r, Specificity of READRvGAT measured as percent of vGAT+ cells among mNeon cells.

[0037] [Figure 13] Evaluation of immune responses of cortical cells after long-term expression of CellREADR vector. a, Schematic diagram of evaluation of the long-term effect of CellREADR in vivo. For each mouse, READRCtip2(3) or CAG-tdT control AAV was injected into the S1 cortex and incubated for 3 months. Fresh brains were dissected and a small piece of cortical tissue from the injection site was collected. Quantitative PCR was performed immediately. S1 tissue from mice without virus injection was used as a control. b, Heat map of the expression level changes of nine genes involved in glial activation and immunogenicity.

[0038] [Figure 14] Axonal projection patterns of L5 / 6 CFPNs in the caudal forelimb motor cortex targeted by AAV READRCtip2 and TRE-ChRger2-eYFP. a, Schematic of binary AAV vectors of READRCtip2(3)-smFlag / tTA2 and TRE-ChRger2-eYFP for optogenetic activation and axonal projection tracing. b, Axonal projection patterns of CFPNs infected with CFA. Representative images showing projections to the striatum (b2), thalamus (b3, b4), pons (b5) and medulla (b6, arrows). c, Schematic location of coronal sections in b.

[0039] [Figure 15]CellREADR targeting of neuronal types in rats a, Schematic of binary AAV vectors for cell type targeting in rats. In the READR vector, the hSyn promoter drives expression of sequences encoding mCherry followed by sesRNA, smFlag and tTA2 effector. Together with READR, the reporter vector drives mNeonG expression from the TRE promoter in response to tTA2 from the READR vector. b, Genomic structure of rat vGAT gene with the location of sesRNA indicated. c, AAV READRvGAT and TRE-mNeon were injected into deep cortex and hippocampus. Binary vector labeled cells are shown in the cortex (c1). c2, Enlarged view of the boxed area in (c1). vGAT mRNA was labeled by in-situ hybridization (c3). Co-labeling with mNeon and vGAT mRNA (c4). Arrows indicate co-labeled cells. d, Cellular labeling pattern in the hippocampal CA1 region by co-injection of AAV READRvGAT and TRE-mNeon. e, Enlarged view of the boxed area in (d). Arrows indicate co-labeled cells. fg, Specificity of rat READRvGAT in rat cortex (f) and hippocampus (g) measured as percentage of vGAT+ cells among mNeon cells. h, Genomic structure of rat Tle4 gene with location of sesRNA indicated. i-j, AAV READRTle4 and TRE-mNeon (Fig. 4i) were co-injected into rat motor cortex labeling cells enriched in deep layers (i1). Tle4+PNs were labeled by TLE4 antibody staining (i2, 3). j, Enlarged view of the boxed area in (i). Arrows indicate co-labeled cells with CellREADR and TLE4 antibodies. k, Specificity of rat READRTle4 in rat cortex measured as percentage of TLE4+ cells among mNeon cells.

[0040] [Figure 16]CellREADR vector targeting of neuronal types in human cortical ex vivo tissue. a, Schematic of the organotypic platform for human cortical ex vivo tissue. b, Schematic of the hSyn-eGFP viral construct used to drive broad neuronal labeling. c.AAVrg-hSyn-eGFP labeled cells were distributed across all layers and displayed diverse morphology (c1). Insets from c1 (c2) and c2 (c3, 4) depict numerous cells with pyramidal morphology, including prominent vertically oriented apical dendrites. d, FOXP2 expression in human neocortex. FOXP2 mRNA expression pattern taken from the Allen Institute human brain map (specimen no. 4312) showing upper and deep layer expression (arrows) (d1). FOXP2 immunostaining (magenta) in the current study also demonstrated both upper and deep layer labeling (d2, 4). NeuN immunostaining (red) representing cortical neurons (d3, 4). Dashed lines delineate the pia and white matter. e, READRFOXP2(1) labeling in organotypic slices derived from the same tissue used in d). Overview of brightfield and mNeon native fluorescence in organotypic slices demonstrating very limited labeling compared to that observed in d. Inset from e2 (e3) showing the morphology of upper layer pyramidal neurons. f, Schematic of the two specific vectors of READRFOXP2. In READRFOXP2(1), the hSyn promoter drives expression cassettes encoding ClipF, sesRNA1, smV5, and tTA2. In READRFOXP2(2), the hSyn promoter drives expression cassettes encoding ClipF, sesRNA2, smFlag, and FlpO. g, Seven days after application of READRFOXP2(2) AAV at DIV 1, tissues were fixed and stained with antibodies against FOXP2 and FLAG. FLAG-labeled cells from READRFOXP2(2) showed relatively small cell bodies with short apical dendrites (arrowheads). Non-specific background fluorescent signals (e.g., blood vessel-like profiles) are indicated by faint arrows in the middle panel.i, Quantification of CellREADR specificity measured as the percentage of V5+ cells (for READRFOXP2(1)) and FLAG+ cells (for READRFOXP2(2)), respectively, labeled by FOXP2 immunostaining.

[0041] [Figure 17] Epilepsy CellREADR targeting of GABA neurons in macaque cortex in vivo. a. Schematic of macaque vGAT gene. b. Binary CellREADR AAV vector. c-e, Labeling of neurons with interneuron morphology in macaque primary visual cortex 2 months after AAV incubation.

[0042] [Figure 18] Epilepsy CellREADR targeting of human PV and SST neurons in human neocortical ex vivo tissue from resected epilepsy patients. a. Human SST gene and sesRNA design. b. Binary AAV vectors to label and manipulate GABA neuron types. c. Human PV gene and sesRNA design. d. Examples of morphological labeling and firing patterns of human PV neurons. e. 14 out of 15 neurons targeted by the PV sensor show fast spiking, a characteristic of PV interneurons.

[0043] [Figure 19] CellREADR targeting of GLU and GABA neuronal types in macaques. a. AAV-READRFOXP2;AAV-TRE3g-mNeon labeled putative FOXP2 cell in V1. Boxed area in b is enlarged to show GFP+ pyramids with apical dendrites (white arrowheads) mainly in L6, and axons in white matter (black arrowheads) suggesting their efferent nature. c. AAV-READRVGAT;AAV-TRE3g-mNeon labeled putative GABA cell in V1. d-g. Example of a multipolar cell from c with sparsely protruding dendrites characteristic of diverse GABA INs.

[0044] [Figure 20] Cell-specific treatment of chronic pain A binary expression vector in which the translation of the transcriptional activator tTA is gated by a NaV1.7 or NaV1.8 RNA sensor, which in turn activates the transcription of an shRNA for NaV1.7 or NaV1.8 RNA.

[0045] [Figure 21] Cell-specific intervention of Alzheimer's disease. Schematic of the READR RNA, which consists of an sesRNA targeting an AD marker RNA and an effector RNA encoding tTA2 driven by the hSyn promoter. Upstream of this cassette, an shRNA against ApoE4 RNA is driven by a TRE enhancer. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0046] explanation definition For the purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to preferred embodiments and specific language will be used to describe the same. Nonetheless, it will be understood that no limitation of the scope of the disclosure is thereby intended, and that such modifications and further variations of the disclosure described herein are contemplated as would normally occur to one of ordinary skill in the art to which the disclosure pertains.

[0047] Thus, one aspect of the present disclosure provides a modular readrRNA molecule comprising: (i) a 5' region comprising a sensor RNA domain, the sensor domain comprising an ADAR editable STOP codon; and (ii) a 3' region comprising an effector RNA (efRNA) domain downstream of and in frame with the sensor domain, wherein the sensor domain of the modular readrRNA molecule specifically binds to cellular RNA encoded by a gene that is differentially expressed in a cell, preferably a cell or group of cells in the cortex, through sequence-specific base pairing to form an RNA duplex, wherein the efRNA encodes a protein, and the ADAR editable STOP codon acts as a translational switch, thereby enabling translation of the efRNA region to produce the effector protein.

[0048] In one embodiment, the modular readrRNA molecule further encodes a self-cleaving 2A peptide located between the sensor domain and the effector RNA region.The self-cleaving 2A peptide is selected from the group consisting of one or more of T2A peptide, P2A peptide, E2A peptide, and F2A peptide.Preferably, the 2A peptide is T2A.

[0049] In one embodiment, the effector (efRNA) domain of the modular readrRNA encodes a detectable protein or a detectable protein fragment (label), and / or a transcriptional activator or repressor.

[0050] In one aspect, the gene(s) differentially expressed in cells of the cortex are selected from the group consisting of Fezf2, Ctip2, PlxnD1, Satb2, Rorb and vGAT.

[0051] Another embodiment of the invention is a CellREADR "system" that includes at least two components, a first component includes a modular readrRNA molecule, and a second component includes a gene that is responsive to an effector domain-encoding protein. In one aspect of the CellREADR system, the efRNA-encoded protein by the modular readrRNA molecule includes a tetracycline-dependent transcription activator tTA2, and the sensor domain of the modular readrRNA molecule specifically binds to a cellular RNA encoded by the Ctip2 gene, and the second component of the CellREADR system includes a gene operably linked to a TRE-3G eukaryotic inducible promoter that is responsive to the tetracycline-dependent transcription activator tTA2. In one aspect of the CellREADR system, the efRNA-encoded protein by the modular readrRNA molecule further includes smFlag. In one aspect of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the calcium indicator GCaMP6s. In some embodiments of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the calcium indicator GCaMP6s. In some embodiments of the CellREADR system, the gene operably linked to the TRE-3G eukaryotic inducible promoter encodes the light-activated ion channel channelrhodopsin-2.

[0052] Another embodiment of the present invention is a CellREADR that responds to mechanical stimulation of the forepaws. Ctip2 / 3 A method for stimulating GCaMP6s signals in the forelimb somatosensory cortex, as measured by photometry, in mice transduced with the CellReadR system, comprising the step of coinfecting the mice with the CellReadR system referred to above.

[0053] Another embodiment of the present invention is the CellREADR Ctip2 / 3A method for stimulating forelimb locomotion in response to light stimulation of a CFA of a mouse transduced with the above-mentioned CellReadR system, comprising co-infecting the mouse with the above-mentioned CellReadR system. In another embodiment, the second gene is operably linked to the TRE-3G eukaryotic inducible promoter, and the second gene (eYFP) encodes enhanced yellow fluorescent protein.

[0054] Another embodiment of the invention is a delivery system comprising a modular readrRNA molecule operably associated with a vehicle for administering the modular readrRNA to an organ, tissue or cell.

[0055] Another embodiment of the present invention is a delivery system comprising the above-referenced CellREADR system operatively associated with a vehicle for administering the above-referenced CellREADR system to an organ, tissue or cell.

[0056] Another embodiment of the present invention is a delivery system, wherein the delivery vehicle is selected from the group consisting of nanoparticles, liposomes, vectors, exosomes, microvesicles, gene guns, and selective endogenous encapsulation for cellular delivery (SEND) systems.

[0057] Another embodiment of the present invention is a delivery system, wherein the delivery vehicle comprises a recombinant viral vector, preferably one of an adeno-associated virus (AAV), an adenovirus, a retrovirus, a lentivirus, a herpes viral vector, a vesicular stomatitis virus, and combinations thereof.

[0058] Another embodiment of the present invention is a pharmaceutical composition comprising the above-mentioned modular readrRNA molecule and / or the above-mentioned CellREADR system and / or the above-mentioned delivery system, as well as a pharma- ceutically acceptable carrier, excipient and / or diluent.

[0059] Another embodiment of the present invention is a cell comprising the above-mentioned modular readrRNA molecule and / or the above-mentioned CellREADR system, or the above-mentioned delivery system, wherein preferentially, the cell is a mammalian cell.

[0060] Another embodiment of the present invention is a kit comprising the above mentioned modular readrRNA molecule, and / or the above mentioned CellREADR system and / or the above mentioned delivery system.

[0061] Another embodiment of the present invention is a method for identifying GABAergic neurons in the mammalian cortex in vivo, comprising targeting vesicular GABA transporter (vGAT) mRNA in the mammalian cortex in vivo, the method comprising: (i) detecting READR vGAT and (ii) a reporter. mNeon to the S1 barrel cortex and hippocampus of a mammal, wherein READRvGAT is a human Syn promoter operably linked to sequences encoding the red fluorescent protein mCherry followed by sesRNA-targeted vGAT mRNA, a 2a protein, smFlag (smV5), a second 2a protein, the tetracycline-dependent transcriptional activator tTA2, and W3SL, in a 5' to 3' transcriptional order of [hSyn-mCherry-sesRNA vGAT- smFlag-tTA2], and a reporter mNeon contains [TRE3g-mNeon-WPRE], Upon administration, the vGAT mRNA in mammalian S1 barrel cortex and hippocampus is co-labeled with magenta and GFP, indicating the identification of GABAergic neurons in mammalian cortex.In one embodiment, sesRNA targeting vGAT mRNA is complementary to the whole or part of exon 1 of vGAT mRNA.

[0062] Another embodiment of the present invention is a method for identifying GABAergic neurons in the mammalian cortex in vivo, comprising targeting transducin-like enhancer protein 4 (Tle4) mRNA, the method comprising: (i) detecting READR vGAT and (ii) a reporter. mNeon to the S1 barrel cortex of a mammal, vGAT contains, in the 5' to 3' transcriptional order [hSyn-mCherry-sesRNAvGAT-smFlag-tTA2], a human Syn promoter operably linked to sequences encoding an RNA encoding the red fluorescent protein mCherry followed by sesRNA targeting Tle4 mRNA, a 2a protein, smFlag (smV5), a second 2a protein, the tetracycline-dependent transcriptional activator tTA2 and W3SL, and a reporter mNeon The method comprises [TRE3g-mNeon-WPRE], and upon administration, Tle4 mRNA in mammalian S1 barrel cortex is co-labeled with magenta and GFP, indicating the identification of GABAergic neurons in mammalian cortex. In one embodiment, the sesRNA targeting Tle4 mRNA is complementary to all or a portion of exon 15 of Tle4 mRNA.

[0063] Another embodiment of the present invention is a method for determining cortical layers expressing human FOXP2, an evolutionarily conserved gene involved in the development of human language skills, in an organ culture platform, comprising: FOXP2 / Reporter mNeon AAV(hSyn-ClipF-sesRNA FOXP2 -smV5-tTA2 and TRE3g-mNeon) to human neocortical slices in an organotypic culture platform, wherein 5 days after administration, mNeon-labeled cell bodies are observed in the upper and deeper layers of the organotypic culture platform cortex, indicating expression of human FOXP2 in the upper and deeper layers.

[0064] Another embodiment of the invention is a method for suppressing neural activity in a subset of cell types that promote focal epileptic seizures comprising targeting a pathophysiological neural ensemble (PNE) involved in seizure activity, comprising cell-type targeted modulation of neural activity of the PNE, wherein a marker for neural activity is rapid upregulation of the immediate early gene (IEG) c-fos, and a READR operably linked to one of three effector genes selected from the group consisting of the voltage-gated potassium channel Kv1.1 (KCNA1), an inhibitory DREADD (hM4D(Gi) inhibitory receptor), and an invertebrate glutamate receptor that is chloride permeable (eGluCL). c-fos wherein during epilepsy, upregulation of c-fos RNA causes effector translation to suppress PNE activity. In one embodiment, the effector gene is an inhibitory DREADD receptor, which is activated by the oral drug olanzapine. In another embodiment, the effector gene is eGluCL, which is activated by the drug ivermectin. In another embodiment, the effector gene is an inhibitory PSEM, which is activated by the drug varenicline.

[0065] Another embodiment of the present invention is a method of treating chronic pain comprising targeting nociceptors with an RNA sensor that targets RNA encoded by the voltage-gated sodium channel TRPV1 or NaV1.8 in the dorsal root ganglion, and using CellReadR cell type-specific short hairpin RNA (shRNA) in a knockdown approach to mediate effector expression to downregulate NaV1.7 and NaV1.8 mRNA in the nociceptors.

[0066] Another embodiment of the present invention is a method of treating Alzheimer's disease targeting marker genes / RNAs including, but not limited to, aldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 1 (EAAT1) in astrocytes, and C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119), ionized calcium binding adaptor molecule 1 (IBA-1) in microglia, comprising using CellReadR cell type specific short hairpin RNA (shRNA) to mediate effector expression to downregulate ApoE4.

[0067] As used herein, the term "stop codon" refers to a sequence of three nucleotides (trinucleotide) in DNA or messenger RNA (mRNA) that transmits a signal to stop protein synthesis in a cell.

[0068] A "codon" in messenger RNA corresponds to a nucleotide triplet that codes for an amino acid. Consecutive codons in RNA are translatable into a protein. Naturally, a stop codon is located at the 3' end of the coding region of an mRNA and signals the termination of translation by binding release factors, which cause the ribosomal subunits to dissociate, thereby releasing the amino acid chain. There are 64 different trinucleotide codons: 61 specific amino acids and three are stop codons (i.e., UAA, UAG, and UGA in RNA, and TAA, TAG, and TGA in DNA).

[0069] As used herein, "editable stop codon" refers to the stop codon that can be edited by cells from the stop codon to a translatable codon.Therefore, in RNA, the editable stop codon that is UAA, UAG or UGA can be edited by cells to UII, UIG or UGI.The editable stop codon functions as a translation switch for any codon downstream of the editable stop codon.The editing of the stop codon occurs in cells that have endogenous ADAR enzymes.

[0070] "Editing" of stop codon occurs when sensory RNA containing editable stop codon forms dsRNA with target RNA, thereby recruiting endogenous ADAR enzyme.ADAR acts on STOP codon and edits A to I, thus converting, for example, UAG STOP to UIG (tryptophan) codon, which allows translation of downstream codon.

[0071] The term "ADAR" is a disambiguation that stands for adenosine deaminase that acts on RNA. ADAR enzymes bind to double-stranded RNA (dsRNA) and convert adenosine to inosine (hypoxanthine) by deamination. ADAR proteins act post-transcriptionally to change the nucleotide content of RNA. The conversion of adenosine to inosine (A to I) in RNA disrupts normal A:U pairing and destabilizes the RNA. Inosine is structurally similar to guanine (G), which results in the binding of inosine to cytosine (I:C). Inosine typically mimics guanosine during translation, even though it can also bind to uracil, cytosine, and adenosine, which is not preferred.

[0072] As used herein, "readrRNA" refers to a molecule having a 5' region and a 3' region, where the readrRNA molecule comprises, consists of, or consists essentially of: (i) a 5' region that includes a sensor (ses) domain, where the sensor domain includes at least one ADAR-editable STOP codon, and (ii) an effector RNA (efRNA) region that is downstream of and in frame with the sensor domain.

[0073] In the readrRNA, an ADAR-editable stop codon is located within the sensor RNA and upstream of the in-frame effector coding region.

[0074] As used herein, an "ADAR-editable STOP codon" refers to a stop codon that is editable in a cell by an ADAR. Schneider, MF, Wettengel, J., Hoffmann, PC, & Stafforst, T. (2014). Optimal guide RNAs for re-directing deaminase activity of hADAR1 and hADAR2 in trans. Nucleic acids research, 42(10), e87. https: / / doi.org / 10.1093 / nar / gku272

[0075] As used herein, a "sensor domain" refers to a contiguous set of nucleotides that form a portion of a readrRNA, where the sensor domain also includes at least one editable stop codon and a downstream effector domain. The sensor domain contains contiguous nucleotides that are complementary to the RNA of a particular cell type through sequence-specific base pairing. The sensor domain can include any number of nucleotides, including at least 10 nucleotides to at least 1000 nucleotides, or more. In some embodiments, the sensor domain comprises, consists essentially of, or consists of about 100 to about 900 nucleotides. In another embodiment, the sensor domain comprises, consists essentially of, or consists of a range of about 200 nucleotides to about 300 nucleotides. The sensor domain may be 10, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000 or more contiguous nucleotides in length.

[0076] At least one editable stop codon in the sensor domain is located somewhere within the sensor domain of the readrRNA. The sensor domain has a 5' to 3' orientation in the readrRNA molecule and includes an upstream (5)' portion and a downstream (3)' portion. The editable stop codon can be located in the upstream portion of the sensor domain or the downstream portion of the sensor domain. The editable stop codon can be located in the upstream portion of the sensor domain near the center of the sensor domain, or the editable stop codon can be located in the downstream portion of the sensor domain near the downstream end of the sensor domain. For example, if the sensor domain is 600 nucleotides long and is spatially divided in half, the first nucleotide represents the 5' end of the sensor domain, the 300th nucleotide represents the center of the sensor domain, and the last (600th) nucleotide of the sensor domain represents the 3' end of the sensor domain, and the editable stop codon can be located in the upstream portion of the sensor domain, or the downstream portion, or near the center. When sensor domains having approximately the same length are divided into quarters, the editable stop codon can be located in the first quarter of the sensor domain (nucleotides 1-250), the second quarter of the sensor domain (nucleotides 150-300), the third quarter of the sensor domain (nucleotides 300-450), or the fourth quarter of the sensor domain (nucleotides 450-600). Thus, for a sensor domain of a given length, the editable stop codon can be located in a selected portion of the sensor domain. In general, the editable stop codon can be located in the downstream half of the sensor domain, or the downstream quarter of the sensor domain. The selected portion of the sensor domain containing the editable stop codon can be within 10-50 nucleotides of the 3' end of the sensor domain.

[0077] As used herein, an "effector RNA (efRNA)" is an RNA that is translatable and encodes an effector protein.

[0078] "Effector protein" is a protein that is encoded by an effector RNA domain and has an effect on the cell in which it is expressed. Effector protein is translated from effector RNA in the cell, and thus, effector protein, like the RNA that encodes it, is introduced into the cell, which may or may not contain the same endogenous protein. Effector protein is a protein that has an effect on the cell in which it is translated, or on the surrounding cells when secreted from the cell. Non-limiting examples of effector proteins include enzymes, detectable proteins, cytokines, toxins, polymerases, transcription or translation factors, tumor suppressors, neuroactivators or inhibitors, apoptotic proteins, or physiological factors.

[0079] As used herein, "effector RNA (efRNA) region" refers to a portion of the readrRNA that is downstream of and in frame with the sensor domain and contains the effector RNA.

[0080] Effector RNA (efRNA) may code for an effector protein of interest. The selection of a desired effector protein is well within the skill of the artisan and depends on the context of the desired use of the readrRNA. For example, if it is desired to treat a given disease, an effector protein may be selected based on its inhibitory effect on cells that are important for establishing and / or prolonging the disease. For example, the effector module of CellREADR (efRNA) can be constructed to manipulate cells in multiple ways, including enhancing activity and function, suppressing activity and function, rescuing the function of mutant cells by reintroducing an intact version of a deleted or mutated protein, altering and editing activity and function, reprogramming cell identity, fate and function, killing and eliminating cell types, increasing or decreasing the production of a certain type of cell number, and cell type-specific genome editing and gene regulation.

[0081] Non-limiting examples of effectors are listed below in Table 1. Table 1 provides a non-limiting list of effector proteins (payloads) useful according to the present invention and their effects on cells. Table 1 [Table 1]

[0082] The term "payload" in the context of an effector RNA "payload" refers to a protein encoded by an RNA that encodes an effector protein.

[0083] As used herein, the phrase "cell type" refers to an organism, an organ, a tissue, a population of cells, or a cell line, or a somatic cell of a hybridoma, a homogeneous or heterogeneous cell population, a resting or quiescent or activated cell, or a cell that is transformed or diseased or stressed or inflamed or heat shocked, or a part of the innate immune system, a part of the natural immune system, a stem cell, a pluripotent stem cell, an intestinal stem cell, a stem cell, a fetal cell, a cell that contributes to homeostasis, a heart or blood vessel related cell, a cell of the digestive system, a cell of the nervous system, a cell of the skeletal structure, a cell of an organ, that can be identified through differential expression of RNA.

[0084] Presumably every cell or group of cells is different, and single-cell RNA analysis provides evidence of this diversity with respect to the lineage of a cell, its activation state, its developmental state, its state as a result of interactions with other cells, tissues and organs, soluble molecules, and / or whether the cell is diseased, transformed or infected.

[0085] As used herein, the term "self-cleaving 2A peptide" or "2A peptide" refers to a class of 18-22 amino acid long peptides that can induce ribosome skipping during protein translation in cells. These peptides share the core sequence motif of DxExNPGP, are found in a wide range of virus families, and aid in the generation of polyproteins by causing ribosomes to fail to make peptide bonds. Suitable examples of 2A peptides include, but are not limited to, T2A, P2A, E2A, F2A, etc. (Liu, Ziqing et al. "Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector." Scientific reports vol. 7,1 2193. 19 May. 2017, doi:10.1038 / s41598-017-02460-2). One such self-cleaving 2A peptide includes the T2A peptide.

[0086] Several 2A peptides have been identified in picornaviruses, insect viruses, and type C rotaviruses. As used herein, T2A is the 2A peptide identified in Tosea Signavirus 2A, P2A is the 2A peptide identified in Porcine Teschovirus-1 2A, E2A is the 2A peptide identified in Equine Rhinitis A Virus (ERAV) 2A, and F2A is the 2A peptide identified as the self-cleaving 2A peptide of Foot and Mouth Disease Virus (FMDV). The following table provides the DNA and corresponding amino acid sequences of various 2A peptides. The underlined sequences code for the amino acid GSG, which is an example of an optional addition to the native 2A sequence designed to improve cleavage efficiency, where P2A is Porcine Teschovirus-1 2A, T2A is Tosea Signavirus 2A, E2A is Equine Rhinitis A Virus (ERAV) 2A, and F2A is FMDV 2A. This is taken from Table 1 in Kim JHet al. (High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice) PLoS One. 2011; 6(4): e18556. Published online 2011 Apr 29. doi: 10.1371 / journal.pone.0018556. Table 2 [Table 2]

[0087] As used herein, a "sequence encoding a self-cleaving 2A peptide" is a nucleic acid, preferably an RNA, that encodes the self-cleaving 2A peptide described above. According to the present invention, the sequence encoding the self-cleaving 2A peptide is typically located between the sensor domain and the effector RNA region.

[0088] The term "modular", when used in the context of the phrase "modular readrRNA molecule", refers to a recombinant readrRNA molecule comprising nucleic acid sequences (preferably RNA sequences) encoding protein domains designed at the nucleic acid level, preferably at the RNA level, where different protein domains can be assembled in the recombinant readrRNA molecule in a desired order with a specific number of repeats (including 0).

[0089] As used herein, "CellREADR" stands for "cell access through RNA sensing by endogenous ADAR [adenosine deaminase acting on RNA]," which is designed as a single modular Readr RNA molecule consisting of a 5' sensor-editing-switch region (sesRNA) and a 3' effector protein (or protein fragment) coding region (ef RNA) of the editing mechanism ubiquitous in all animal cells, such as by ADAR editable STOP codons, separated by a linking sequence encoding the self-cleaving peptide T2A. CellREADR provides a mechanism for detecting the presence of cellular RNA and for switching on the translation of effector proteins to monitor and manipulate the physiology, function and / or structure of cell types. The following table provides cell types of various tissues with an indication of the enriched mRNAs. Table 3 [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4]

[0090] As used herein, the "CellREADR system" includes the following components: (i) a sensor RNA domain that includes a contiguous set of nucleotides that are complementary to a portion of a selected cellular RNA; (ii) an effector RNA (efRNA) domain that encodes an effector protein, where the efRNA domain is downstream of and in frame with the sensor RNA domain; (iii) an ADAR editable STOP codon that is within the sensor RNA domain or between the sensor and effector RNA domains; and (iv) a second protein-encoding nucleic acid or a gene that optionally includes a genetic control element, where (iv) may or may not be physically linked to the sensor RNA and effector RNA domains. The CellREADR system may include an exogenous gene (DNA or RNA) that is not physically linked to the readrRNA (e.g., on a separate vector). The CellREADR system may include a cell that contains a readrRNA nucleic acid, where the nucleic acid encodes a second protein, and the cell is used for delivery to a multicellular organism, a plant, an animal, or a human.

[0091] As used herein, "delivery system" refers to a system comprising a vehicle for administering a modular readrRNA molecule and / or the CellREADR system, where the vehicle includes, but is not limited to, a nanoparticle, a liposome, a vector, an exosome, a microvesicle, a gene gun, a SEND system, and combinations thereof.

[0092] The "SEND system" is an mRNA delivery system that includes humanized virus-like particles (VLPs) based on retroelements present in the human genome (Segel M, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021;373:882-889. doi: 10.1126 / science.abg6155). Vectors of such delivery systems include, but are not limited to, recombinant viral vectors, such as adeno-associated viruses (AAV), adenoviruses, retroviruses, lentiviruses, herpes virus vectors, vesicular stomatitis viruses, and combinations thereof. In one embodiment, the viral vector comprises an AAV vector.

[0093] As used herein, "capable of forming a duplex with" means that a "corresponding stretch of contiguous nucleotides" can base pair with a stretch of contiguous nucleotides of a sensor domain RNA.

[0094] As used herein, a "corresponding section" means sequences that are the same length of nucleotides and that match through base pairing.

[0095] A "section" refers to a length of at least 15 or more contiguous nucleotides, including 20 bases, 25 bases, 30 bases, 40 bases, 50 bases, 60 bases, 75 bases, 100 bases, 125 bases, 150 bases, 175 bases, 200 bases, 225 bases, 250 bases, 275 bases, 300 bases, 325 bases, 350 bases, 375 bases, 400 bases, 425 bases, 450 bases, 475 bases, 500 bases, 525 bases, 550 bases, 575 bases, 600 bases, 625 bases, 650 bases, 675 bases, 700 bases, 725 bases, 750 bases, 775 bases, 800 bases, 825 bases, 850 bases, 875 bases, 900 bases, 925 bases, 950 bases, 975 bases, 1000 bases, and more.

[0096] As used herein, a "translational switch" is a component of a readrRNA molecule that contains an ADAR-editable STOP codon component, which upon binding to an upstream sensor RNA complementary to a target RNA to form a double-stranded RNA structure, results in ADAR-mediated editing of the subsequent AUG stop codon and translation of a downstream RNA encoding an effector protein.

[0097] As used herein, "cellular RNA" refers to RNA present in a given cell, regardless of whether the RNA is endogenous to the cell (i.e., transcribed from a gene endogenous to the cell) or present in the cell because it has been transcribed from a gene introduced into the cell or from a pathogen (such as a virus, bacterium, fungus or another microorganism) that has infected the cell.

[0098] As used herein, "cellular RNA of a cell" refers to RNA present in a cell that is identifiable as having particular characteristics because the RNA is known to be present in cells with particular characteristics.

[0099] As used herein, "cellular RNA that defines a cell state" refers to one or more RNA sequences present in a selected cell or group of cells of interest, the presence of which identifies the state of a given cell, including, but not limited to, the physiology of a particular cell, a particular developmental stage of a cell, a particular transformation of a cell, or the activation state of a cell.

[0100] That is, the specific physiology of a cell is determined in large part by its expression of a unique repertoire of RNA transcripts.A unique repertoire of RNA transcripts is one way of identifying a specific cell or group of cells of interest, or identifying a specific activation state of a specific cell or group of cells of interest, or identifying a specific developmental stage of a specific cell or group of cells of interest, or identifying any one of a number of physiological states of a cell or a specific cell or group of cells of interest.

[0101] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids and may be interrupted by non-amino acids. The terms also encompass amino acid polymers that have been modified, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.

[0102] In the context of the polypeptides and molecules provided herein, the terms "fusion," "fused," "combined," and "linked" are used interchangeably herein. These terms refer to the joining together of two or more protein components by any means, including chemical conjugation or recombinant means. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence. In general, "operably linked" means that the DNA sequences being linked are contiguous and in reading phase or in frame. As used herein, the term "in-frame" or "in frame" refers to the joining of two or more open reading frames (ORFs) to form a continuous, longer ORF in a manner that maintains the correct reading frame of the original ORF. The resulting recombinant molecule is thus a single protein containing two or more segments that correspond to the polypeptides encoded by the original ORFs (the segments are not normally so linked in nature).

[0103] In the context of a polypeptide, a "linear sequence" or "sequence" is the order of amino acids in a polypeptide in the direction from the amino terminus to the carboxyl terminus, in which adjacent residues in the sequence are contiguous in the primary structure of the polypeptide. A "subsequence" is a linear sequence of a portion of a polypeptide that is known to contain additional residues in one or both directions.

[0104] "Heterologous" means derived from a genotypically distinct entity from that of the remainder of the entity to which it is being compared. For example, a glycine-rich sequence removed from its native coding sequence and operably linked to a coding sequence other than the native sequence is a heterologous glycine-rich sequence. The term "heterologous" as applied to polynucleotides, polypeptides means that the polynucleotide or polypeptide is derived from a genotypically distinct entity from that of the remainder of the entity to which it is being compared.

[0105] The terms "polynucleotide", "nucleic acid", "nucleotide" and "oligonucleotide" are used interchangeably. They refer to polymeric forms of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, locus(s) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides may contain modified nucleotides, e.g., methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may be further modified after polymerization, e.g., by conjugation with a labeling component.

[0106] The phrases "complementary to" and "complement of a polynucleotide" refer to a polynucleotide nucleic acid molecule having a complementary base sequence in a 5' to 3' or 3' to 5' direction that base pairs with a nucleic acid having a reverse base sequence. As described herein, a sensor RNA is complementary to a specific target RNA, except for unavoidable mismatch codons (preferably AUG in the sensor RNA).

[0107] The phrase "portion that is complementary to cellular RNA" in the context of a sensor domain refers to consecutive nucleotides of the sensor nucleic acid domain that are capable of base pairing with corresponding consecutive nucleotides of the cellular RNA.

[0108] The phrase "portion that is complementary to a messenger RNA (mRNA)" in the context of a sensor domain refers to consecutive nucleotides of the sensor nucleic acid domain that are capable of base pairing with corresponding consecutive nucleotides of the mRNA.

[0109] The term "cellular RNA" refers to nucleic acid in a cell that is composed of nucleotides that are substantially ribonucleotides, although it may contain deoxyribonucleotides. Types of cellular RNA include, but are not limited to, mRNA, rRNA, tRNA, and microRNA. Cellular RNA has a length sufficient to form a nucleic acid duplex with a sensor RNA that contains a mismatch, which attracts ADAR to edit and repair the mismatch. Thus, cellular RNA is at least 10 residues long, and may be 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000 nucleotides long, or longer.

[0110] "Recombinant" as applied to a polynucleotide means that the polynucleotide is the product of various combinations of in vitro cloning, restriction and / or ligation steps, and other procedures that result in a construct that can potentially be expressed in a host cell.

[0111] The terms "gene" or "gene fragment" are used interchangeably herein. They refer to a polynucleotide containing at least one open reading frame that can code for a particular protein after being transcribed and translated. The term "gene" includes not only the open reading frame but also at least a promoter operably associated with the open reading frame to initiate transcription of the open reading frame in the presence of appropriate transcription factors. A gene or gene fragment can be genomic or cDNA, so long as the polynucleotide contains at least one open reading frame, which can cover the entire coding region or a segment thereof. A "fusion gene" is a gene composed of at least two heterologous polynucleotides that are linked together.

[0112] "Homology" or "homology" refers to the sequence similarity or interchangeability between two or more polynucleotide sequences or two or more polypeptide sequences. When using a program such as BestFit to determine sequence identity, similarity or homology between two different amino acid sequences, default settings may be used, or an appropriate scoring matrix, such as blosum45 or blosum80, may be selected to optimize identity, similarity or homology scores. Preferably, a homologous polynucleotide hybridizes under stringent conditions as defined herein and has at least 70%, preferably at least 80%, more preferably at least 90%, more preferably 95%, more preferably 97%, more preferably 98%, and even more preferably 99% sequence identity with the sequence.

[0113] As used herein, "treatment", "therapy" and / or "therapeutic regimen" refer to a clinical intervention undertaken in response to a disease, disorder or physiological condition exhibited by or to which the patient may be susceptible. The objectives of treatment include reducing or preventing symptoms, slowing or halting the progression or worsening of a disease, disorder or condition, and / or ameliorating a disease, disorder or condition. As used herein, the terms "prevent", "preventing", "prevention", "prophylactic treatment" and the like refer to reducing the probability of the occurrence of a disease, disorder or condition in a subject who does not have the disease, disorder or condition but is at risk of or suspected of developing it. The term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to produce beneficial or desired biological and / or clinical results.

[0114] Effective amount as used herein also includes, in various contexts, an amount sufficient to delay the onset of disease symptoms, change the course of disease symptoms (for example, but not limited to, delay the progression of disease symptoms), or reverse disease symptoms. Therefore, it is generally not feasible to specify an exact "effective amount". However, for any given case, the appropriate "effective amount" can be determined by those skilled in the art using only routine experimentation.

[0115] Effective dose, toxicity, and therapeutic efficacy can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine LD50 (the dose lethal to 50% of the population) and ED50 (the dose therapeutically effective in 50% of the population). The effect of any particular dosage can be monitored by a suitable bioassay, for example, an assay for tumor growth and / or size, among others. Dosage can be determined by a physician and, if necessary, can be adjusted to satisfy the observed effect of treatment.

[0116] As used herein, the term "administering" an agent, e.g., a therapeutic entity, to an animal or cell is intended to refer to distributing, delivering, or applying the substance to the intended target. In terms of a therapeutic agent, the term "administering" is intended to refer to contacting or distributing, delivering, or applying the therapeutic agent to a subject by any suitable route for delivery of the therapeutic agent to a desired location in an animal, including delivery by either parenteral or oral routes, intramuscular injection, subcutaneous / intradermal injection, intravenous injection, intrathecal administration, buccal administration, transdermal delivery, topical administration, and administration by intranasal or airway routes.

[0117] The term "biological sample" as used herein includes, but is not limited to, samples containing tissue, cells, and / or bodily fluids isolated from a subject. Examples of biological samples include, but are not limited to, tissue, cells, biopsy, blood, lymph, serum, plasma, urine, saliva, mucus, and tears. Biological samples may be obtained directly from a subject (e.g., by blood or tissue sampling) or from a third party (e.g., received from an intermediary such as a health care provider or laboratory assistant).

[0118] As used herein, the term "condition and / or disease" includes, but is not limited to, any abnormal state and / or disorder of structure or function affecting a part of an organism. This may be caused by external factors, such as infectious disease, or by internal dysfunction, such as cancer, cancer metastasis, genetic disorders / mutations (both congenital and environmental), etc.

[0119] As used herein, monogenic somatic disorders that contain underlying genetic mutations in genes refer to monogenic disorders caused by variants in a single gene.Variants can be present in one or both of a pair of chromosomes.Non-limiting examples of monogenic disorders are cystic fibrosis, Huntington's disease and sickle cell disease.

[0120] As known in the art, cancer is generally considered to be uncontrolled cell growth.The method of the present invention can be used to treat any cancer, including but not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia, and any metastasis thereof.More specific examples of such cancer include breast cancer, prostate cancer, colon cancer, squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, liver cancer, bladder cancer, hepatoma, colorectal cancer, cervical cancer, endometrial cancer, salivary gland cancer, mesothelioma, kidney cancer, vulvar cancer, pancreatic cancer, thyroid cancer, liver cancer, skin cancer, melanoma, brain cancer, neuroblastoma, myeloma, various types of head and neck cancer, acute lymphocytic leukemia, acute myeloid leukemia, Ewing's sarcoma, and peripheral neuroepithelioma.

[0121] "Contacting" as used herein, for example, in "contacting a sample", refers to contacting a sample or cell directly or indirectly in vitro, ex vivo, or in vivo (i.e., in a subject as defined herein). Contacting a sample can include adding a compound (e.g., a readrRNA molecule provided herein and / or a delivery system comprising a readrRNA molecule provided herein) to the sample or administering it to a subject. Contacting includes administration to a solution, cell, tissue, mammal, subject, patient, or human. Additionally, contacting a cell includes adding an agent to a cell culture.

[0122] As used herein, the terms "subject" and "patient" are used interchangeably herein and refer to both human and non-human animals. The term "non-human animal" in the present disclosure includes all vertebrates, e.g., mammals and non-mammals, e.g., non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc. The methods and compositions disclosed herein can be used on samples either in vitro (e.g., isolated cells or tissues) or in vivo in a subject (i.e., a living organism, e.g., a patient).

[0123] The terms "reduce", "reduced", "reduction" and "inhibit" are all used herein to mean a statistically significant amount of reduction. In some embodiments, "reduce", "reduction" or "reduce" or "inhibit" typically means a reduction of at least 10% compared to a reference level (e.g., the absence of a given treatment or agent), and may include, for example, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or more reductions. As used herein, "reduce" or "inhibit" does not encompass complete inhibition or reduction compared to a reference level. "Complete inhibition" is 100% inhibition compared to a reference level. The decrease may preferably be to a level accepted as within the normal range for individuals without a given disorder.

[0124] The terms "increased," "increase," "enhance," or "activate" are all used herein to mean a statistically significant amount of increase. In some embodiments, the terms "increased," "increase," "enhance," or "activate" can mean an increase of at least 10% compared to a reference level, including, for example, an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to 100% compared to a reference level, or any increase between 10-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold, or at least about 10-fold, or any increase of 2-fold to 10-fold or higher compared to a reference level. In the context of a marker or condition, "increase" is a statistically significant increase in such level.

[0125] The central nervous system (CNS) has three main components: the brain, the spinal cord, and neurons (or nerve cells).

[0126] It is one of two parts of the nervous system. The other part is the peripheral nervous system, which consists of the nerves that connect the brain and spinal cord to the rest of the body.

[0127] The major cell types of the central nervous system include neurons, glial cells (astrocytes, oligodendrocytes, ependymal cells, and microglia), choroid plexus cells, cells associated with blood vessels and linings. The peripheral nervous system includes efferent neurons (motor neurons), afferent neurons (sensory neurons), and Schwann cells.

[0128] As used herein, "subject" refers to a human or an animal. Usually, an animal is a vertebrate, such as a primate, a rodent, a livestock animal, or a game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Livestock and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, canine species, such as dogs, foxes, wolves, avian species, such as chickens, emus, ostriches, and fish, such as trout, catfish, and salmon. In some embodiments, the subject is a mammal, such as a primate, such as a human. The terms "individual," "patient," and "subject" are used interchangeably herein.

[0129] Preferably, the subject is a mammal. The mammal can be, but is not limited to, a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow. A non-human mammal can be advantageously used as a subject that represents an animal model of cancer. The subject can be male or female.

[0130] The subject may be previously diagnosed or identified as suffering from or having a condition (e.g., cancer) that requires treatment or one or more complications associated with such a condition, and may, if necessary, have already undergone treatment for the condition or one or more complications associated with the condition. Alternatively, the subject may also be previously undiagnosed as having a condition or one or more complications associated with the condition. For example, the subject may be one that shows one or more risk factors for the condition or one or more complications associated with the condition, or one that does not show risk factors.

[0131] A "subject in need" of treatment for a particular condition can be a subject who has the condition, has been diagnosed with the condition, or is at risk for developing the condition.

[0132] In some embodiments, the polypeptides described herein (or nucleic acids encoding such polypeptides) may be functional fragments of one of the amino acid sequences described herein.As used herein, a "functional fragment" is a peptide fragment or segment that retains at least 50% of the activity of the wild-type reference polypeptide according to the assay described herein below.Functional fragments may include conservative substitutions of the sequences disclosed herein.

[0133] In some embodiments, the polypeptides described herein may be variants of the sequences described herein. In some embodiments, the variants are conservatively modified variants. Conservative substitution variants can be obtained, for example, by mutation of native nucleotide sequences. "Variants" as referred to herein are polypeptides that are substantially homologous to native or reference polypeptides, but have amino acid sequences that differ from those of native or reference polypeptides due to one or more deletions, insertions or substitutions. DNA sequences encoding variant polypeptides include sequences that, when compared to native or reference DNA sequences, contain one or more additions, deletions or substitutions of nucleotides, but encode variant proteins or fragments thereof that retain activity. A wide variety of PCR-based site-directed mutagenesis approaches are known in the art and can be applied by those skilled in the art.

[0134] In some embodiments, the polypeptide may include one or more amino acid substitutions or modifications. In some embodiments, the substitutions and / or modifications may prevent or reduce proteolysis and / or extend the half-life of the polypeptide in a subject. In some embodiments, the polypeptide may be modified by conjugating or fusing it to other polypeptides or polypeptide domains, for example, by way of non-limiting examples, transferrin (W006096515A2), albumin (Yeh et al., 1992), growth hormone (US2003104578AA), cellulose (Levy and Shoseyov, 2002), and / or Fc fragment (Ashkenazi and Chamow, 1997). The references in the preceding paragraphs are incorporated herein by reference in their entirety.

[0135] As used herein, the term "nucleic acid" or "nucleic acid sequence" refers to any molecule, preferably a polymeric molecule, that is an incorporated unit of ribonucleic acid, deoxyribonucleic acid, or analogs thereof. A nucleic acid can be either single-stranded or double-stranded. A single-stranded nucleic acid can be one nucleic acid strand of a denatured double-stranded DNA. Alternatively, it can be a single-stranded nucleic acid that is not derived from any double-stranded DNA. In one embodiment, the nucleic acid can be DNA. In another embodiment, the nucleic acid can be RNA. Suitable DNA can include, for example, genomic DNA or cDNA. Suitable RNA can include, for example, mRNA.

[0136] The term "expression" refers to the cellular processes involved in the production of RNA and proteins, and, where appropriate, secreted proteins, including, but not limited to, for example, transcription, processing of the transcript, translation, and protein folding, modification, and processing, where applicable. Expression can refer to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from one or more nucleic acid fragments of the invention, and / or the translation of mRNA into a polypeptide.

[0137] In some embodiments, the expression of the biomarkers, targets, or genes / polypeptides described herein is tissue-specific. In some embodiments, the expression of the biomarkers, targets, or genes / polypeptides described herein is global. In some embodiments, the expression of the biomarkers, targets, or genes / polypeptides described herein is systemic.

[0138] "Expression products" include RNA transcribed from a gene and polypeptides obtained by translation of mRNA transcribed from a gene. The term "gene" refers to a nucleic acid sequence (DNA) that is transcribed into RNA in vitro or in vivo when operably linked to appropriate regulatory sequences. A gene may or may not include regions preceding and following the coding region, such as 5' untranslated (5'UTR) or "leader" sequences, and 3'UTR or "trailer" sequences, as well as intervening sequences (introns) between individual coding segments (exons).

[0139] "Operably linked" refers to an arrangement of elements in which the components so described are configured to perform their normal functions. Thus, control elements operably linked to a coding sequence can effect expression of the coding sequence. Control elements need not be contiguous with the coding sequence, so long as they function to direct its expression. Thus, for example, intervening, yet untranslated, transcribed sequences can be present between the promoter sequence and the coding sequence, and the promoter sequence would still be considered "operably linked" to the coding sequence. Moreover, they need not be physically linked.

[0140] A "marker" in the context of the present invention refers to an expression product, e.g., a nucleic acid or polypeptide, that is differentially present in a sample obtained from a subject with diabetes or cancer compared to a comparable sample obtained from a control subject (e.g., a healthy subject). The term "biomarker" is used interchangeably with the term "marker."

[0141] In some embodiments, the methods described herein relate to measuring, detecting, or determining the level of at least one marker. As used herein, the term "detecting" or "measuring" refers to observing a signal from a probe, a label, or a target molecule, for example, that indicates the presence of an analyte in a sample. Any method known in the art for detecting a particular label moiety can be used for detection. Exemplary detection methods include, but are not limited to, spectroscopic, fluorescent, photochemical, biochemical, immunochemical, electrical, optical, or chemical methods. In some embodiments of any of the aspects, measuring can be a quantitative observation.

[0142] In some embodiments of any of the aspects, the polypeptide, nucleic acid, or cell described herein can be engineered. As used herein, "engineered" refers to an aspect that has been manipulated by the hand of man. For example, a polypeptide is considered to be "engineered" if at least one aspect of the polypeptide, e.g., its sequence, has been manipulated by the hand of man so that it differs from the naturally occurring aspect. As is common practice and understood by those skilled in the art, the descendants of engineered cells are typically still referred to as "engineered", even if actual manipulation has been performed on the previous entity.

[0143] The term "exogenous" refers to a substance present in a cell other than its native origin. The term "exogenous" as used herein may refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or polypeptide that has been introduced into a biological system by a process involving the hand of man, e.g., a cell or organism in which it is not normally found, and one wishes to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, "exogenous" may refer to a nucleic acid or polypeptide that has been introduced into a biological system by a process involving the hand of man, e.g., a cell or organism in which it is found in relatively low amounts, and one wishes to increase the amount of the nucleic acid or polypeptide in the cell or organism, e.g., to create ectopic expression or levels. In contrast, the term "endogenous" refers to a substance that is native to a biological system or cell. As used herein, "ectopic" refers to a substance that is found in an unusual place and / or amount. An ectopic substance may be one that is normally found in a given cell, but in very low amounts and / or at a different time. Ectopic also includes a substance, e.g., a polypeptide or nucleic acid, that is not naturally found or expressed in a given cell in its natural environment.

[0144] In some of the aspects described herein, the nucleic acid sequence encoding a given polypeptide described herein, or any module thereof, is operably linked to a vector. The term "vector" as used herein refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral. The term "vector" encompasses any genetic element that can replicate and transfer gene sequences to cells when associated with appropriate control elements. Vectors can include, but are not limited to, cloning vectors, expression vectors, plasmids, phages, transposons, cosmids, chromosomes, viruses, and virions.

[0145] In some embodiments of any of the aspects, the vector is recombinant, e.g., it comprises sequences originating from at least two different sources. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different species. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different genes, e.g., it comprises a fusion protein or a nucleic acid encoding an expression product operably linked to at least one non-native (e.g., heterologous) genetic control element (e.g., promoter, repressor, activator, enhancer, response element, etc.).

[0146] As used herein, the term "expression vector" refers to a vector that directs the expression of RNA or polypeptide from a sequence linked to a transcriptional regulatory sequence on the vector. The sequence to be expressed is often, but not necessarily, heterologous to the cell. An expression vector may contain additional elements, for example, an expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example, in human cells for expression, and in prokaryotic hosts for cloning and amplification.

[0147] As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin and has the ability to be packaged into a viral vector particle. A viral vector can contain a nucleic acid encoding a polypeptide as described herein in place of a non-essential viral gene. The vector and / or particle can be utilized for the purpose of transferring any nucleic acid into cells, either in vitro or in vivo. Many forms of viral vectors are known in the art.

[0148] It should be understood that in some embodiments, the vector described herein can be combined with other suitable compositions and treatments.In some embodiments, the vector is episome.The use of suitable episome vector provides a means to maintain the target nucleotide in the subject with high copy number of external chromosomal DNA, thereby eliminating the potential effect of chromosomal integration.

[0149] In some embodiments of any of the aspects, preventive methods of treatment are described herein. As used herein, "prophylactic" refers to the timing and intent of treatment for a disease or condition, i.e., treatment is administered before the clinical detection or diagnosis of a particular disease or condition to protect the patient from the disease or condition. Prophylactic treatment may include reducing the severity or speed of the onset of a disease or condition, or may contribute to faster recovery from a disease or condition. Thus, the methods described herein may be preventive against metastasis or tumor formation. In some embodiments of any of the aspects, prophylactic treatment is not the prevention of all symptoms or signs of a disease.

[0150] As used herein, "combination" refers to a group of two or more substances for use together, for example, for administration to the same subject. The two or more substances can be present in the same formulation, for example, in admixture, solution, mixture, suspension, colloid, emulsion, in any molecular or physical arrangement. The formulation can be a homogeneous or heterogeneous mixture. In some embodiments of any of the aspects, the active compounds of the two or more substances can be contained in the same or different superstructures, for example, nanoparticles, liposomes, vectors, cells, scaffolds, etc., where the superstructure is a solution, mixture, admixture, suspension with a solvent, carrier, or part of the two or more substances. Alternatively, the two or more substances can be present in two or more separate formulations, for example, in a kit or package containing multiple formulations in separate containers, to be administered to the same subject.

[0151] A kit is a collection of materials or components, including at least one reagent as described herein. The exact nature of the components that are configured in the kit depends on its intended purpose. In some embodiments of any of the aspects, the kit includes instructions for use. "Instructions for use" typically include visual expressions that describe the techniques used to use the components of the kit, for example, for treating or administering to a subject. In further accordance with the present invention, "instructions for use" may include visual expressions that typically describe the preparation of at least one reagent as described herein for the intended purpose, such as dilution, mixing, or incubation instructions. Optionally, the kit also contains other useful components, such as measuring tools, diluents, buffers, syringes, pharma- ceutically acceptable carriers, or other useful tools that are readily recognized by those skilled in the art.

[0152] The materials or components assembled into the kit may be provided for storage by the practitioner in any convenient and suitable manner that preserves their operability and usefulness. For example, the components may be in dissolved, dehydrated, or lyophilized form, and they may be provided at room, refrigerated, or frozen temperatures. The components are typically contained in suitable packaging materials. As used herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as the inventive composition. The packaging material is preferably constructed by well-known methods to provide a sterile, contaminant-free environment. The packaging may also preferably provide an environment that protects from light, moisture, and oxygen. As used herein, the term "package" refers to a suitable solid matrix or material capable of holding individual kit components, such as glass, plastic, paper, foil, polyester (such as polyethylene terephthalate, or Mylar), and the like. So, for example, the package may be a glass vial used to contain a suitable amount of a composition that contains a volume of at least one reagent described herein. The packaging material generally has an exterior label that indicates the contents and / or purpose of the kit and / or its components.

[0153] As used herein, the term "nanoparticle" refers to a particle that is on the order of about 1 to 1,000 nanometers in diameter or width. The term "nanoparticle" includes nanospheres, nanorods, nanoshells, and nanoprisms, which may be part of a nanonetwork. The term "nanoparticle" also encompasses liposomes and lipid particles that have the size of a nanoparticle. Exemplary nanoparticles include lipid nanoparticles or ferritin nanoparticles. Lipid nanoparticles may include multiple components, including, for example, ionizable lipids (such as MC3, DLin-MC3-DMA, ALC-0315, or SM-102), pegylated lipids (such as PEG2000-C-DMG, PEG2000-DMG, ALC-0159), phospholipids (such as DSPC), and cholesterol.

[0154] Exemplary liposomes can contain, for example, DSPC, DPPC, DSPG, cholesterol, hydrogenated soy phosphatidylcholine, soybean phosphatidylcholine, methoxypolyethylene glycol (mPEG-DSPE) phosphatidylcholine (PC), phosphatidylglycerol (PG), distearoylphosphatidylcholine, and combinations thereof.

[0155] As used herein, the term "administering" refers to the placement of a compound disclosed herein into a subject by a method or route that results in at least partial delivery of the agent at a desired site. A pharmaceutical composition comprising a compound disclosed herein can be administered by any suitable route that results in an effective treatment in a subject. In some embodiments, administration includes physical human activity, such as injection, an act of ingestion, an act of application, and / or the operation of a delivery device or machine. Such activity can be performed, for example, by a medical professional and / or by the subject being treated.

[0156] As used herein, "contacting" refers to any suitable means for delivering or exposing an agent to at least one cell.Exemplary delivery methods include, but are not limited to, direct delivery into cell culture medium, perfusion, injection, or other delivery methods known to those skilled in the art.In some embodiments, contacting includes physical human activities, such as the act of injecting, dispensing, mixing, and / or decanting, and / or the operation of a delivery device or machine.

[0157] The terms "statistically significant" or "significantly" refer to statistical significance, generally meaning a difference of 2 standard deviations (2 SD) or greater.

[0158] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as being modified in all instances by the term "about." The term "about," when used in conjunction with percentages, can mean ±1%.

[0159] As used herein, the term "comprising" means that other elements may be present in addition to the defined elements presented. The use of "comprising" indicates inclusiveness rather than limitation.

[0160] The term "consisting of" refers to compositions, methods, and individual components thereof described herein, excluding any element not recited in that description of an embodiment.

[0161] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristics of that embodiment of the invention.

[0162] As used herein, the term "specific binding" refers to a chemical interaction between two molecules, compounds, cells and / or particles, in which a first entity binds to a second target entity with higher specificity and affinity than it binds to a third, non-target entity. In some embodiments, specific binding may refer to an affinity of a first entity for a second target entity that is at least 10 times, at least 50 times, at least 100 times, at least 500 times, at least 1000 times, or more, higher than its affinity for a third, non-target entity. A reagent specific for a given target is one that exhibits specific binding to that target under the conditions of the assay employed.

[0163] Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings commonly understood by those skilled in the art to which this disclosure belongs. It should be understood that the present invention is not limited to the specific methodology, protocols, and reagents, etc. described herein, which as such may vary. The terminology used herein is solely for the purpose of describing specific embodiments, and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-0911910421); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), WWNorton & Company, 2016 (ISBN 0815345054, 978-0815345053); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated herein by reference in their entirety.

[0164] Those skilled in the art can readily identify chemotherapeutic agents to use (see, e.g., Physicians' Cancer Chemotherapy Drug Manual 2014, Edward Chu, Vincent T. DeVita Jr., Jones & Bartlett Learning; Principles of Cancer Therapy, Chapter 85 in Harrison's Principles of Internal Medicine, 18th edition; Therapeutic Targeting of Cancer Cells: Era of Molecularly Targeted Agents and Cancer Pharmacology, Chs. 28-29 in Abeloff's Clinical Oncology, 2013 Elsevier; and Fischer DS (ed): The Cancer Chemotherapy Handbook, 4th ed. St. Louis, Mosby-Year Book, 2003).

[0165] mCherry is a basic (constitutively fluorescent) red fluorescent protein from Discosoma sp., published in 2004. It is reported to be a monomer with low acid sensitivity and very rapid maturation, resulting in virally expressed mCherry pseudocolored magenta. SmV5 stands for spaghetti monster V5. smFLAG refers to Spaghetti Monster FLAG: 10 copies of the epitope tag FLAG-(DYKDDDDK). tTA2 is a tetracycline-dependent transcriptional activator.

[0166] W3SL is a truncated woodchuck hepatitis posttranscriptional regulatory element and polyadenylation signal cassette (Choi et al., 2014). Choi JH, Yu NK, Baek GC, Bakes J, Seo D, Nam HJ, Baek SH, Lim CS, Lee YS, Kaang BK (2014).

[0167] eYFP is an enhanced yellow fluorescent protein.

[0168] The PT enhancer is the mscRE4 enhancer, which labels L5 pyramidal tract (PT) neurons, a subset of CFPNs.

[0169] Calcium-saturated GCaMP6s are 27% brighter than their parent fluorescent protein, enhanced fluorescent protein (EGFP).

[0170] PlxnD1 (intracerebellar-IT PNs in L2 / 3 and L5a), Satb2 (IT PNs across both upper and lower layers), Rorb (L4 pyramidal neurons), and vGAT (pan-GABAergic neurons).

[0171] Fezf2 is a FEZ family zinc finger 2 gene. Diseases associated with FEZF2 include partial fetal alcohol syndrome and thymic dysplasia.

[0172] Ctip2 tip2 / Bcl11b is a zinc finger transcription factor with dual actions (repression / activation) that combines epigenetic regulation with gene transcription during development of various tissues. The transcription factor COUP TF1 interacting protein 2 (CTIP2) plays a key role during axonal outgrowth and pathfinding by subcortical projection neurons of the cerebral cortex (Arlotta et al., 2005). Here, we report that within the striatum, Ctip2 is uniquely expressed by MSNs, specifically marking this important neuronal population from early postmitotic stages. Loss of Ctip2 function results in failure of MSN differentiation, disruption of patch-matrix organization of MSNs, and differential changes in the expression of multiple genes, including novel molecular identifiers of the patch compartment. Defects in patch cohesion also result in abnormal dopaminergic innervation of the striatum. Finally, there is altered expression of molecules involved in cell repulsion and the appearance of ectopy in the mutant striatum, strongly suggesting that loss of Ctip2 disrupts normal mechanisms of cell repulsion during development. Journal of Neuroscience 16 January 2008, 28 (3) 622-632; DOI: doi.org / 10.1523 / JNEUROSCI.2986-07.2008.

[0173] Cortico-descending projection neurons (CFPNs) constitute the cortical output channels, including PlxnD1 (intracene-IT PNs in L2 / 3 and L5a), Satb2 (IT PNs spanning both upper and lower layers), Rorb (L4 pyramidal neurons), and vGAT (pan-GABAergic neurons). hSyn refers to the human synapsin 1 gene promoter, which is art recognized to confer highly neuron-specific, long-term transgene expression from adenoviral vectors in the adult rat brain.

[0174] TRE-3G refers to a eukaryotic inducible promoter, where the TRE is composed of a Tet operator (tetO) sequence concatemer fused to a minimal promoter (usually a minimal promoter sequence derived from the human cytomegalovirus (hCMV) immediate early promoter). In the absence of Tc or Dox, tTA binds to the TRE and activates the transcription of the target gene.

[0175] mNeonGreen is a basic (constitutively fluorescent) green / yellow fluorescent protein derived from Branchiostoma lanceolatum and published in 2013.

[0176] The WPRE is a Woodchuck Hepatitis Virus post-transcriptional regulatory element (WPRE) that increases transgene expression from various viral vectors, although the exact mechanism is unknown. The WPRE is most effective when placed downstream of the transgene, proximal to the polyadenylation signal.

[0177] The dTomato gene is a gene encoding dTomato, which is a basic (constitutively fluorescent) orange fluorescent protein derived from Discosoma sp.

[0178] tdTomato is a genetic fusion of two copies of the dTomato gene; tdTomato is an exceptionally bright red fluorescent protein.

[0179] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0180] Detailed Description The present disclosure is based, in part, on the discovery of dual-function RNA molecules (readrRNAs) that enable (i) targeting of selected somatic cells based on their transcriptional profile, and (ii) translation in the selected cells of a desired effector protein encoded by the RNA molecule, the translation of the effector protein being carried out by RNA editing mediated by adenosine deaminases acting on RNA (ADARs).

[0181] ADAR-mediated RNA editing RNA editing is a widespread post-transcriptional process that alters the sequence of RNA encoded by DNA templates that are ubiquitous in all metazoan cells. Across the animal kingdom, the most widespread form of RNA editing is the conversion of adenosine to inosine (A to I) catalyzed by enzymes of the ADAR (adenosine deaminase acting on RNA) family, which has three members in mammals (ADAR1, ADAR2, ADAR3). The edited inosine then base pairs with cysteine ​​instead and is recognized as guanosine (G) by various cellular mechanisms. ADAR-mediated AI editing is ubiquitous in all metazoan cells. See Figure 3.

[0182] There are millions of ADAR editing sites in the transcriptome of humans and animals, and only a small percentage of these edits occur in coding mRNAs, altering the properties of proteins. The majority are in non-coding regions, where they can affect RNA splicing, microRNA, and shRNA function. Their most essential role is to self-produce dsRNA, protecting cells from the innate immune response while allowing the immune system to destroy viral dsRNA during infection.

[0183] Read rRNA "readrRNA" refers to an RNA-based molecule having a 5' region and a 3' region, the readrRNA molecule comprising, consisting of, or consisting essentially of (i) a 5' region comprising a sensor (ses) domain, the sensor domain comprising at least one ADAR-editable STOP codon, and (ii) an effector RNA (efRNA) region downstream of and in frame with the sensor domain. The dual-function readrRNA of the applicant's invention allows the recruitment of ADAR deaminase to edit a specific site in the readrRNA by the formation of a dsRNA with a mismatch with a target RNA expressed in the selected somatic cell. Upon ADAR-mediated removal of the stop codon from the readrRNA molecule, translation of a downstream operably linked effector protein encoded by the readrRNA occurs in the selected somatic cell. Figure 4. In the absence of the target RNA in the selected somatic cell, the readrRNA remains inactive in the cell.

[0184] Because readrRNA detects or "senses" target RNA in selected somatic cells, readrRNA is an integral component of the system contained in CellREADR (Cell Access through RNA Sensing by Endogenous ADARs), a programmable RNA sensing technology that leverages RNA editing mediated by ADARs (adenosine deaminases acting on RNA) to couple detection of cell-type-defining RNA with translation of effector proteins in somatic cells.

[0185] RNA that defines cell types RNA is a central and universal mediator of genetic information that underlies the diversity of cell types and cell states, which together shape tissue organization and organismal function across species and life spans. Despite advances in RNA sequencing and the large accumulation of transcriptomic datasets across the life sciences, the paucity of technologies that leverage RNA to observe and manipulate cell types remains a prohibitive bottleneck in biology and medicine. (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0186] Cell types are products of evolution; they are the fundamental functional units of organisms. The entire repertoire of cell types in the brain and body is constructed through a sequential and parallel series of spatially and temporally coordinated developmental events starting from a single fertilized egg zygote. This developmental program executes a remarkable plan of action that unravels the identity of all cell types encoded in the genome throughout evolution. Transcriptional and epigenetic regulatory programs unfold from the genomic sequence and drive a cascading series of cell proliferation and differentiation processes, resulting in the manifestation of diverse cell phenotypes. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0187] RNA expression profiles arguably underlie all phenotypic characteristics of a cell at the time or state when the cell is characterized and are a one-time snapshot of the cell. A key point of distinction is whether the RNAs expressed in a selected cell represent a particular cellular state - a transient or dynamically responsive property of a cell against a background - or cell type, as cell types may exist in different states. Cell type-specific changes in RNA expression associated with different cellular states can be seen during circadian cycles, fluctuating metabolic states, development, aging, or behavioral, pharmacological, or pathological conditions (Mayr et al., 2019; Morris, 2019). (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0188] A single-cell transcriptome is a one-time snapshot of a single cell. However, transcriptomes collected at different time points or from different behavioral, physiological, or pathological states can be compared. The distinction between cell type and cell state is a challenge, especially during development, as cells continuously change their states and, at certain critical times, they may switch their cell type identity. However, it is reasonable to assume, although not absolute, that transcriptome changes tend to be more continuous during cell state transitions but more abrupt or discrete when cells switch their types. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0189] For a meaningful cell type definition, this would ideally relate to what the cell type does. So, in addition to defining a cell type based on the RNA that defines it, a cell type is defined by relating its RNA expression to anatomical and functional information. So far, it has been shown that transcriptome types have an excellent correspondence with their spatial distribution patterns. Since spatial distribution patterns are defined during development, this suggests that the transcriptome may hold a developmental plan. (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0190] Systematic single-cell transcriptomic, epigenomic and spatially resolved transcriptomic profiling with high temporal resolution, combined with lineage tracing and other phenotypic characterization, holds tremendous potential to capture key sets of genes and genomic regulatory networks involved in these sequences of events and begin to resolve the extremely complex spatial and temporal transitions of cell types and states that result in the adult stage repertoire of cell types (Allaway et al., 2021;Bandler et al., 2022;Bhaduri et al., 2021;Cao et al., 2019b;Chen et al., 2022;Delgado et al., 2022;Di Bella et al., 2021;Klingler et al., 2021;La Manno et al., 2021;Romanov et al., 2020;Schmitz et al., 2022;Sharma et al., 2020;Shekhar et al., 2022;Tiklova et al., 2019;Zhu et al., 2018). (Zeng et al. https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0191] Stepwise organization of transcriptomically defined cell types As used herein, the term "brain cell" refers to any cell type found in the mammalian brain.

[0192] Within each of these major brain structures, there are multiple regions and subregions, each with many cell types. The basic structure of the mammalian brain (Swanson, 2000, 2012) consists of the telencephalon, diencephalon, mesencephalon (midbrain), and rhombencephalon (hindbrain). (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0193] The telencephalon (consisting of five major brain structures: (1) the cortex, (2) the hippocampal formation [HPF], (3) the olfactory cortex, (4) the cortical subplate, and (5) the cerebral nuclei). The telencephalon and diencephalon (including the thalamus and hypothalamus) are collectively called the forebrain. The mesencephalon (midbrain) is divided into the tectum and tegmentum. The hindbrain (hindbrain) is divided into the pons, medulla, and cerebellum. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0194] In the cortex, the first (highest) level of branching is the separation of neurons and various non-neuronal cell classes (Figure 2A). For neurons, the second level of branching is determined by major brain structures / regions, and the third level involves various cell subclasses and cell types within each major brain structure, although there may be cell types that cross or are shared between brain structures due to cell trafficking during development. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0195] The cortex is composed of multiple cortical areas (including visual and motor areas), each mediating a sensory, motor, or associative function. In each of these areas, there are two classes of neurons based on the predominant neurotransmitters they release: glutamatergic and GABAergic, as well as several non-neuronal classes. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0196] Glutamatergic excitatory neurons, for the most part, have long-range axonal projections to other cortical and / or subcortical regions. They are divided into nine subclasses based on their layer specificity and long-range projection patterns: L2 / 3 intratelencephalic projections [IT], L4 / 5 IT, L5 IT, L6 IT, Car3 IT, L5 extratelencephalic projections [ET], L5 / 6 proximal projections [NP], L6 corticothalamic projections [CT], and L6b. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0197] GABAergic inhibitory neurons have their axonal projections mostly restricted within local regions. They are divided into six subclasses named after standard marker genes: Lamp5, Sncg, Vip, Sst, Sst-Chodl, and Pvalb. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0198] Within each glutamatergic or GABAergic subclass, as well as each non-neuronal cell class, there are several transcriptomic clusters or types, resulting in a total of 110 transcriptomic cell types in each cortical region (Brain Initiative Cell Census Network, 2021; Tasic et al., 2018). This organization is highly consistent with existing knowledge of cortical cell types, which have been extensively studied in a variety of phenotypic modalities over the past 50 years (Harris and Shepherd, 2015;Tremblay et al., 2016;Yuste et al., 2020;Zeng and Sanes, 2017), suggesting that single-cell transcriptomics alone can neatly capture the entirety of cell type organization at the class and subclass level (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031).

[0199] However, within the cortex, both cell types that are specific to cortical regions or shared between regions have been identified. Shared cell types often show gradient distribution or gradient gene expression across regions where discrete and continuous variation between cell types coexists. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0200] Distinct variations exist within cell subclasses and major cell types, usually at higher branches of the hierarchy. Continuous variations are usually found within closely related transcriptomic clusters or subtypes at lower branches, e.g., many IT neuron types spanning the cortical depths of L2 / 3–L6 (Figure 2C). Cells at opposite ends of the continuum have clearly distinct transcriptomic profiles, but the transition from one end to the other is gradual within the cells that make up the continuum. (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0201] Integration of transcriptomics and MERFISH, a spatially resolved transcriptomic method, reveals the spatial organization of mouse motor cortex cell types (Zhang et al., 2021a). A key finding of this study is that in addition to the expected laminar distribution of glutamatergic neuron subclasses, uniform GABAergic types within each subclass exhibit laminar selective localization, and the continuous variation within individual glutamatergic or GABAergic types correlates well with their continuous distribution along cortical layers / depths (in a notable example, all of the excitatory L2 / 3–L6 IT types line up along the L2 / 3–L6 cortical depths). (Zeng https: / / doi.org / 10.1016 / j.cell.2022.06.031)

[0202] However, it is often unclear whether cell types defined by different phenotypic features coincide with each other or which features are correct for defining a cell type.

[0203] By coupling the targeting of specific RNA transcripts with the expression of encoded effector molecules such as fluorescent proteins, the cell readrRNA system provides a system to simultaneously monitor cell types and their states on a transcript-based and spatial / morphological basis.

[0204] The invention described herein is based on Watson-Crick base pairing and RNA editing, and CellREADR 1) has unique and absolute specificity for cellular RNA and cells defined by RNA expression; 2) is easy to design, construct, use, and disseminate (e.g., DNA vectors); 3) is highly scalable for targeting of all RNA-defined cell types in any tissue; a library of "cellular medicine equipment;" 4) is generalizable to most animal species, including humans; 5) is comprehensive for most cell types and tissues; 6) is general across animal species; 7) is applicable to human biology and medicine; and 8) is programmable to achieve cross-targeting of two or more RNA-defined cells, as well as multiplexed targeting and manipulation of several cell types in the same tissue. CellREADR technology

[0205] The core of CellREADR technology is readrRNA, which is a switch operably linked to RNA sequence-specific molecular sensor-effector molecule. It is a single modular readrRNA that contains a 5'-prime sensing-editing-switch domain (sesRNA) and a 3'-prime effector domain (efRNA). The target specificity of sesRNA is due to its interaction with complementary sequence in target mRNA. The degree of complementarity determines whether ADAR-mediated editing of sesRNA exists. SesRNA that is completely complementary to target RNA induces ADAR-mediated editing of sesRNA at ADAR-editable stop codon.

[0206] The readrRNA can be made from a conventional DNA expression vector. These vectors consist of a promoter, DNA cassettes encoding sesRNA and efRNA, and a 3' untranslated region, which can be assembled by routine DNA synthesis and molecular cloning. In one embodiment, the sesRNA coding cassette can be about 200-300 base pairs, and the effector gene cassette can be about 1-2 kilobase pairs. These expression vectors can be easily packaged into a variety of viral particles. The readrRNA can also be made by direct single-stranded oligonucleotide synthesis, with incorporation of chemically modified nucleotides, if desired. Modular readrRNA

[0207] Thus, one aspect of the present disclosure provides a modular readrRNA molecule comprising, consisting of, or essentially consisting of (i) a 5' region that comprises a sensor domain, the sensor domain comprising at least one ADAR-editable STOP codon, and (ii) an effector RNA (efRNA) region downstream of and in frame with the sensor domain. The term "modular" when used in the context of the phrase "modular readrRNA molecule" refers to a recombinant readrRNA molecule that comprises a combination of a very small number of linked structural units, where each structural unit encodes a protein molecule that functions independently.

[0208] The modular design of readrRNA molecules, in which different protein-coding domains are designed at the RNA level and assembled into recombinant readrRNA molecules in a desired order with a specific number of repeat designs, allows the production of readrRNA molecules with diverse properties. The translation machinery also has high fidelity, so that the desired readrRNA molecules have a specific amino acid sequence.

[0209] Generally, readrRNA molecules are composed of modular domains that confer specific functions, including, but not limited to, facilitating cell-cell interactions, sensing environmental stimuli, and generating responses to environmental stimuli, including generating spatiotemporal input / output in biological systems. Sensor domains of modular readrRNAs

[0210] The sensor domain (sesRNA) comprises a set of nucleotides that are complementary to a particular cell type and capable of detecting the particular cell type through sequence-specific base pairing with RNA present in the particular cell type. The sensor domain may comprise any number of nucleotides. In some embodiments, the sensor domain comprises at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500, at least 550, at least 600, at least 650, at least 700, at least 750, at least 800, at least 850, at least 900, at least 950, at least 1000. In some embodiments, the sensor domain comprises a range of about 100 to about 900 nucleotides. In other embodiments, the sensor domain comprises a range of about 200 nucleotides to about 300 nucleotides. Preferably, the sensor domain (sesRNA) contains about 200 nucleotides that are complementary to, and therefore capable of detecting, a specific cell-type RNA through base pairing.

[0211] The sensor domain also contains one or more ADAR-editable STOP codons that act as a translation switch (referred to herein as a sensing-editing-switch RNA (sesRNA)). The sensor domain thus functions as a sensing-editing-switch RNA (sesRNA). The sensor RNA contains a nucleotide sequence that is complementary to a cellular RNA.

[0212] The modular readrRNA molecule may also contain a sequence encoding a self-cleaving 2A peptide. In such embodiments, the 2A peptide is located between the domains, preferably between the sensor domain and the effector RNA region and / or between additional domains / regions that may be present in the readrRNA molecule or the CellREADER system, as further discussed herein.

[0213] In-frame effector RNA (efRNA) coding region of modular readrRNA Downstream of the sensor domain is an in-frame effector RNA (efRNA) coding region, optionally separated by a sequence encoding a self-cleaving 2A peptide. The effector RNA (efRNA) may code for an effector protein of interest, for example, a label that allows visualization of the labeled cell. The effector RNA (efRNA) may code for an effector protein that alters the physiology of the cell. For example, in the case of treating a disease caused by a mutation in a single gene, the encoded effector protein may be a corrected copy of the mutated gene. In the case of treating a disease by providing a certain protein that is endogenous or exogenous to the organism, the protein may be encoded in the effector region.

[0214] The choice of a given efRNA depends on the desired use of the readrRNA of the readrRNA molecule (e.g., disease treatment, protein / pathway research, etc.), and can be easily determined by those skilled in the art. For example, the effector module (efRNA) of CellREADR can be constructed to manipulate cells in multiple ways, including enhancing activity and function, suppressing activity and function, rescuing the function of mutant cells by reintroducing an intact version of a deleted or mutated protein, altering and editing activity and function, reprogramming cell identity, fate and function, killing and eliminating cell types, increasing or decreasing the production of a certain type of cell number, and cell type-specific genome editing and gene regulation.

[0215] In cells expressing the target RNA, the sesRNA forms a dsRNA that recruits endogenous ADAR enzymes. An A to I edit at the STOP codon converts the STOP to a TI(G)G tryptophan codon, switching on the translation of the efRNA and the production of the effector protein. The resulting fusion protein, containing the N-terminal peptide T2A and the C-terminal effector, is then self-cleaved by T2A, releasing the functional effector protein. In cells that do not express the target RNA, the readrRNA remains inactive.

[0216] The efRNA-encoded protein may include any protein that is involved in or can affect cell replication, gene expression, and / or transcription / translation. Suitable examples include, but are not limited to, transcription activators, transcription inhibitors, and DNA recombinases.

[0217] Effector proteins include, but are not limited to, A) enzymes, e.g., proteases, phosphatases, glycosylases, acetylases, or lipases; b) proteins that mimic the function of host cell proteins; c) transcription factors; d) protein partners that facilitate protein-protein interactions; d) proteins that modify the structure and function of host cells (virulence factors or toxins), e.g., by facilitating infection and / or triggering a defense response and / or promoting morphogenesis (Cachat, E., Liu, W., Hohenstein, P. et al. A library of mammalian effector modules for synthetic morphology. J Biol Eng 8, 26 (2014). https: / / doi.org / 10.1186 / 1754-1611-8-26).

[0218] For example, exemplary effector proteins are listed in Table 4 below. [Table 4]

[0219] Thus, effector functions can affect the activities of innate immune cell responses, including phagocytosis, secretion of cytokines, trafficking of immune cells, or promoting function, migration, survival and proliferation.

[0220] Thus, the encoded effector molecule can be a transactivator or transrepressor, which stimulates or represses, respectively, expression of the gene of interest by binding to the promoter / enhancement region of the gene of interest, either an endogenous gene or an exogenous gene administered as part of the system behind the cell.

[0221] Transcriptional activators are proteins or small molecules that bind to one or more specific regulatory sequences in DNA (or, in the case of retroviruses, RNA) and stimulate transcription of one or more nearby genes. Most activators enhance the binding of RNA polymerase (formation of the closed complex) or its transition to the open complex required for the initiation of transcription. Most activators interact directly with subunits of RNA polymerase.

[0222] Transcriptional repressors are sequence-specific DNA-binding proteins that are generally thought to function by recruiting coregulator complexes that contain multiple proteins, including histone-modifying enzymes.

[0223] As used herein, "modulated" means regulated, in the sense of activated or inhibited.

[0224] As used herein, pathogens include organisms that cause disease in humans, including, but not limited to, bacteria, viruses, parasites, insects, algae, prions, and fungi.

[0225] Reporter genes in CellREADR system 2 Another aspect of the present disclosure provides a CellREADR system, which includes at least two components, the first component includes a modular readrRNA molecule as described herein, and optionally an additional component including a response gene operably linked (in this embodiment, not physically linked) to the efRNA-encoded protein (e.g., transcriptional regulators, e.g., AP1 and SP1) of the readrRNA molecule. This allows the readrRNA molecule to activate, increase, decrease, or suppress the transcription of another protein encoded in a physically separate, externally added nucleic acid molecule, e.g., a caspase molecule that leads to cell death. ADAR-mediated programmability and cross-targeting

[0226] The sensor and effector modules are combinatorial and easily programmable, which allows for the manipulation of each cell type in multiple ways, each in a specific and coordinated manner, and the manipulation of multiple cell types in a tissue simultaneously. As provided above, in some embodiments, the modular readrRNA molecule comprises, consists of, or essentially consists of a 5' sensor-editing-switch region (sesRNA) and a 3' effector coding region (efRNA), separated by an optional linkage of a sequence encoding the self-cleaving peptide 2A. In some embodiments, the sesRNA contains about 200 to about 300 nucleotides that are complementary to, and therefore capable of detecting, a specific cell type RNA through base pairing, but also contains one or more ADAR editable STOP codons that act as a translational switch and downstream are in-frame effector coding regions that generate various effector proteins of interest.

[0227] In cells expressing the target RNA, sesRNA forms dsRNA with the target RNA that recruits endogenous ADAR enzymes. Editing A to I at the STOP codon converts STOP to a TI(G)G tryptophan codon, switching on the translation of efRNA and the production of effector protein. The resulting fusion protein, which contains the N-terminal peptide 2A and the C-terminal effector, is then self-cleaved by 2A, releasing the functional effector protein. Importantly, in cells that do not express the target RNA, the readrRNA remains inactive. Therefore, the modular readrRNA molecule can be deployed as a single RNA molecule in this way, and can be easily adapted to viral vectors (e.g., AAV vectors) since ADAR is endogenous to the cell.

[0228] In some situations, ADAR proteins are not highly expressed in cells, or in some cases, are not present.In such cases, the present disclosure provides the addition of ADAR proteins (e.g., ADAR2) that are included in modular readrRNA molecules and / or added to the system via separate vectors.The most fundamental feature of CellREADR is that it is an RNA sequence that operates based on Watson-Crick base pairing, which confers a number of highly desirable properties, including, but not limited to, (i) unique and absolute specificity to cellular RNA, (ii) ease of design, construction, use and sharing (DNA vector), (iii) highly scalable library of "cell medicine equipment", (iii) comprehensive for most cell types and tissues, (iv) general across animal species, and (v) human biology and medicine.Therefore, a comprehensive combinatorial CellREADR sensor-effector library can be constructed to identify, characterize and manipulate cell types across organ systems and animal species.

[0229] The programmability of the modular readrRNA molecules provided herein provides additional capabilities.Accordingly, another embodiment of the present disclosure provides cross-targeting using programmable modular readrRNA molecules and / or modular readrRNA molecules provided herein.

[0230] First, two or more RNA sensors can be designed to detect two or more separate cellular RNAs to achieve cross-targeting of two or more specific cell types. Second, the same RNA sensor can be linked to different effectors to label, record, and manipulate the same cell type. Third, a cohort of multiple RNA sensors can be designed to target several cell types in the same tissue, each expressing a different effector, to coordinately modulate tissue function. Fourth, RNA sensors can be designed to detect different threshold levels of target RNA to monitor and manipulate different cellular states defined by RNA levels.

[0231] In one embodiment, the present disclosure provides two sensors that are designed to detect two separate cellular RNAs to achieve cross-targeting of more specific cell types.In one aspect, each sensor module can have a STOP codon and be an effector molecule that is expressed only when both are removed.In one embodiment, each sensor contains at least one STOP codon.In another embodiment, the same sensor can be used to express different effectors to label, record, and manipulate the same cell type.In yet another embodiment, multiple sensors are designed to target several cell types in the same tissue, each expressing different effectors, thereby coordinating modules of tissue function.

[0232] Therefore, the RNA sensing domain has the ability to detect any cellular RNA, and therefore has the ability to access any RNA-defined cell type and cell state in any human tissue.The effector domain has the ability to code for any protein, and therefore has the ability to monitor, manipulate and edit many cellular properties. Generality of targeting cell types and cell states

[0233] RNA sensor domains can detect RNA markers that define cell types and cell states. Recent advances in single-cell RNA sequencing are generating large-scale data sets in all human and animal tissues. 1、2、3 Several major efforts are driving progress, including the Human Cell Atlas project (on the World Wide Web at humancellatlas.org), the NIH Human Biomolecular atlas program at (commonfund.nih.gov / hubmap), the BRAIN Initiative Cell Census Network (biccn.org / ), and the Allen Brain Cell Atlas (portal.brain-map.org / ).

[0234] All single-cell transcriptome data sets are publicly accessible. RNA markers have been identified for most, if not all, of the major human cell types. 1、2、3 Furthermore, RNA markers have been identified for many diseased cell states. 4 All these RNA markers can be used by CellREADR to target cell types and cell states. Some of these markers are listed in Table 5. Table 5 [Table 5]

[0235] References [ka] [ka]

[0236] delivery Since ADARs are endogenous to cells, CellREADR can be deployed as a single RNA molecule. It is also <4.7Kb and can be easily adapted to AAV viral vectors. In fact, the entire readrRNA is several kilobases, depending on which specific sensors and effectors are incorporated into the molecule, and therefore can be delivered to cells through a delivery system. In cells expressing the target RNA, sesRNA forms dsRNA with the target, which recruits ADAR to assemble an editing complex. At the editable STOP codon, ADAR converts A to I, which pairs with the opposite C in the target RNA. This A→G substitution converts the TAG STOP codon to a TI(G)G tryptophan codon, switching on the translation of efRNA. In-frame translation generates a fusion protein containing the N-terminal peptide 2A (if used) and the C-terminal effector, which is then self-cleaved by 2A to release the functional effector protein (see, for example, Figure 1a). The readrRNA remains inactive in cells that do not express the target RNA.

[0237] According to the present disclosure and knowledge in the art, the modular readrRNA molecule or any of its components, its nucleic acid molecule, and / or its component coding or providing nucleic acid molecule, as well as any of the CellREADR systems provided herein, can be delivered by various delivery systems. Examples of such delivery systems include, but are not limited to, DNA or RNA transfection methods: chemical reagents (such as PEI, lipofectamine, calcium phosphate, etc.) or electroporation, and DNA expression vectors can be packaged in liposome nanoparticles. The readrRNA can be transcribed or synthesized in vitro and packaged into liposomal nanoparticles, nanoparticles, liposomes, recombinant viral vectors (viral vectors: adeno-associated virus (AAV), lentivirus, and vesicular stomatitis virus are preferred viral vehicles), electroporated exosomes, microvesicles, gene guns, selective endogenous encapsulation (SEND) systems for cellular delivery, mRNA delivery systems including humanized virus-like particles (VLPs) based on retroelements present in the human genome (Segel M, et al. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery. Science. 2021;373:882-889. doi: 10.1126 / science.abg6155), combinations thereof, and the like.

[0238] Any of the modular readrRNA molecules and / or RNA (e.g., sesRNA, efRNA, etc.) and / or any accessory proteins and / or CellREADR system can be delivered using a suitable vector, e.g., a plasmid or recombinant viral vector, e.g., adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus vector, vesicular stomatitis virus, and other viral vectors, or combinations thereof. Proteins, e.g., sesRNA, efRNA, efRNA-responsive genes, protein-coding or non-coding RNA (e.g., sgRHA, shRNA, etc.), CellREADR system, etc., can be packaged into one or more vectors, e.g., a plasmid or viral vector. For example, in some embodiments, a second expression vector comprising an efRNA-responsive gene operably linked to an efRNA-encoded protein is co-delivered with the readrRNA molecule and / or CellREADR system, where upon successful translation of the modular readrRNA molecule and effector RNA, successful binding and activation of the reporter product occurs. In some embodiments, the efRNA responsive gene comprises a reporter gene (e.g., reporter genes including, but not limited to, GFP, mRuby, mCherry, ChR2, DTA, Gcamp, TK, interferon, etc.). In other embodiments, the efRNA responsive gene comprises a second effector gene.

[0239] For bacterial application, where applicable, the nucleic acid encoding any of the components of the modular readrRNA molecular system described herein can be delivered to bacteria using phage.Exemplary phage include, but are not limited to, T4 phage, μ, λ phage, T5 phage, T7 phage, T3 phage, Φ29, M13, MS2, Qβ, and ΦX174.In such an embodiment, the addition of exogenous ADAR may be required.

[0240] In some embodiments, vectors, such as plasmids or recombinant viral vectors, are delivered to target tissues, for example, by intramuscular injection, intravenous administration, transdermal administration, intranasal administration, oral administration, or mucosal administration. Such delivery can be via either single dose or multiple doses. Those skilled in the art will understand that the actual dosage delivered herein can vary widely depending on a variety of factors, such as the choice of vector, target cell, organism, tissue, the general condition of the subject being treated, the degree of transformation / modification desired, the route of administration, the mode of administration, the type of transformation / modification desired, etc.

[0241] In some embodiments, the recombinant viral vector comprises at least 1×10 5 In some embodiments, the dose is preferably at least about 1×10 6 Individual particles, at least about 1×10 7 Individual particles, at least about 1×10 8 individual particles, and at least about 1×10 9 It is an individual adenovirus particle.

[0242] In some embodiments, delivery is via recombinant adeno-associated virus (rAAV) vector.For example, in some embodiments, modified AAV vectors may be used for delivery.Modified AAV vectors may be based on one or more of several capsid types, including AAV1, AV2, AAV5, AAV6, AAV8, AAV 8.2, AAV9, AAV rhlO, modified AAV vectors (e.g., modified AAV2, modified AAV3, modified AAV6) and pseudotyped AAV (e.g., AAV2 / 8, AAV2 / 5 and AAV2 / 6), AAV-PHP.eB and any variants thereof, AAV-PHP.S and any variants thereof, AAV-PHP.V1 and any variants thereof, etc.Exemplary AAV vectors and techniques that can be used to generate rAAV particles are known in the art.

[0243] In some embodiments, delivery is via a plasmid. The dosage may be a sufficient number of plasmids to elicit a response. In some cases, a suitable amount of plasmid DNA in a plasmid composition may be about 0.1 to about 2 mg. A plasmid generally includes (i) a promoter, (ii) a sequence encoding a modular readrRNA molecule and / or CellREADR system provided herein, each operably linked to a promoter (e.g., the same promoter or a different promoter), (iii) a selectable marker, (iv) an origin of replication, and (v) a transcription terminator downstream of and operably linked to (ii). The plasmid may also encode other RNA components, although one or more of these may instead be encoded on a different vector. The frequency of administration is within the purview of a medical or veterinary practitioner (e.g., physician, veterinarian), or one of ordinary skill in the art.

[0244] In those cells / systems (e.g., bacterial cells and certain plant cells) in which ADAR proteins are not expressed or are expressed at low levels, the plasmids (either alone or expressing the modular readrRNA molecules and / or CellREADR systems provided herein) may further contain sequences encoding ADAR genes (e.g., Adar1, Adar2, etc.).

[0245] Exogenous ADARs or engineered ADARs (i.e., with improved functionality) may increase the efficiency of the CellREADR system. Exogenous ADARs can be delivered to animal (or plant) cells in the following manner. 1) ADAR1 or ADAR2 are delivered using separate constructs / DNA vectors (derived from the Readr construct) carrying the CMV, CAG promoter by transfection or viral infection (AAV, lentivirus, etc.). 2) ADAR1 or ADAR2 is placed in front of a SesRNA sequence in the same CellReadr construct / DNA vector and delivered to cells by transfection or viral infection. 3) ADAR1 or ADAR2 mRNA is delivered to cells by CellReadr DNA vectors or RNA-bearing LNPs. 4) ADAR1 or ADAR2 protein is delivered to cells by CellReadr DNA vector or RNA-carrying LNPs or VLPs (virus-like particles).

[0246] In another embodiment, delivery is via liposome or lipofection formulations, etc., and can be prepared by methods known to those skilled in the art. Such methods are described, for example, in WO2016205764, and U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, each of which is incorporated herein by reference in its entirety.

[0247] In some embodiments, delivery is via nanoparticles or exosomes. For example, exosomes have been shown to be particularly useful in delivering RNA.

[0248] Another means of introducing one or more components of the modular readrRNA molecule system provided herein into cells is by using cell-penetrating peptides (CPPs). In some embodiments, cell-penetrating peptides are linked to the modular readrRNA molecules. In some embodiments, the modular readrRNA molecules and / or any components thereof are combined with one or more CPPs to efficiently transport them inside cells (e.g., plant protoplasts). In some embodiments, the modular readrRNA molecules and / or any components thereof are encoded by one or more circular or non-circular DNA molecules combined with one or more CPPs for cellular delivery.

[0249] CPPs are short peptides of less than 35 amino acids derived from proteins or chimeric sequences that can transport biomolecules across cell membranes in a reporter-independent manner. CPPs can be cationic peptides, peptides with hydrophobic sequences, amphipathic peptides, peptides with proline-rich and antimicrobial sequences, and chimeric or bipartite peptides. Examples of CPPs include, for example, Tat (a nuclear transcription activator protein required for viral replication by HIV type 1), penetratin, Kaposi's fibroblast growth factor (FGF) signal peptide sequence, integrin 3 signal peptide sequence, polyarginine peptide Args sequence, guanine-rich molecular transporter, and sweet arrow peptide.

[0250] Yet another means of introducing one or more components of the modular readrRNA molecule system provided herein into cells is by using SEND (see, e.g., Segel, M. et al., 2021. Science 373:6557; 882-889, the contents of which are hereby incorporated by reference in their entirety). In such an embodiment, a retrovirus-like protein, e.g., PEG10, which directly binds and secretes its own mRNA in an extracellular virus-like capsid, is pseudotyped with a fusogen to deliver a functional mRNA cargo (i.e., a modular readrRNA molecule provided herein) to a mammalian cell.

[0251] Other embodiments of the present disclosure provide modifications of the modular readrRNA molecules provided herein. Such modifications can be for any purpose, such as increasing stability, the ability of the modular readrRNA molecule to evade the immunity of a subject, and the like. For example, in an example in which the modular readrRNA molecule comprises a circular RNA molecule, one such modification can include an N6-methyladenosine modification. For example, the inclusion of an N6-methyladenosine leader YTHDF2 sequence allows for the sequestration of N6-methyladenosine-circular RNA, thereby allowing for the suppression of innate immunity (see, for example, Chen, YGet al., (2019) Molecular Cell (76):1; 96-109, the contents of which are hereby incorporated by reference in their entirety). In other embodiments, such modifications may include replacement of uridine with pseudouridine, which aids in evading a subject's immune system (see, e.g., Dolgin, E. (2021) Nature 597; 318-324, the contents of which are hereby incorporated by reference in their entirety). Pharmaceutical Compositions

[0252] In another aspect, the present disclosure provides compositions comprising one or more of the modular readrRNA molecules described herein or delivery systems comprising the modular readrRNA molecules provided herein (used herein simply or together as "molecule"), and a suitable carrier, excipient or diluent. The exact nature of the carrier, excipient or diluent will depend on the desired use for the composition and may range from suitable or acceptable for veterinary use to suitable or acceptable for human use. The composition may optionally include one or more additional compounds and / or therapeutic agents.

[0253] Pharmaceutical compositions may be in a form suitable for virtually any mode of administration, including, for example, topical, ophthalmic, oral, buccal, systemic, nasal, injectable, transdermal, rectal, vaginal, etc., or in a form suitable for administration by inhalation or insufflation.

[0254] Alternatively, other pharmaceutical delivery systems may be used. Liposomes and emulsions are well-known examples of delivery vehicles that can be used to deliver molecules. Certain organic solvents such as dimethylsulfoxide (DMSO) may also be used, although usually at the expense of higher toxicity.

[0255] The pharmaceutical compositions may be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the molecules, if desired. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

[0256] The molecules described herein, or pharmaceutical compositions thereof, are generally used in an amount effective to achieve the intended result, for example, an amount effective to treat or prevent the particular disease being treated.Therapeutic benefit refers to eradication or amelioration of the underlying disorder being treated, and / or eradication or amelioration of one or more symptoms associated with the underlying disorder, such that the patient reports that he / she feels better or in a better state, even though he / she may still suffer from the underlying disorder.Therapeutic benefit also generally includes the halting or slowing of the progression of the disease, regardless of whether or not improvement is perceived.

[0257] The determination of the effective dosage of a molecule for a particular use and mode of administration is well within the capabilities of a person skilled in the art. The effective dosage can be initially estimated from in vitro activity and metabolism assays. For example, the initial dosage of a compound for use in animals can be formulated to achieve a circulating blood or serum concentration of a metabolite of the active compound (e.g., efRNA product) that is at or above the IC50 of the particular compound, as measured in an in vitro assay. It is well within the capabilities of a person skilled in the art to calculate the dosage to achieve such a circulating blood or serum concentration, taking into account the bioavailability of the particular compound via the desired route of administration. The initial dosage of a compound can also be estimated from in vivo data, such as animal models. Animal models useful for testing the effectiveness of active metabolites to treat or prevent various diseases described above are well known in the art. Animal models suitable for testing the bioavailability of a compound and / or its metabolism to active metabolites are also well known. A person skilled in the art can routinely adapt such information to determine the dosage of a particular compound suitable for human administration.

[0258] Dosage depends on, among other factors, the activity of the active compound, the bioavailability of the compound, its metabolic kinetics and other pharmacokinetic properties, the mode of administration, and various other factors discussed above. Dosage amount and interval can be adjusted individually to provide a plasma level of the compound and / or active metabolites that is sufficient to maintain therapeutic or prophylactic effect. For example, the compound may be administered once a week, several times a week (e.g., every other day), once a day, or multiple times a day, depending on, among other things, the mode of administration, the specific indication being treated, and the judgment of the prescribing physician. In cases of local administration or selective uptake, e.g., topical administration, the effective local concentration of the compound and / or active metabolites may not be related to the plasma concentration. Those skilled in the art can optimize the effective dosage without undue experimentation. cell manipulation

[0259] To monitor and / or change the physiology of a cell or group of cells of interest, the cell of interest is identified based on the differential expression of one or more RNA transcripts of the cell through the SES component of readrRNA.Through ADAR-mediated editing, the effector molecule operably linked to the cell can be translated and fluorescently label the cell and / or cause some desired changes in the physiology of the cell, including cell death.

[0260] In addition to the physical linkage of the SES component of the readrRNA to the effector encoded by the readrRNA, the cell of interest can further comprise a second nucleic acid entity that is under the control of the effector encoded by the readrRNA and comprises a system called the CellREADR system. For example, the effector of the readrRNA can encode a transactivator that can activate any gene encoded on a second nuclear entity, where the second nuclear entity is endogenous to the cell and encodes a gene under the control of a transactivator that is endogenous to the cell, and / or the second nuclear entity is added externally to the cell and encodes a gene under the control of a transactivator that is exogenous and / or endogenous to the cell.

[0261] A transactivator or repressor can also silence or reduce the expression of a particular endogenous gene in a cell by controlling the expression of an exogenous gene that codes for a silencing tight hairpin loop (shRNA). It should also be noted that, instead of being located on a second nuclear entity, the gene under the control of the transactivator can be located on the readrRNA molecule itself, if desired. In the case of a cell containing a mutant gene that ultimately causes a disease or disorder in a patient, the effector can code for a functional gene and / or cause the expression of a nuclear coding for a functional gene.

[0262] Thus, cells or tissues express modular readrRNA molecules and systems that include such modular readrRNA molecules.Therefore, another aspect of the present disclosure provides a cell that includes the modular readrRNA molecules provided herein or a delivery system that includes the modular readrRNA molecules provided herein.The readrRNA molecules provided herein can be expressed in prokaryotic and eukaryotic cells.In some embodiments, the cell includes a eukaryotic cell.In one embodiment, the eukaryotic cell includes a mammalian cell or a plant cell.

[0263] Another aspect of the present disclosure provides an animal or plant model comprising the cells provided herein. treatment

[0264] The disclosure further includes methods comprising the readrRNA molecules provided herein and in the Examples below.

[0265] Another aspect of the present disclosure provides a method for detecting the presence or dynamics of a cellular RNA that defines the cellular state of one or more effector proteins and / or switching on the translation thereof, comprising, consisting of, or consisting essentially of detecting / hybridizing a target effector RNA using a modular readrRNA molecule provided herein, or a delivery system comprising a modular readrRNA molecule provided herein, or a pharmaceutical composition provided herein, wherein a sensor domain detects and binds to a specific cell-type RNA through sequence-specific base pairing, and one or more ADAR editable STOP codons act as a translation switch, thereby enabling translation of the effector RNA encoding the effector protein.

[0266] In some embodiments, the effector protein is intracellular.

[0267] Detecting / evaluating the dynamic state of cells is important for diagnosis and for detecting disease in individuals.Detecting / evaluating the dynamic state of cells is important for targeted treatment of disease in individuals by providing specific therapeutic agents to specific target cells where therapeutic agents can be most effective and with reduced multifaceted side effects.However, effector molecules can then function outside of specific cells, for example, secreted cytokines and interleukins, and in the case of T-CAR.

[0268] Another aspect of the present disclosure provides a method of treating a condition and / or disease in a subject in need thereof, comprising, consisting of, or consisting essentially of administering to the subject a modular readrRNA molecule provided herein, or a delivery system comprising a modular readrRNA molecule provided herein, such that the condition and / or disease is treated in the subject.

[0269] In some embodiments, the condition and / or disease is selected from the group consisting of cancer, infectious diseases, genetic disorders, and the like.

[0270] As used herein, "treating" a condition and / or disease is to ameliorate any condition or symptoms associated with the condition and / or disease. When compared to an equivalent untreated control, such reduction is at least 5%, 10%, 20%, 40%, 50%, 60%, 80%, 90%, 95%, 99%, or more, as measured by any standard technique. Various means for administering the compositions described herein to a subject are known to those skilled in the art. Such methods may include, but are not limited to, oral, parenteral, intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, dermal, topical, injection, or intratumoral administration. Administration may be local or systemic. In some embodiments of any of the aspects, administration is subcutaneous.

[0271] Examples of somatic cell type specific gene therapy include cell type specific complementation of normal mRNA / protein in monogenic diseases including, but not limited to, muscular dystrophy, cystic fibrosis, congenital deafness, Duchenne muscular dystrophy, familial hypercholesterolemia, hemochromatosis, neurofibromatosis type 1 (NF1), sickle cell disease and Tay-Sachs disease.

[0272] Treatment of cancer: (e.g., solid tumors; leukemia) includes using readrRNA and cellREADR to detect cancer cells by their upregulated and / or abnormal morphology of RNA, and to eliminate cancer cells by expression of one or more cell death proteins, including, but not limited to, caspase, programmed cell death protein 1, caspase 8, Bcl-2 associated X protein, PDL-L1, caspase 3, CFLAR, Bcl-xl, SMAC / Diablo, Diablo homolog, Bcl-2 homolog antagonist killer, FADD, BECN1, Death receptor 5, PDCD6, RIP1 kinase, RIP3 kinase, and granzyme; or receptors that recruit immune killer cells, including, but not limited to, CD16, chemokine receptors (CCR2, CCR5, CXCR3 and CX3CR1) and β2-integrin LFA-1.

[0273] readrRNA and cellREADR can be used to treat liver disease, including, but not limited to, chronic hepatitis B, C, non-alcoholic steatohepatitis (NASH) (including the benefit of lipid nanoparticle delivery via the portal vein), heart disease, and infectious diseases, including, but not limited to, latent viral infections (intracellular parasites), and resistant infections, e.g., Epstein-Barr virus, herpes, tuberculosis, prions, Zika, HIV.

[0274] readrRNA and cellREADR can be used for the treatment of chronic pain: broad and widespread effects; e.g., diabetic neuropathy; NIDA, NINDS HEAL-initiated non-addictive pain. readrRNA and cellREADR can modulate ion channel and receptor expression in specific sensory neuron and glial cell types in peripheral ganglia by targeted local AAV vector injection.

[0275] readrRNA and cellREADR can be used for the treatment of epilepsy, which is currently often treated by surgical resection of brain tissue. Epilepsy often results from abnormal neural activity in certain neuronal cell types. That is, epilepsy is characterized by hypersynchronized neural activity of pathological brain networks. Brain circuits contain multiple excitatory and inhibitory cell types, each uniquely contributing to information processing and excitation-inhibition balance. Neuronal activity in some cell types is promoted while suppressing seizures at different stages (initiation, maintenance) of epilepsy in other cell types. Using readrRNA and cellREADR for cell type-specific modulation of brain circuit activity through RNA sensor-effectors (e.g., druggable GPCRs, ion channels, etc.) is a promising approach to control and treat epilepsy. Therefore, readrRNA and cellREADR can be used for cell type-targeted modulation of neural activity to suppress and treat epilepsy.

[0276] kit The present disclosure further provides a kit that includes the composition provided herein and is used to carry out the subject method provided herein.For example, in one embodiment, the subject kit can include, consist of, or essentially consist of one or more of the following: (i) the modular readrRNA molecule provided herein, (ii) the CellREADR system provided herein, (iii) the delivery system that includes the modular readrRNA and / or CellREADR system provided herein, (iv) the cell that includes the modular readrRNA and / or CellREADR system and / or the delivery system that includes the modular readrRNA and / or CellREADR system provided herein, and / or (v) the pharmaceutical composition provided herein.

[0277] In other embodiments, the kit may further include other components. Such components may be provided individually or in combination and in any suitable container, e.g., vial, bottle, or tube. Examples of such components include, but are not limited to, (i) one or more additional reagents, e.g., one or more dilution buffers, one or more reconstitution solutions, one or more wash buffers, one or more storage buffers, one or more control reagents, etc., (ii) one or more control expression vectors or RNA polynucleotides, (iii) one or more reagents for in vitro production and / or maintenance of the molecules, cells, delivery systems, etc. provided herein. Components (e.g., reagents) may also be provided in a form that can be used in a particular assay or that requires the addition of one or more other components prior to use (e.g., concentrated or lyophilized form). Suitable buffers include, but are not limited to, phosphate buffered saline, sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. The components of the kit may be provided individually or in combination and may be provided in any suitable container, such as a vial, bottle, or tube. In some embodiments, the kits disclosed herein include one or more reagents for use in the embodiments disclosed herein.

[0278] In addition to the components mentioned above, the subject kits can further include instructions for using the components of the kit to carry out the subject methods. The instructions for carrying out the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic. As such, the instructions may be presented in the kit as a package insert, such as on the label of the container of the kit or its components (i.e., associated with the packaging or subpackaging). In other embodiments, the instructions are presented as an electronic storage data file present on a suitable computer-readable storage medium, such as a CD-ROM, diskette, flash drive, etc. In still other embodiments, the actual instructions are not present in the kit, but a means is provided for obtaining the instructions from a remote source, for example, via the Internet. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

[0279] Another aspect of the present disclosure provides all that is described and explained herein. The following examples are offered by way of illustration and not by way of limitation. EXAMPLES

[0280] General Methods Common to the Working Examples Below Supplementary Video 1. Optogenetic Activation in Mice Injected with Binary CellREADR Viral Vectors Binary READR Cti p 2 / 3 / Reporter ChR g er2-eYFP Optogenetic activation (CFA, 0.5 s) in AAV-injected mice induces stepping forelimb movements. The upward movement involves sequential flexion and subsequent extension of the elbow, wrist, and fingers.

[0281] Supplementary Video 2. Optogenetic Activation in Mice Injected with Binary PT Enhancer Viral Vectors PT enhancer / reporter ChRger2-eYFP Optogenetic activation (CFA, 0.5 sec) in AAV-injected mice induces elbow extension accompanied by digit extension.

[0282] Methods used in the working examples Plasmids All constructs were made using standard molecular cloning procedures. The vector backbone was linearized using restriction enzyme digestion and DNA fragment inserts were made using PCR or gBlock synthesis (IDT). Information on all plasmids is included in Table 6. All sesRNA inserts were made by gBlock synthesis (IDT) and the sesRNA sequences used in this study are included in Table 7.

[0283] Cell culture and transfection: HeLa cell line was obtained from A. Krainer laboratory (Cold Spring Harbor Laboratory). Mouse neuroblastoma Neuro-2a (N2a) cells were purchased from Millipore-Sigma (Sigma, catalog 89121404). HEK293T and KPC1242 cell lines were obtained from D. Fearon laboratory (Cold Spring Harbor Laboratory). HEK293T, Hela and N2a cell lines were cultured in Dulbecco's modified Eagle's medium (Corning, 10-013-CV) with 10% fetal bovine serum (FBS) (Gibco, catalog 16000036) at 37°C under 5% CO2. The medium was supplemented with 1% penicillin-streptomycin. Cells were transfected with Lipofectamine2000 (Invitrogen, Cat. 11668019) DNA transfection reagent according to the manufacturer's instructions. For interferon treatment, medium containing 1 nM recombinant mouse IFN-β (R&D, Cat. 8234-MB) was used and changed every 24 h during the transfection process. For tetracycline treatment, medium containing the indicated tetracycline concentrations was used 24 h after transfection and replaced with tetracycline-free medium for 48 h before analysis. For apoptosis assays, cells were incubated for 72 h after transfection and apoptosis levels were quantified using the RealTime-GloTM Annexin V Apoptosis and Necrosis Assay (Promega JA1011).

[0284] SURVEYOR Assay The Cas9 target region was amplified from a heterogeneous population of modified and unmodified cells using PCR of genomic DNA (primers for DYRK1A, forward: GGAGCTGGTCTGTTGGAGAA; reverse: TCCCAATCCCATAATCCCACGTT), and the PCR products were slowly reannealed to create heteroduplexes. The reannealed heteroduplexes were cleaved by SURVEYOR nuclease, while the homoduplexes remained intact (IDT: Alt-R Genome Editing Detection Kit). The Cas9-mediated cleavage efficiency (indel %) was calculated based on the percentage of cleaved DNA. 31 .

[0285] animal Mice aged 6–20 weeks (both male and female) were used in this study. A wide variety of mice were purchased from Jackson Laboratory (C57BL / 6J, 000664). Fezf2-CreER and Rosa26-LoxpSSTOLoxp-H2bGFP mice were used as previously described. 39、56 Fezf2 + To label cortical pyramidal neurons, a 200 mg / kg dose of tamoxifen (T56648, Sigma) was administered by intraperitoneal injection 2 days prior to AAV injection. Long Evans rats (Rattus norvegicus, 12 weeks old, 50-250 g) were obtained from Charles River. All animals were maintained on a 12 h:12 h light:dark cycle with a maximum of five animals per cage for mice and one animal per cage for rats. All animal maintenance and experimental procedures were performed in accordance with the guidelines established by Cold Spring Harbor Laboratory and Duke Medical Center.

[0286] ADAR1 knockout cell line construction: ADAR1 knockout cell line was created via CRISPR-Cas9 genome editing. gRNA was cloned into pSpCas9(BB)-2A-puro(pX459) (Addgene, Cat. 62988). gRNA sequences were 5'GGATACTATTCAAGTCATCTGGG 3' (gRNA1) and 5'GTTATTTGAGGCATTTGATG 3' (gRNA2). Briefly, ADAR1 knockout cells were created with two gRNAs targeting exon 2, which is shared by both ADAR1-p110 and ADAR1-p150 isoforms. HEK293T cells were seeded in 6-well plates and transfected with 1ug of pX459-gRNA1 and pX459-gRNA2 plasmid mixture using Lipofectamine 2000 (Thermo Fisher Scientific, Cat. 11668019). The next day, all media containing transfection reagent was removed and replaced with fresh media supplemented with puromycin (final concentration 2ug / ml). Fresh media with puromycin was replaced with old media three times every two days. Cells remaining after puromycin selection were harvested using TrypLE (Gibco, Cat. 12605036) and distributed into 96-well plates with 1-2 cells per well. Expanded single clones were screened for ADAR1 deletion by Western blot, and disruption of the ADAR1 genomic locus was confirmed by Sanger sequencing.

[0287] Flow cytometry analysis: Two days after transfection, cells were harvested using TrypLE (Gibco, Catalog 12605036), distributed into 96-well round-bottom plates, and centrifuged at 500 rpm for 1 min at 4°C. The supernatant was removed and cells were resuspended in 1% PFA buffer and incubated at 4°C overnight or longer. Cells were then resuspended in 200ul of flow cytometry staining buffer (Invitrogen, Catalog 00-4222-26) prior to analysis using an LSR Fortessa (BD Biosciences). The Fortessa was run by FACSDIVA (BD Biosciences) software. Data analysis was performed using FlowJo 10 (FlowJo, LLC). For sorting, cells were subjected to the same procedure as for flow cytometry analysis, but without 1% PFA treatment, and processed using a BD FACSAria (BD Biosciences).

[0288] CellREADR efficiency for exogenous or endogenous transcripts To assay CellREADR efficiency using fluorescent reporter genes, HEK293T cells or HEK293T ADAR1 knockout cells were first seeded in 24-well plates. After 24 hours, cells were co-transfected with a total of 1.5 μg of plasmids. At 48 hours post-transfection, cells were harvested, fixed with 1% PFA, and prepared for FACS analysis. To calculate CellREADR efficiency from FACS data, cells expressing the READR vector were gated by the fluorescent protein expressed by the spacer (e.g., BFP in Figure 1b-d), and the efficiency was calculated as the ratio of double-positive cells expressing both efRNA and target RNA within all target RNA-expressing cells within the gate. When the spacer was not a fluorescent protein (Figure 1h and Figure 2), the ratio was calculated directly as the ratio of double-positive cells expressing both efRNA and target RNA within target RNA-expressing cells. For some controls, CellREADR efficiency was calculated as the percentage of efRNA-expressing cells within all counted cells.

[0289] sesRNA design The following procedure is used for sesRNA design: 1) sesRNA is complementary, i.e., antisense, to a coding or non-coding RNA sequence of a particular cell; 2) the optimal length of sesRNA is 200-300 nucleotides; 3) the readrRNA consists of sesRNA and efRNA arranged in a continuous translation reading frame; 4) one or more STOP codons (TAG) are placed near the middle of the sesRNA (ranging between about 80-220 nucleotides from the 5' end); 5) find a 5'-CCA-3' sequence in the target RNA that is complementary to the 5'-TGG-3' sequence in the sesRNA, and then replace the 5'-TGG-3' with 5'-TAG-3', resulting in an AC mismatch with the sesRNA. 6) to ensure that no other STOP codons are present in the sesRNA, all other TAG, TAA, TGA sequences in the sesRNA are converted to GAG, GAA, GGA, respectively, and preferably the converted STOP codons are not close to (i.e., more than 10 bp from) the TAG defined in step 5; 7) to eliminate the possibility of unintended translation initiation, the TAG defined in step 5 should not be followed by an ATG (start codon); 8) the sesRNA may be directed to any region of a cellular transcript, including exons, introns, UTR regions, or mature mRNA after splicing; 9) to avoid sesRNA with complex secondary structures.

[0290] CellREADR A to I edit rate To evaluate the editing rate of A to I, HEK293T cells were seeded in 12-well plates. 48 hours after transfection, cells were harvested and RNA was extracted. RNA was purified using RNeasy Mini kit (Qiagen Cat. No. 74106) and converted to cDNA using TaqManTM reverse transcription reagents (Thermo Fisher, N8080234). PCR products covering the entire sesRNA region were generated with CloneAmp HiFi PCR Premix (Takara, Cat. No. 639298) and purified with NucleoSpin Gel and PCR Clean-up kit (Takara, Cat. No. 74061) for Sanger sequencing. Editing efficiency was calculated as the ratio of Sanger peak heights G / (A + G). Three biological replicates were performed.

[0291] Transcriptome-wide RNA sequencing analysis A readrRNA carrying a red fluorescent protein (tdTomato) expression cassette Ctrl or readrRNA PCNA , readrRNA EEF1A1-CDS The expression plasmid was transfected into 293T cells. +Cells (approximately 5×10^5) were enriched by FACS sorting 48 hours after transfection, and RNA was purified using the RNeasy Mini kit (Qiagen catalog 74106). To prepare libraries, RNA samples were processed with TrueSeq Stranded mRNA library Prep kit (Illumina, 20020594) and TrueSeq RNA Single Indexes (Illumina, 20020492). Deep sequencing analysis was performed on an Illumina NextSeq500 platform at Cold Spring Harbor Laboratory NGS Bioinformatics Center. FastQC was applied to the RNA-seq data to check the sequencing quality. All samples that passed the quality check were mapped against the reference genome (GRCh38-hg38). Genes were annotated using STAR (version 2.7.2) and RSEM (version 1.3.2). TPM values ​​were calculated from RSEM. For all genes with at least one of the libraries with reads above zero, the average expression values ​​across biological replicates were compared between samples to detect differentially expressed genes using DESeq2. 36 Genes with adjusted p-values ​​<0.01 and fold changes >2 or <0.5 were identified as significantly differentially expressed. For global A-to-G editing rate analysis, A-to-G editing rate calculations were performed using the RNA Editing Detection Pipeline (REDP), a python wrapper for the REDItool. 37 Parameters were set to default values. The alignment step was performed using STAR v2.7.8a with default and coordinate sorting parameters. Genomic references from Gencode GRCH38.p13 were used and concatenated with known sequences from target genes including EEF1A1 and PCNA.

[0292] Western blot Primary antibodies against ADAR1 (Santa Cruz, sc-271854, 1:500), GFP antibody (Cell Signaling Technology, Catalog 2956, 1:10000), and β-actin antibody (Cell Signaling Technology, Catalog 3700, 1:10000) were used in this study. Standard Western blot protocols were used. Briefly, approximately 2 × 10 6 Individual cells were lysed and equal amounts of each lysate were loaded for SDS-PAGE. Sample proteins were then transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories) and immunoblotted with primary antibodies against ADAR1 or GFP, followed by secondary antibody incubation (1:10,000) and exposure.

[0293] Luciferase complementation assay 48 hours after transfection, HEK293T cells expressing firefly luciferase gene were washed in PBS, harvested by trituration, and transferred to 96-well plates. Promega luciferase assay system (Promega, E1500) was used. Firefly luminescence was measured using SpectraMax Multi-Mode microplate reader (Molecular Devices).

[0294] qRT-PCR RNA was extracted and purified using the RNeasy Mini kit (Qiagen Cat. 74106). RNA was converted to cDNA using TaqManTM reverse transcription reagents (Thermo Fisher, N8080234). qRT-PCR was performed using Taqman probes on a QuantStudio 6 Flex real-time PCR system. The housekeeping gene TBP was used for normalization. Gene probes were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, EEF1A1:Hs01591985, PCNA:Hs00427214, XIST:Hs00300535, ACTB:Hs03023943, Mda5:Mm00459183_m1, Rig-I:Mm01216853_m1, Ifnb1:Mm00 439552_s1, Il6:Mm00446190_m1, Ccl2:Mm00441242_m1, Fgf2:Mm01285715_ m1, Cd40:Mm00441891_m1, Iba1:Mm00479862_g1, Cxcl10:Mm00445235_m1). The housekeeping gene TBP (Thermo Fisher Scientific, human TBP: Hs00427620, mouse Tbp: Mm01277042_m1) was used for normalization.

[0295] Virus production To generate READR and reporter viruses, HEK293T cells were transiently transfected with READR or reporter plasmid, AAV serotype plasmid, and pHelper using PEI MAX (catalog 24765, Polysciences Inc.). 72 hours after transfection, cells were harvested in cell culture medium and centrifuged at 4,000 rpm for 15 minutes. The supernatant was discarded, and the pellet was resuspended in cell lysis buffer and frozen and thawed three times using a dry ice / ethanol bath. The cell lysate was centrifuged at 4,000 rpm for 20 minutes. Contaminating DNA in the supernatant was removed by adding benzonase and incubated at 37°C for 30 minutes. The crude solution of virus was loaded onto an iodixanol density gradient and spun at 60,000 rpm for 90 minutes using a Beckman Ti70 rotor. After centrifugation, 3-4 ml of crude virus preparation was collected from the 40-60% layer using an 18-gauge needle attached to a 10 ml syringe. The crude virus solution was concentrated to 200-250 μl using an Amicon Ultra-15 centrifugal filter (100 kDa), washed once with 8 ml PBS, and concentrated to the appropriate volume. Aliquots were stored at -80°C until use. Mouse and rat READR and reporter viruses were packaged as AAV-DJ or AAV-PHP.eB serotypes. PT enhancer-tTA2 virus was packaged as PHP.eB using a vector from Addgene (no. 163480). Human READR and reporter viruses were packaged as AAV2-Retro serotypes. pAAV(DJ)-hSyn-Adar2-sesRNA Fez f 2 -tTA2 and pAAV(PHP.eB)-hSyn-ADAR2-sesRNA Ctip2(1) -tTA2 was packaged from Vigene Inc.

[0296] Immunohistochemistry Mice or rats were anesthetized (using Avertin) and perfused intracardially with saline followed by 4% paraformaldehyde (PFA) in 0.1M PBS buffer. After overnight fixation at 4°C, brains were rinsed three times and sectioned at a thickness of 50 μm using a Leica 1000s vibratome. Sections were placed in blocking solution containing 10% normal goat serum (NGS) and 0.1% Triton®-X100 in PBS1X for 1 hour, then incubated overnight at 4°C with primary antibodies diluted in blocking solution. Anti-GFP (1:1000, Aves, GFP-1020), anti-CTIP2 (1:250, Abcam 18465), anti-TLE4 (1:500, Scbt:sc-365406), anti-Rorb (1:300, Novus Biologicals NBP1-82532) were used. Sections were rinsed three times in PBS and incubated with the corresponding secondary antibodies (1:500, Life Technologies) for 1 h at room temperature. Sections were dry mounted on slides using Fluoromount (Sigma, F4680) mounting medium.

[0297] For human tissues, after viral expression peaked or after patch clamp recording, cortical slices were fixed overnight in 4% PFA, then rinsed in PBS and stored in PBS with azide for 1-7 days. For biocytin retrieval, tissues were permeabilized for 30 minutes at room temperature in PBS with 10% Triton®X100, 5% NGS, 100uM glycine, and 0.5% BSA on a shaker plate. Both primary and secondary antibodies were incubated for 24 hours at 4°C. Biocytin was developed directly with Alexa647-conjugated streptavidin or indirectly with an enzymatic metallography method using peroxidase-labeled streptavidin treated with a silver ion substrate with metallic silver deposited at the active site. Recovered cells were imaged on a Keyence BZ-X800 with a 10x or 20x objective. Large overview images of native mNeon fluorescence were made on a Leica SP8 upright confocal microscope. For immunohistochemical labeling of FOXP2 and NeuN, tissues were cryoprotected in 30% sucrose for at least 24 hours and then resectioned at 40um using a sliding microtome. Free-floating sections were permeabilized in PBS with 1% Triton®X100, 5% NGS, and 100uM glycine for 30 minutes at room temperature and labeled with primary antibodies (rabbit anti-FOXP2 Abcam #16046 1:500, rat anti-Flag 1:500 Novus NBP1-06712, mouse anti-NeuN Ab 1:500, Cell Signaling #94403S) overnight at 4°C. For secondary antibodies, tissues were incubated with biotinylated anti-rabbit Ab (1:1000, ThermoFisher 31822) for 2 h at room temperature, followed by streptavidin AlexaFluor647 for 1 h at room temperature (FOXP2), or goat anti-mouse Ab (1:1000, ThermoFisher 32723) for 2 h at room temperature (NeuN).

[0298] In situ hybridization All probes were ordered from Molecular Instruments (mouse Satb2 Cat. No. PRM128, mouse PlxnD1 Cat. No. PRK885, mouse Fezf2 Cat. No. PRA339, mouse vGAT Cat. No. PRE853, rat vGAT Cat. No. PRN024 and human VGAT Cat. No. PRM351). Mouse brains were sliced ​​into 50 μm thick slices after PFA perfusion fixation and sucrose protection. In situ hybridization chain reaction was performed via the floatation method in 24-well plates. First, brain slices were exposed to probe hybridization buffer with HCR probe set for 24 hours at 37°C. Brain slices were washed with probe wash buffer, incubated with amplification buffer and amplified for 24 hours at 25°C. On the third day, brain slices were washed and counterstained as necessary.

[0299] Stereotaxic viral injection Adult mice aged 8 weeks or older were anesthetized by inhalation of 2% isoflurane delivered at a constant air flow (0.4 L / min). Ketoprofen (5 mg / kg) and dexamethasone (0.5 mg / kg) were administered subcutaneously as preemptive analgesia and to prevent cerebral edema, respectively, and lidocaine (2–4 mg / kg) was applied prior to surgery. Mice were mounted in a stereotactic head frame (Kopf Instruments, 940 series or Leica Biosystems, Angle Two). Stereotaxic coordinates were identified. An incision was made on the scalp and a small burr hole was drilled in the skull to expose the brain surface. A 20-30 μm pulled glass pipette tip containing the virus suspension was lowered into the brain and a 500 nl volume of single or mixed viruses was delivered to the injection site at 300 um and 700 um (1:1 volume) using a Picospritzer (General Valve Corp) at a rate of 30 nl / min, the pipette was left in place for 10 minutes to prevent backflow before being withdrawn, after which the incision was closed with nylon suture (Ethilon Nylon Suture, Ethicon Inc. Germany) or Tissueglue (3M Vetbond) and the animals were kept warm on a heating pad until fully recovered. For targeting of the rat Tle4 cell type, READR Tle4 A 3:1 mixture of READR and reporter AAV was stereotaxically injected into the cortex (0 mm posterior, 3.5 mm lateral), with a 1000 ul volume injected at -2 mm ventral and a 1000 ul volume injected at -1 mm ventral, respectively. vGAT A 3:1 mixture of and reporter AAV was stereotaxically injected into the cortex (-4mm posterior, 3.5mm lateral), with a 1000ul volume injected at -2.5mm ventral and a 1000ul volume injected at -1.5mm ventral, respectively. Further experiments of immunohistochemistry or in situ hybridization were performed 3 weeks after virus incubation.

[0300] Physiological function in mice -Stereotaxic surgery and virus injection. All surgeries were performed under sterile conditions and body temperature was maintained using a heating pad. Standard surgical procedures were used for stereotaxic injection and fiber optic implantation. Mice were anesthetized with isoflurane (2-5% at the start and 0.8-1.2% during rest during the surgical procedure), placed in a stereotaxic frame and maintained at 34-37 °C on a heating pad. Ketoprofen (5 mg / kg) was administered intraperitoneally (IP) as pre- and post-operative analgesia, and lidocaine (2%) was applied subcutaneously under the scalp before surgery. The scalp and connective tissue were removed to expose the dorsal surface of the skull. The skin was pushed aside and the skull surface was cleaned using saline. A digital mouse brain atlas was coupled to the stereotaxic frame to guide the identification and targeting of different brain regions (Angle Two Stereotaxic System, Leica Biosystems). The following coordinates were used for injections and implantations in the SSp-ul: -0.09 from bregma, 2.46 mm lateral to the midline, CFA: 0.37 mm from bregma, 1.13 mm lateral to the midline.

[0301] For virus injections, a small burr hole was drilled in the skull to expose the brain surface. A 20-30 μm pulled glass pipette tip containing the virus suspension was lowered into the brain and a 500 nl volume was delivered at a rate of 10-30 nl / min using a Picospritzer (General Valve Corp), and the pipette was left in place for 5 min to prevent backflow before being pulled back. Injections were performed at a depth of 700 μm. An optical fiber (diameter 200 μm; NA, 0.39) was then embedded in the CFA or SSsp-ul for optogenetic activation or fiber photometry, respectively. The optical fiber was embedded with its tip touching the brain surface. To fix the optical fiber to the skull, silicone glue (Kwik-Sil, WPI) was applied to cover the hole, followed by a layer of dental cement (C&B Metabond, Parkell), then black instant glue (Loctite 426), and dental cement (Ortho-Jet, Lang Dental). A titanium head bar was fixed to the skull around lambda using dental cement. Mice were transferred onto a heating pad until fully recovered. Further experiments of optogenetic activation or fiber photometry were performed 8 weeks after virus incubation.

[0302] - In vivo optogenetic activation. Mice were first briefly anesthetized with isoflurane (2%) and fitted with a reflective marker on the back of their left paw. Mice were then transferred to the tube, head fixed to the stage, and allowed to fully recover from anesthesia before stimulation began. A fiber-coupled laser (5-ms pulses, 10-20 mW; λ = 473 nm) was used to stimulate multiple times for 0.5 s at 20 and 50 Hz. The interval between stimuli was 9.5 s. Two cameras (FLIR, FL3-U3-13E4C-C), one front and one side camera, were mounted on the stage to capture high frame rate (100 Hz) videos. The two cameras were synchronized by a TTL signal controlled by a custom-written MATLAB program. Videos and TTL signal states were acquired simultaneously using a workflow in Bonsai software. Four LED light lamps were used for illumination (two for each camera).

[0303] - Behavioral video analysis. The two cameras were calibrated using the Camera Calibrator App in MATLAB®. For tracking of the left paw using MATLAB®, images from the video were smoothed using a Gaussian low-pass filter (size 9, sigma 1.8). The centroid of the reflective marker on the paw was first detected by a combination of brightness and hue thresholds, and then tracked by a feature-based tracking algorithm (PointTracker in Computer Vision Toolbox). The tracking results were manually verified and errors were corrected accordingly. Trials in which the mouse performed locomotor activity before the onset of the stimulus (within 0.5 seconds) were excluded from further analysis.

[0304] - Paw stimulation. To stimulate the left paw, mice were lightly anesthetized with isoflurane (0.75-1%). Body temperature was maintained using a feedback-controlled heating pad. A piezo bender (BA4510, PiezoDrive), driven by a miniature piezo driver (PDu100B, PiezoDrive), was insulated with Kapton tape to which a blunt needle was glued. The tip of the needle was attached to the back of the paw to stimulate it by vibration (100 Hz, sine wave, 1 s). The stimulation interval was 10 s.

[0305] -In vivo fiber photometry and data analysis. Calcium activity from the SSp-ul was recorded using a commercial fiber photometry system (Neurophotometrics). A patch cord (fiber core diameter, 200 μm; Doric Lenses) was used to connect the photometry system with an implanted optical fiber. The intensity of blue light (λ = 470 nm) for GCaMP excitation was adjusted to about 60 μW at the tip of the patch cord. Violet light (λ = 415 nm, about 60 μW at the tip) was used to acquire an isobestic control signal to detect calcium-independent artifacts. The emitted signal was band-pass filtered and focused on the sensor of a CMOS camera. The photometry signal and the stimulus onset were aligned based on the TTL signal generated by a multifunction I / O device (PCIe-6321, National Instruments). The average value of the signal from the ROI was calculated and saved by using Bonsai software and exported to MATLAB for further analysis.

[0306] To process the recorded photometric signals, an initial baseline correction of each signal was performed using the Adaptively Iteratively Reweighted Penalized Least Squares (airPLS) algorithm (https: / / at github.com / zmzhang / airPLS) to remove slope and low-frequency fluctuations in the signal. The baseline-corrected signals were normalized (Z-scored) on a trial-by-trial basis using the median and standard deviation of a 5-s baseline period. The normalized 415 nm excitation isobestic signal was fitted to the normalized 470 nm excitation GCaMP signal using robust linear regression. Finally, the normalized isobestic signal was adjusted using the parameters of the linear regression and reverted from the normalized GCaMP signal to obtain the calcium-dependent signal.

[0307] Human organ sample preparation Human neocortical tissue (frontal, parietal, and temporal) was obtained from pediatric and adult patients (N=6; ages 6-60 years) undergoing brain resection for epilepsy. Informed consent was obtained for tissue donation under Duke University IRB protocol 00103019.

[0308] Tissue preparation is generally performed according to the literature 41、57、58 The method described in was followed. The dissection solution contained 75 mM sucrose, 87 mM NaCl, 25 mM glucose, 26 mM NaHCO3, 2.5 mM KCl, 1.2 mM NaH2PO4, 10 mM MgCl2, 0.5 mM CaCl2 bubbled with 95 / 5% O2 / CO2 (pH 7.4). The cortex was carefully dissected under ice-cold (approximately 4°C) oxygenated dissection solution and the pia mater was removed. Single gyri were blocked for slicing and cut at a thickness of 300 um on a Leica VT1200. The slices were rinsed in Hank's buffered saline and placed on a PTFE membrane (Millipore, catalogue no. PICMORG50) in a 6-well plate. The tissue was then cut in a 300 um thick 30-well plate using a 100-mm thick plate. The tissue was then cut in a 300 um thick plate using a 100-mm ... 40The slices were cultured in conditioned medium as described in. The conditioned medium also contained antibiotic / antimycotic (1x, Gibco by ThermoFisher) for the first 7 days in vitro, and cyclosporine (5ug / mL) throughout the culture period. HEPES (20mM) was added to the medium for the first hour after slicing. AAV retrograde (AAV-rg) virus was suspended in conditioned medium and applied directly to the slice surface by pipette on the day of plating. Expression of the mNeon reporter was monitored from DIV 3 anteriorly, and tissues were used for immunohistochemistry and patch clamp experiments from DIV 6 to DIV 14.

[0309] Electrophysiology in human organ samples Cultured human neocortical tissue was transferred to a heated recording bath (32-34 °C) on the platform of an Olympus BX-50 upright microscope. The recording solution contained 118 mM NaCl, 3 mM KCl, 25 mM NaHCO3, 1 mM NaH2PO4, 1 mM MgCl2, 1.5 mM CaCl2, 30 mM glucose, fully saturated with 95 / 5% O2 / CO2. Borosilicate patch pipettes were pulled with a resistance of 4.0-5.5 MΩ and filled with an internal solution containing 134 mM K-gluconate, 10 mM HEPES, 4 mM ATP triphosphate Mg salt, 3 mM GTP triphosphate Na salt, 14 mM creatine phosphate, 6 mM KCl, 4 mM NaCl, pH adjusted to 7.4 with KOH. Biocytin (0.2%) was added to the internal solution to allow identification of morphology after recording. Patched cells were kept in whole-cell mode for a minimum of 12 min to ensure complete saturation with biocytin. Cells expressing mNeon were patch-clamped under visual guidance using an Axopatch 700B amplifier (Molecular Devices). Data were digitized (Digidata 1550B) and recorded using pClamp 10 (Molecular Devices). Membrane voltages were recorded at 100 kHz and low-pass filtered at 10 kHz. No correction for liquid junction potentials was made. Pipette capacitance and series resistance were offset at the start of each recording and periodically checked for stability of the recording setup. Integral membrane properties were measured using a current step of -10 pA. Firing rheobases were measured using gradient currents of 1 s duration and final amplitudes of 100-300 pA. Input-output curves were generated from a series of current steps starting at -50 pA and increasing in 10 pA increments until maximal firing rates were elicited. Data were analyzed using NeuroMatic and in-house routine Igor Pro (Wavemetrics).

[0310] Microscopy and image analysis: Cell imaging in tissue culture was performed on a ZEISS Axio Observer (CSHL St. Giles Advanced Microscopy Center). Imaging from serially mounted brain sections was performed on a Zeiss LSM 780 or 710 confocal microscope (CSHL St. Giles Advanced Microscopy Center) and a Nikon Eclipse 90i fluorescent microscope using 63x and 5x objectives for fetal tissues and 20x objectives for adult tissues, as well as on a Zeiss Axioimager M2 system with MBF Neurolucida software (MBF) at 5x. Quantification and image analysis were performed using Image J / FIJI software. Graph statistics and plots were performed using GraphPad Prism 9.

[0311] Statistics: Unpaired two-tailed Student's t-test was used for group comparison. Statistical analysis was performed with Prism 9 (GraphPad Software, Inc.). DESeq2 was used to analyze the statistical significance of transcriptome-wide RNA-seq data.

[0312] All references, publications, online resources, patents and / or non-patent literature referenced herein are hereby incorporated by reference in their entirety.

[0313] Overview of cell-type access through programmable RNA sensing Diverse cell types in multicellular organisms are essential intermediates that build their genomes and organize the phenotype of the organism. Deciphering the organizational logic of this biological information flow and its alterations in disease requires methods that allow specific and comprehensive analysis of cell types across diverse species. The following example describes CellREADR (Cell Access through RNA Sensing by Endogenous ADARs), which combines detection of RNAs that define somatic cell types with translation of desired effector proteins, performed through RNA editing mediated by adenosine deaminases acting on RNA (ADARs). The following example demonstrates that CellREADR senses specific RNA sequences that translate reporter proteins in human and mouse cell lines, and in different neuronal types of the mouse cerebral cortex when delivered by viral vectors. This RNA programmable technology highlights the potential to discover, monitor, and edit animal cell types in a specific, simple, versatile, and general manner across organ systems and species, with broad applications in biology, medicine, and biotechnology.

[0314] Example 1 CellREADR design and validation in mammalian cells RNA editing is a widespread and robust post-transcriptional mechanism essential to the regulatory toolkit of metazoan genes involved in recoding, splicing, microRNA targeting, and other RNA processing and cellular processes [20,21]. The most widespread form of RNA editing is adenosine to inosine (A → I) conversion catalyzed by ADARs, where inosine is recognized as guanosine (G) by the cellular machinery

[21] . ADARs recognize and are recruited by base-paired stretches of double-stranded (ds)RNA

[20] , and thus can operate as sequence-guided base editing machines and have been exploited for transcriptome editing [22-26]. Because ADARs are ubiquitous in animal cells

[27] , CellREADR was designed as a single and modular readrRNA molecule (Figure 1a). The 5' region of the readrRNA contains a sensor domain of about 300 nucleotides, which is complementary to a specific cell-type RNA through sequence-specific base pairing and thus detects it. This sensor domain contains one or more ADAR-editable STOP codons that act as translational switches, which leads to the nomenclature of this region for sensing-editing-switch RNA (sesRNA). Downstream of the sesRNA and in frame with the STOP is a sequence that codes for the self-cleaving peptide 2A, followed in frame by an effector RNA (efRNA) region that codes for various effector proteins. The entire readrRNA is several kilobases long, depending on the specific sensor and effector, and thus can be delivered to cells through viral vectors or liposomal nanoparticles. In cells expressing the target RNA, the sesRNA forms a dsRNA with the target, which recruits the ADAR to assemble an editing complex. At the editable STOP codon, the ADAR converts A to I, which pairs with the opposite C in the target RNA. This A→G substitution converts the TAG STOP codon into a TI(G)G tryptophan codon, switching on translation of efRNA.In-frame translation generates a fusion protein containing the N-terminal peptide 2A and the C-terminal effector, which is then self-cleaved by 2A to release the functional effector protein (Figure 1a). The readrRNA is expected to remain inactive in cells that do not express the target RNA.

[0315] Example 2 Manipulation in human cells We constructed a proof-of-principle version of CellREADR and tested it in a human 293T cell line. An expression vector (PGK-tdT) was used to express the tdTomato gene as an exogenous target RNA to label transfected cells. We then designed a READR vector (READRtdT-GFP) expressing a readrRNA, consisting of a tdT sequence (sesRNAtdT) with an embedded TAG STOP codon from the 5' sensor region, a 2A coding sequence, and a 3' coding cassette for green fluorescence (GFP), Figure 6. Co-transfection of READRtdT-GFP and PGK-tdT resulted in GFP expression in a subset of tdT+ cells (Figure 6). To verify this result, we replaced the GFP coding region of the READR vector with that of a tetracycline-inducible transcriptional activator (tTA2) driving expression of the firefly luciferase gene (Luc) from a tetracycline response element (TRE) promoter (Figure 6). Co-transfection of READRtdT-tTA2 and TRE Luc with PGK-tdT resulted in a dramatic induction of luminescence compared to the empty vector control (Figure 6). Little and weak GFP or luciferase expression was observed from READRtdT-tTA2 / TRE Luc when co-transfected with READRtdT-GFP alone or the empty PGK vector, respectively (Figure 6b-f), which could result from accidental read-through of the STOP codon in the sesRNA

[28] .

[0316] Example 3 Spacer The spacer sequence reduced the leakage of readrRNA according to one embodiment of the present disclosure. Inclusion of an approximately 600 bp in-frame spacer region before the sesRNA substantially eliminated residual GFP translation, FIG. 2a. FIG. 6g and 6i are schematic READRtdT-GFP vectors in which a spacer sequence is inserted before the sesRNAtdT coding region. FIG. 6J is a representative FACS analysis of GFP and RFP expression in 293T cells transfected with READRtdT-G'P vectors encoding spacers of variable length with (top) or without (bottom) tdT target RNA expression, respectively. (FIG. 6j) Longer spacers reduced the effectiveness of readrRNA in the presence of tdT target RNA (FIG. 6h), and quantification of the conversion ratio calculated as the percentage of GFP+ cells in RFP+ cells shown in FIG. 6J.

[0317] Example 4 Quantification To characterize CellREADR efficiency more quantitatively, a BFP coding cassette was inserted upstream of the sesRNAtdT region in READRtdT-GFP, which not only served as a spacer but also labeled all READRtdT-GFP transfected cells together with CAG-tdT transfected cells (Fig. 1b, c). CellREADR efficiency was calculated as the ratio of GFP+ cells in RFP+ cells gated on BFP+ cells in FACS analysis. In the absence of tdT target RNA, READRtdT-GFP did not show leaky GFP expression. In the presence of tdT RNA, the efficiency of READRtdT-GFP was 15.2% (Fig. 1c, d), while the control READR vector expressing sesRNACtrl with a scrambled coding sequence containing a STOP codon did not show GFP translation.

[0318] Example 5 CellREADR efficiency correlates with target RNA levels We next investigated whether CellREADR efficiency correlated with target RNA levels. The efficiency of READRtdT-GFP increased with increasing amounts of CAG-tdT vector in 293T cell transfection. We further designed a tetracycline-inducible expression vector in which ChETA (a variant of light-gated channelrhodopsin-2) coding sequence was fused to blue fluorescent protein (BFP) and driven by TRE, and in this way, BFP fluorescence levels showed Cheta transcription levels correlated with tetracycline concentrations in the culture medium. Increasing tetracycline concentrations and BFP expression levels increased READRCheta-GFP efficiency in a Cheta RNA-dependent manner. Figure 1e-f. With a constitutive promoter driving BFP-Cheta expression, READRCheta-GFP efficiency reached as high as 41.5%. These results demonstrated the target RNA level dependency and robustness of CellREADR. To demonstrate the ability of effector RNAs to mediate physiological functions, we constructed READRtdT-Cas9 29 to express Cas9 protein for genomic DNA editing, and READRtdT-taCas3 / TEV 30 to express functional caspase 3 protein for programmed cell death. Efficient gene editing (Figure 7a-d) and increased cell apoptosis (Figure 7e-f), respectively, were induced only in the presence of tdT target RNA.

[0319] Example 6 The role of ADAR proteins in CellREADR function To investigate the role of ADAR proteins in CellREADR function, an ADAR1 gene knockout (KO) 293T cell line was created using CRISPR. Since ADAR1 is highly expressed in 293T cells while ADAR2 is barely expressed, ADAR1KO 293T essentially represented an ADAR null cell line. Removal of ADAR1 largely eliminated READRtdT-GFP functionality (Fig. 5h, i), which was rescued by exogenous expression of either p110 or p150 ADAR1 isoforms and ADAR2 protein (Fig. 5h, i). Overexpression of ADAR2 in wild-type cells abolished READRtdT-GFP functionality (Fig. 5h, i). tdT-GFP The efficiency was increased by approximately 25-30% (Fig. 5h, i). Sanger sequencing confirmed the A to I / G edit at the intended site, converting the TAG STOP codon to a TGG tryptophan codon (Fig. 5j, k). Because ADAR expression can be induced by interferon stimulation [32, 33], we further confirmed that ADAR1-p110 and ADAR1-p150 ADARs were induced by interferon stimulation in wild-type 293T cells, thus demonstrating that READRtdT-GFP efficiency was increased.

[0320] Example 7 CellREADR function in a wide range of cells In addition to 293T cells, CellREADR functionality was demonstrated in several other cell lines originating from different tissues or species, including human HeLa, mouse N2a, and mouse KPC1242 cell lines. Collectively, these results demonstrate that by exploiting cell-endogenous ADARs, CellREADR can combine detection of cellular RNA with translation of effector proteins in a specific, effective, and robust manner.

[0321] Example 8 Properties of sesRNA confer CellREADR programmability Because sesRNA is a key component of CellREADR, several properties of sesRNA were examined using ADAR2-overexpressing READRAdar2-tdT-GFP vector as a robust assay. We found that sesRNA of increasing length positively correlated with CellREADR efficiency, with an optimal length of 200-250 nt, while sesRNA of less than 100 nucleotides was mostly ineffective.

[0322] Example 9 The Role of Mismatch in Programmability In terms of sequence mismatches with the target RNA, the sesRNA of approximately 200 nt tolerates up to 10 mismatches (of 5% of the sequence length) or in-frame indels without a significant decrease in READRAdar2-tdT-GFP efficiency (Figure 2), a property that confers flexibility on sesRNA design (see Methods).

[0323] However, mismatches in the vicinity of the editing site significantly reduced CellREADR efficiency. To explore the effect of location along the target transcript in sesRNA design, we used the EF1a-Cheta-tdT expression vector and tested five sesRNAs targeting the promoter, different coding regions, and 3'UTR, respectively. All four sesRNAs targeting the transcribed region showed robust efficiency, except for the one targeting the promoter. Finally, we investigated whether the inclusion of more STOP codons could further increase the stringency of sesRNA (i.e., reduce basal translation in the absence of target RNA). Using luciferase as a sensitive indicator of read-through translation, sesRNAs with two STOP codons showed reduced leakiness with comparable efficiency compared to those with one STOP codon, whereas three STOP codons significantly reduced efficiency (Figure 2d-f). Together, these results suggest strategies to enhance the stringency, efficiency, and flexibility of CellREADR.

[0324] Example 10 CellREADR is inherently programmable Built on Watson-Crick base pairing, CellREADR is inherently programmable, giving the possibility to cross-target two or more cellular RNAs for more specific cell type definition.To investigate this property, we designed double or triple sesRNA arrays that target different regions of the same transcript.All tested sesRNA arrays showed robust CellREADR efficacy, comparable to that of single sesRNA.

[0325] To investigate the possibility for cross-targeting of two target RNAs, we designed a sesRNA array consisting of sesRNAtdT and sesRNACheta (sesRNAtdT / Cheta) arranged in tandem. Although the single target RNAs, tdTomato or Cheta, failed to induce GFP or Luc expression by readrRNAtdT / Cheta, a significant increase in GFP expression or luminescence was observed, respectively, when both tdTomato and Cheta vectors were transfected. This result demonstrated the possibility of cross-cell type targeting based on the programmability of CellREADR. Figure 2.

[0326] Example 11 Endogenous RNA sensing by CellREADR Compared with synthetic genes expressing exogenous RNA, endogenous genes often have more complex genomic structures, including numerous exons, introns, and regulatory elements, and transcribed endogenous RNA undergoes multiple elaborate post-transcriptional steps, such as splicing and chemical modification, before being processed into mature mRNA. To investigate the ability of CellREADR to target cell-endogenous RNA, we first selected the EEF1A1 housekeeping gene, which is highly expressed in 293T cells, and systematically designed a set of sesRNAs targeting its various exons, introns, 5' and 3' UTRs, and mRNA (Figure 3). These sesRNAs were effective in sensing all intended EEF1A1 regions to switch on efRNA translation, with exons being better targets than UTRs and introns. Notably, sesRNAs complementary to the mRNA region connected from two exons achieved comparable efficacy to those contained within the exons, indicating that CellREADR acted on mRNA and pre-mRNA. CellREADR efficacy against EEF1A1 RNA increased with incubation time after cell transfection. Several other endogenous RNAs, including highly expressed ACTB, moderately expressed PCNA, and long non-coding RNA XIST, were further tested in 293T cells. Robust CellREADR efficacy for all of these RNAs (Fig. 3d) was observed. Exogenous ADAR2 overexpression rather resulted in a moderate increase in CellREADR efficacy of about 30% (Fig. 3c, d). Together, these results suggest that cell-endogenous ADARs enable effective and robust CellREADR functionality against cell-endogenous RNAs.

[0327] Example 12 Effect of CellREADR on the levels of targeted transcripts CellREADR did not alter the levels of targeted transcripts as assayed by quantitative PCR (qPCR) (Fig. 3e), a result that also ruled out a possible effect of RNA interference induced by readrRNA. RNA sequencing analysis was further performed to determine the level of sesRNA. EEF1A or sesRNA PCNA The transcriptomic effect of CellREADR was evaluated by comparing the transcriptomic profile of 293T cells expressing sesRNA with those expressing scrambled sesRNACtrl. Correlation analysis showed that sesRNAEEF1A or sesRNAPCNA expression had no significant effect on the global transcriptome (Fig. 3f), and DESeq2 analysis showed that sesRNA EEF1A or sesRNA PCNA and sesRNA Ctrl No significant differential gene expression between groups was revealed, demonstrating that CellREADR has no significant effect on the cellular transcriptome.

[0328] Example 13 Further endogenous RNA sensing with CellREADR Compared with synthetic genes expressing exogenous RNAs, endogenous genes often have more complex genomic structures, including numerous exons, introns, and regulatory elements, and transcribed endogenous RNAs undergo multiple elaborate post-transcriptional steps, such as splicing and chemical modifications, before being processed as mature mRNAs. To examine the ability of CellREADR to detect cell-endogenous RNAs, we first selected EEF1A1, a housekeeping gene highly expressed in 293T cells, and systematically designed a set of sesRNAs targeting its various exons, introns, 5' and 3' UTRs, and mRNA (Fig. 3a, b). These sesRNAs were effective in sensing all intended EEF1A1 regions to switch on efRNA translation, and exons appeared to be better targets than introns (Fig. 3c). Notably, sesRNA complementary to the mRNA region connected from two spliced ​​exons achieved an efficiency comparable to that contained within the exon, indicating that sesRNA can be designed to target both pre-mRNA and mRNA sequences.CellREADR efficacy against EEF1A1 RNA increased with incubation time after cell transfection.

[0329] Example 14 sensitivity To examine the sensitivity of CellREADR to target RNA levels, several other endogenous RNAs, including highly expressed ACTB, moderately expressed PCNA, and long non-coding RNA XIST, were further tested in 293T cells. Several endogenous RNAs with expression ranging from high (ACTB, PCNA), to moderate (TP53, XIST), to low (HER2, ARC) levels were selected. Robust CellREADR efficacy for all these RNAs (Fig. 3d) was observed. Exogenous ADAR2 overexpression rather resulted in a moderate increase in CellREADR efficacy of about 30% (Fig. 3c, d). CellREADR was much less efficient, but was able to reliably detect even low levels of ARC RNA. Together, these results suggest that cell-intrinsic ADARs enable effective and robust CellREADR functionality for cell-intrinsic RNAs.

[0330] Summary of Examples 1 to 14 CellREADR was tested in human and mouse cell lines by constructing a reporter RNA editing assay in human 293T cells, where the target RNA is made from an RFP expression vector, the sensor RNA is antisense to the RFP target, and then follows the tTA transcription activator in a third vector, which activates and amplifies GFP expression. Once transfected into cells, the sensor RNA pairs with the RFP RNA, and ADAR is recruited to edit the STOP codon and switch on the translation of tTA, which activates GFP, thereby turning the cells from red to green. Editing can also be quantified by a fluorescently activated cell sorting [FACS] assay, where the upper right quadrant is RFP / GFP positive cells.

[0331] This conversion was ADAR-mediated since it did not occur in ADAR1 knockout cell lines, which could then be rescued by expression of Adar2. Sanger sequencing demonstrated that this was indeed due to an intended AI(G) conversion that released the STOP codon.

[0332] This system also works in human Hela cells, and mouse N2a cells and intrinsic RNA in cells.When different regions of Ef1a gene and pre-mRNA are used as targets, exons and coding regions are found to be better sensing targets than introns and non-translated regions.In addition, it works for five other cellular RNAs, including non-coding RNAs.

[0333] Example 15 Neural cell types targeted with CellREADR CellREADR, which is used to access specific cell types in animal tissues, including neural tissues and cells, includes both specific vector systems and binary vector systems (Figure 4b). In the specific vector system, i.e., the specific READR vector contains, for example, the hSyn promoter, which drives the transcription of a gene encoding mCherry red fluorescent protein followed by sesRNA and efRNA encoding smFlag and tTA2. This specific READR vector directly combines RNA detection with effector gene expression, and its efficiency and specificity are evaluated by the colocalization of mCherry, smFlag, and target mRNA or protein.

[0334] The binary system includes an additional reporter vector, which contains a TRE promoter that drives mNeonGreen (mNeon) or other effector proteins in response to the tetracycline-dependent transcription activator (tTA2) translated from the READR vector (Figure 4b). The binary vector provides amplification of effector gene expression, as well as combinatorial flexibility to express different effector genes in different cell types by pairing the READR and reporter vectors.

[0335] In vitro targeting of Fezf2 or Ctip2 A set of READR vectors targeting mRNAs that define the major glutamatergic projection neuron (PN) types in mouse cerebral cortex were first tested and screened by co-expressing individual sesRNA-targeting neuronal RNA sequences, in this case Ctip2 and Fezf2 sequences, in 293T cells (Figure 9a, b, d). The zinc finger transcription factor Fezf2 labels the majority of cortical subduction projection neurons (CFPNs) in layers 5b (L5b) and L6 that constitute cortical output channels, whereas Ctip2 preferentially labels a subset of L5b / L6 CFPN neurons. 38、39 All sesRNAs showed variable but significant CellREADR efficiencies in 293T cells in the presence of exogenous Fezf2 or Ctip2 target sequences (Figure ​(Figure9e–f).

[0336] In vivo targeting of Fezf2 or Ctip2 We administered these sesRNAs to mouse cortex by local injection into the somatosensory cortex (S1) or motor cortex (M1) of the whisker barrel using AAV vectors. When delivered with binary vectors, Fezf2 sesRNA1 showed 86.4% specificity, and Ctip2 sesRNAs 3 and 8 reached >90% specificity, as assayed by Ctip2 antibody staining (Figure 9j-k).

[0337] Ctip2 sesRNA3 was the focus of the following experiments: Ctip2 / 3 When infected with , FLAG immunofluorescence was concentrated in the deep layers (Fig. 4c), and colocalization of CTIP2 and FLAG immunolabeled cells (Fig. 4c, d) showed a specificity of 94.1% (Fig. 4e). Ctip2 / 3 / Reporter mNeonIn AAV-coinfected S1 cortex, mCherry expression from the READR vector labeled cells throughout the cortical layer, whereas mNeon expression from the reporter vector specifically labeled L5b and some L6 neurons (Fig. 4f), and CTIP2 immunofluorescence showed a specificity of 90.4% (Fig. 4g). Ctip2 / 3 The efficiency of the ion exchange reaction reached 84.2% (Fig. 4h).

[0338] ADAR2 overexpression To test whether ADAR2 overexpression from the READR vector could enhance CellREADR functionality, the mCherry module in the READR vector was replaced with ADAR2 cDNA. Ctip2 / 3 / Reporter mRuby3 or binary READ Fezf2 / Reporter mRuby3 Mouse cortices co-infected with were tested for expression of sesRNAs for Fezf2 and Ctip2 (FIG. 10a-c). We found that ADAR2 overexpression did not significantly enhance specificity or efficiency compared to binary vectors that rely on endogenous ADARs (FIG. 10c-i).

[0339] Example 16 RNA expression levels and CellREADR In addition to Ctip2 and Fezf2 mRNAs that mark CFPNs (cortical subduction neurons that send their axons to extracortical regions, including the thalamus and spinal cord), several other mRNAs are expressed at a range of levels and target sesRNAs. 40were constructed in binary vectors containing PlxnD1 (intracene projection neurons (IT PNs) in L2 / 3 and L5a), Satb2 (IT PNs across both upper and lower layers), Rorb (L4 pyramidal neurons), and vGAT (pan-GABAergic neurons), respectively (Figure 11). Several sesRNAs that achieved 75% or greater specificity were identified (Figure 12). These results indicate that CellREADR is a robust method and that targeting of specific cell types can be achieved by testing multiple sesRNAs for each target.

[0340] (Example 17) Long-term effects of CellREADR To evaluate the long-term effects of CellREADR sesRNA in vivo, Ctip2 / 3 and control CAG-tdT AAV were monitored in mouse cortex for 3 months. Quantitative RT-PCR assays for the expression of nine genes involved in glial activation and immunogenicity were performed using the READR Ctip2 / 3 No significant changes were noted in infected versus control tissues (Figure 13). (Example 18) Recording and controlling neuronal types with CellREADR

[0341] We used CellREADR validation to record and control neural function in mice. As a benchmark, we compared CellREADR to a cell-type targeting approach based on transcriptional enhancers. We identified the mscRE4 enhancer to activate L5 pyramidal track (PT) neurons, a subset of CFPNs. 18 Thus, we compared the effectiveness of the mscRE4 enhancer (i.e., the PT enhancer) and Ctip2 sesRNA3 by using the same tTA-TRE binary vector to express the genetically encoded calcium indicator GCaMP6s and the light-activated ion channel channelrhodopsin2 (Figure 4i-p).

[0342] PT enhancer-tTA2 / reporter in mouse forelimb somatosensory cortex GCaMP6s or READR Cti p 2 / 3 / Reporter GCaMP6s In AAV-co-infected mice, mechanical stimulation of the forepaw downregulates the PT enhancer and the READR Ctip2 / 3 In both infected mice, we induced a robust and time-locked increase in GCaMP6s signals in the forelimb somatosensory cortex as measured by fiber photometry ( Figure 4 i–l ), indicating that the effector gene expression levels achieved by CellREADR were sufficient to monitor cell physiology in living animals.

[0343] PT enhancer-tTA2 / reporter in the caudal forelimb motor cortex (CFA) ChRger2-eYFP or READR Cti p 2 / 3 / Reporter ChR g er2-eYFP In AAV-co-infected mice, light stimulation of the CFA induced robust and time-locked forelimb movements, which were significantly greater than those in READR-infected mice compared with PT enhancer-infected mice. Ctip2 / 3 (Fig. 4m-p, Extended Data Movie 1). This result indicates that the effector gene expression levels achieved by CellREADR were sufficient to control cell function in behaving animals. Anatomical analysis of eYFP expression demonstrated that READR regulates YFP expression in the striatum, thalamus, pons, and subcortical targets, including the medulla. Ctip2 / 3 We confirmed L5 PT neuron labeling by .

[0344] (Example 19) CellREADR targeting of neuronal types across mammalian species A series of experiments in rat and human brains were performed to demonstrate the generalizability of CellREADR across mammalian species. GABAergic neurons were targeted in rats by using a binary AAV vector targeting vGAT mRNA, a pan-GABAergic transcript (Figure 15b).vGAT (hSyn-mCherry-sesRNA vGAT -smFlag-tTA2) and reporter mNeon Co-injection of (TRE3g-mNeon) AAV (Figure 15a) into rat S1 barrel cortex and hippocampus specifically labeled GABAergic interneurons in the cortex (Figure 15c) and hippocampus (Figure 15d-c). vGAT mRNA (magenta) and READR vGAT Specificity, assayed by co-labeling with GFP (GFP), was 91.7% for the cortex and 93.8% for the hippocampus, respectively (Figure 15f-g). Tle4 is a conserved transcription factor that marks L6 corticothalamic (CT) pyramidal cells in rodents. Binary READR Tle4 AAV-delivered sesRNA targeting exon 15 of Tle4 mRNA (Fig. 15h) labeled deep layer neurons by co-labeling with TLE4 antibody in 62.5% of cases (Fig. 15i-k).

[0345] (Example 20) Neocortical Organotypic Culture Platform An organotypic culture platform was established to study CellREADR in human neocortical specimens collected from epilepsy surgery. 41 (Fig. 16a). Infection of these samples with a GFP construct driven by the hSyn promoter (AAVrg-hSyn-eGFP) showed dense viral labeling across multiple layers, with the observed morphology and innervation of many pyramidal neurons characterized by prominent apical dendrites (Fig. 16b, c). It is expressed in cortical and striatal projection neurons and may be involved in human language skill development. 42 Two sesRNAs targeted FOXP2 mRNA (forkhead box protein P2), an evolutionarily conserved gene involved in aging (Fig. 5a, b). In situ hybridization and immunostaining showed that FoxP2 expression is restricted to L6 CT neurons. 39 Unlike mouse, human FOXP2 is expressed throughout the cortex (FIG. 16d). FOXP2 / ReportermNeon AAV(hSyn-ClipF-sesRNA FOXP2 Five days after application of TRE3g-smV5-tTA2 and TRE3g-mNeon to human neocortical slices, mNeon-labeled cell bodies were observed in upper and deeper layers (Fig. 5c; Extended Data in Fig. 16e). FOXP2 immunostaining was observed in the binary READR FOXP2 The specificity of the labeled neurons was approximately 80% (Fig. 5d, e). The labeled neurons also showed electrophysiological (Fig. 5f) and morphological (Fig. 5g) properties consistent with glutamatergic pyramidal neurons. 43 Two specific READRs with different sesRNAs FOXP2 Using the vector, greater than 97% specificity of targeting FOXP2 neurons was observed (Figure 16f-i).

[0346] Example 21 Targeting human neocortical GABAergic cells Human neocortical GABAergic cells were targeted to VGAT using sesRNA (Figure 5h). VGAT / Reporter mNeon Using , we observed cell labeling across neocortical layers (Fig. 5i), with labeled cells displaying diverse morphological characteristics of interneurons, including multipolar and smooth dendrites (Fig. 5j), and a strikingly high density of vertically oriented axons (Fig. 5i, k). In situ hybridization for VGAT mRNA showed a specificity of 76.5% (Fig. 5l, m), an underestimation likely due to the potentially reduced sensitivity of in situ hybridization in cultured ex vivo tissue. In support of this possibility, very few labeled cells were observed with pyramidal morphology (Fig. 5i-l). READR 7 days after viral application VGAT / Reporter mNeon Targeted patch-clamp recordings of labeled interneurons revealed a variety of intrinsic properties, including coordinated, fast, and delayed-onset firing (Fig. ​(Fig.5n).5n) The physiological properties (Fig.5n) and partially reconstructed morphology (Fig.5o) of the patched cells were consistent with those of mammalian neocortical interneurons. 44Together, these results demonstrate the cross-species generalizability and utility of CellREADR.

[0347] Example 22 Targeting neuronal types and pathological neuronal ensembles to treat epilepsy Disease and clinical background Epilepsy affects approximately 1% of the population, and in developed countries, up to 30% of patients continue to experience seizures despite optimal antiepileptic drug therapy. 1 The most effective treatment for focal epilepsy is surgery, which is preferred for very few patients due to the unacceptable effects of removing brain tissue. There is an urgent need to identify novel therapeutic targets and develop new treatment strategies. Gene therapy may modulate neuronal excitability in refractory epileptic foci while preserving function. 1 However, the current lack of sufficient cell type and disease state specificity remains a major obstacle for effective gene therapy. 2 .

[0348] Focal epilepsy results from an imbalance of excitation and inhibition characterized by hypersynchronized neuronal activity in pathological brain networks. 1 Brain circuits contain multiple excitatory and inhibitory cell types, each of which contributes uniquely to information processing and excitation-inhibition balance. 3,4 Neuronal activity promotes seizures in some cell types but inhibits seizures in others 2 It is therefore important to achieve cell-type targeted modulation of neuronal activity at appropriate stages of epilepsy progression, e.g., initiation, maintenance, etc. 1、2Methods to suppress pathophysiological ensembles, those that are actually involved in seizure activity, may be particularly effective. CellREADR technology can use RNA sensors to achieve cell type- and disease state-specific modulation of brain circuit activity through the expression of druggable modulatory receptors (e.g., GPCRs) and ion channels, thus presenting a promising approach to control and treat focal epilepsy.

[0349] Targeting GABAergic inhibitory neuron types GABAergic interneurons mediate inhibitory control of brain circuits and include diverse neuronal types 4 The vesicular GABA transporter (vGAT) is expressed in all GABA neurons, whereas parvalbumin (PV), somatostatin (SST), calretinin (CR), and VIP mark several major subpopulations / types. The role of these interneuron types in the pathogenesis of seizures remains incompletely understood. PV neurons have subtly different roles and have been shown to promote or suppress seizures at different stages of epilepsy. CellREADR technology has been applied to the neocortex of mice, rats, and humans. 9 (see Table A), and more recently to help target GABA interneurons in the neocortex of macaque monkeys (Figure 17). Sensors for targeting human PV and SST neurons (Figure 18) are used in all human ex vivo cortical tissue dissected from the temporal or frontal lobes of epilepsy patients. Table A [Table A-1] [Table A-2]

[0350] Effectors and expected outcomes for GABA inhibitory neurons A chemical genetic approach using two ligand-gated mechanisms to activate SST neuron-mediated inhibition to suppress seizure activity 1 Chemical genetics relies on the modification of endogenous receptors or the production of engineered chimeric receptors that respond to exogenous ligands.

[0351] First, excitatory DREADDs (designer receptors exclusively activated by designer drugs; hM3Dq excitatory receptors). 10 DREADDs can be specifically activated by the FDA-approved drugs clozapine-n-oxide or olanzapine. 11 The dose of the drug can be titrated to suppress seizures without adverse effects.

[0352] Second, excitatory PSAMs (pharmacologically selective actuator modules / pharmacologically selective effector molecules) 12 Varenicline, a drug approved for smoking cessation 13 A new version of PSAM has been developed that is sensitive to

[0353] The advantage of the chemical genetic approach is that the gene therapy is inactive until the drug is given, so it is possible to turn the gene therapy "off and on". Also, the magnitude of the effect depends on the dose of the ligand. Thus, it is possible to set the dose of the drug to avoid any possible side effects but still optimize efficacy. The cell-specific chemical genetic strategy based on CellREADR can be generalized to target other GABAergic and glutamatergic neuronal types to treat seizures and other neurological disorders.

[0354] Targeting Pathophysiological Neural Ensembles (PNE) A particularly effective strategy for managing or treating epilepsy is to suppress or control even just the neurons and neural ensembles that cause excessive activity, i.e., pathophysiological neural ensembles (PNEs). CellREADR is useful for this purpose. Excessive and synchronized neural activity leads to rapid upregulation of the immediate early gene (IEG) c-fos. 14、15 , which marks the majority of glutamatergic excitatory neurons that compose the PNE. A c-fos RNA sensor has been constructed to target and modulate the PNE. A panel of four sensors has been tested, many of which have already shown promising results in neuronal cultures. In addition to c-fos, other IEGs that could also be used to target the PNE 15 There is an extended list of

[0355] Effector genes Three effector genes are combined with the c-fos sensor.

[0356] First, the voltage-gated potassium channel Kv1.1 (KCNA1) reduces spiking in neurons of the PNE. 16 This inhibits the firing of neurons in the PNE.

[0357] The second is an inhibitory DREADD (hM4D(Gi) inhibitory receptor). 10 , which can be activated by the oral drug olanzapine.

[0358] The third is the chloride-permeable invertebrate glutamate receptor (eGluCL). 17、18 eGluCL binds to glutamate released during seizure activity and can also be activated by the FDA-approved drug ivermectin, and the resulting chloride influx inhibits neuronal activity. Ivermectin can also be given to reduce neuronal activity, either chronically or as a rescue medication.

[0359] The inherent advantage of this approach to targeting PNE is that it is a "closed loop" control. Under normal physiological conditions, c-fos is not significantly expressed, and therefore there is no effector expression. During epilepsy, upregulation of c-fos RNA triggers effector translation to suppress PNE activity. The strategy can be generalized to target other IEGs to treat seizures and other neurological disorders.

[0360] delivery All of the above CellREADR vectors are delivered to the epilepsy lesion using AAV vectors (serotypes 2 / 9 and php.eb). Instead of removing brain tissue from the epilepsy lesion during traditional epilepsy surgery, the therapeutic CellREADR AAV is injected into the lesion, preserving the brain tissue.

[0361] Expected outcomes and improvements to current procedures With the SST sensor and CellREADR vector, oral administration of olanzapine (for excitatory DREADDs) or varenicline (for excitatory PSEMs) activates SST interneurons and suppresses focal epilepsy. With the c-fos sensor and CellREADR vector, oral administration of olanzapine (for inhibitory DREADDs) or varenicline (for inhibitory PSEMs) reduces the firing of glutamatergic neurons in the PNE and suppresses epilepsy. Together, these RNA therapeutics specific to specific cell types and specific disease states will transform the management and treatment of epilepsy. References [ka] [ka] [ka]

[0362] Example 23 Neuronal CellREADR targeting in non-human primates We developed RNA sensors for macaque Foxp2 and vGAT, which mark a subset of glutamatergic pyramidal neurons and GABAergic interneurons, respectively. We then created binary AAV6 vectors expressing conditional EGFP for RNA sensing. Using these AAV CellREADR vectors targeting macaque FOXP2 and vGAT mRNA (Figure 17), we generated binary READR FOXP2 / Reporter mNeon and READR FOXP2 / Reporter mNeon AAV was injected into the V1 region of the macaque cortex. FOXP2 Fluorescence microscopy of infected cortex revealed that mNeon in subgranular pyramidal neurons, their apical dendrites, and efferent axons in the white matter were indicative of glutamatergic pyramidal neurons. vGAT mNeons from infected cortex were restricted to morphologically diverse putative inhibitory neurons throughout cortical layers, thus demonstrating that CellREADR is valid in non-human primates in vivo.

[0363] (Example 24) Cell-specific treatment of chronic pain Disease and clinical background The incidence of chronic pain is estimated to be 20-25% worldwide. Few patients with chronic pain obtain complete relief from currently available medications, and more than half report incomplete relief. 1 Although an intact central nervous system (CNS) is necessary for the conscious perception of pain, changes in the CNS are clearly evident in chronic pain states, and ongoing peripheral nociceptive input plays a major role in the maintenance of chronic pain. 1Nociceptors in the skin, muscles, joints and viscera, which respond selectively to noxious or potentially tissue-damaging stimuli and mediate peripheral pain, input into the CNS. Despite detailed characterization of the mechanisms underlying nociceptor excitability, combined with the identification of several ion channels, receptors and second messenger signaling molecules that serve as focal points, effective therapeutic interventions for the management of pain without adverse side effects remain elusive. 1 The anatomical, physiological, and functional heterogeneity among nociceptive afferents is rooted in their differential gene expression and contributes to the difficulty in identifying new therapeutic agents, as well as several notable failures to translate preclinical data into effective clinical interventions. 1 .

[0364] Among the signaling mechanisms within nociceptors following sensory stimulation, the firing of an action potential is the final output of the afferent nerve signal to the CNS. Nociceptive action potentials are primarily driven by the voltage-gated sodium channels NaV1.7 and NaV1.8. Human genetic studies have highlighted a critical role for NaV1.7 in nociceptive processing: gain-of-function mutations are associated with pain syndromes such as erythromelalgia and paroxysmal acute pain, whereas loss-of-function mutations are associated with congenital analgesia. 2 Nociceptors therefore present an important therapeutic target for chronic pain. A previous CRISPR-dCas9-based approach for downregulation of Nav1.7 achieved long-term pain relief in mice without alteration of motor function. 3 CellREADR technology enables modulation of sodium channels and other signaling mechanisms within specific types of nociceptors to achieve therapeutic efficacy while reducing side effects.

[0365] Targeting of nociceptors and effector expression in the dorsal root ganglion NaV1.8 and TRPV1 are specifically expressed in nociceptors. Use RNA sensors for TRPV1 and NaV1.8 to establish specific access to nociceptors. Use cell type specific short hairpin RNA (shRNA) based on CellREADR in knockdown approach to downregulate NaV1.7 and NaV1.8 mRNA in nociceptors. Generate binary expression vector (Figure 20) in which the translation of transcription activator tTA is gated by NaV1.7 or NaV1.8 RNA sensor, and then tTA activates the transcription of shRNA for NaV1.7 or NaV1.8 RNA. This binary CellREADR vector is packaged into AAV9.

[0366] Delivery by intrathecal injection into the cerebrospinal fluid via lumbar puncture These AAV vectors are delivered by intrathecal injection into the cerebrospinal fluid and infect neurons in the dorsal root ganglion. CellREADR is specifically expressed in the RNA sensor that defines nociceptors.

[0367] Expected outcomes and improvements to current procedures CellREADR-mediated modulation of NaV1.7 and NaV1.8, as well as other signaling mechanisms, within certain types of nociceptors is more effective in achieving therapeutic effects with low side effects.

[0368] Targeting astrocytes and satellite glial cells Astrocytes are important for maintaining homeostasis in the CNS. Several neurological disorders, including chronic pain, can result from astrocytic "gliopathy." 4 Astrocytes can regulate nociceptive synaptic transmission through neuronal-glial and glial-glial interactions, as well as the involvement of spinal and supraspinal astrocytes in modulating pain signaling and maintaining neuropathic pain. 4In addition, astrocyte-mediated neuroinflammation is a key mechanism underlying the maintenance of chronic pain. 4 Targeting specific pathways responsible for astrogliopathy presents a novel approach to develop treatments for chronic pain.

[0369] Multiple cell types interact with nociceptive neurons and contribute to pain pathogenesis through distinct signaling mechanisms, including satellite glial cells, T cells, oligodendrocytes, and microglia. 5 CellREADR is used to modulate neuro-glial interactions for chronic pain treatment by targeting specific glial cell types.

[0370] Satellite glial cells localize to the dorsal root ganglia of the peripheral nervous system and express markers such as Kir4.1 and FABP7 6 An RNA sensor for FABP7 targets satellite glial cells. The potassium channel Kir4.1 is downregulated in pathological pain states. 6 Kir4.1 function is restored by expressing a potassium channel to FABP7+ satellite glial cells.

[0371] vGluT1 is downregulated in the spinal cord under pathological conditions, leading to glutamate receptor hyperactivation and chronic pain 4 RNA sensors for Aldh1l1 (astroglia-specific marker) to target astrocytes and Fabp7 to target satellite glial cells. The vesicular glutamate transporter vGluT1 is expressed in Aldhl1+ astrocytes. Notably, the intrathecal route may target not only sensory neurons in the DRG but also satellite glial cells in the DRG and astrocytes in the spinal cord.

[0372] CellREADR is a useful approach to specifically label satellite glial cells in the DRG and astrocytes in the spinal cord after intrathecal delivery. Furthermore, the CellREADR-based approach can restore the function of satellite glial cells and astrocytes in pathological conditions, resulting in long-term relief and reversal of chronic pain. References [ka]

[0373] (Example 24) Cell-specific intervention in Alzheimer's disease Disease and clinical background Neuroinflammation is a central mechanism involved in neurodegeneration, as observed in Alzheimer's disease (AD), the most common form of neurodegenerative disease.1, 2 Apolipoprotein E4 (APOE4), the strongest genetic risk factor for AD, directly influences disease development and progression by interacting with the major pathological hallmarks of AD, including amyloid-β plaques, neurofibrillary tau tangles, and neuroinflammation.1, 2 In the CNS under basal conditions, astrocytes produce most apoE, and in the setting of brain injury or neurodegeneration, APOE expression is strongly upregulated in microglia.

[0374] Microglia and astrocytes, the two major immune cells in the brain, exist in a state of immune vigilance, providing immunological defense and housekeeping functions that promote neuronal health. Under disease conditions, these immune cells become progressively dysfunctional in regulating metabolic and immunoregulatory pathways, thereby promoting chronic inflammation-induced neurodegeneration, and a key component of this pathological process is elevated microglia-mediated synaptic phagocytosis.

[0375] Astrocyte-derived apoE particles are considerably larger and therefore contain more lipids compared to apoE secreted by microglia. Astrocyte-secreted apoE4, either alone or together with other molecules such as C1q, may serve as an opsonin for specific microglial receptors to activate microglial responses. In the P301S tau mouse model of AD, ablation of astrocytic APOE4 significantly reduced tau-mediated neurodegeneration and reduced phosphorylated tau (pTau) pathology, as well as disease-associated gene signatures in neurons, oligodendrocytes, astrocytes, and microglia,3. Ablation of astrocytic APOE4 further reduced tau-induced synaptic loss and microglial phagocytosis of synaptic elements, suggesting a critical role for astrocytic apoE in synaptic degeneration,3.

[0376] target cell type Brain, specifically astrocytes and microglia in the cerebral cortex. Marker genes / RNAs include: - Astrocytes: aldehyde dehydrogenase family 1 member L1 (Aldh1L1), glial fibrillary acidic protein (GFAP), excitatory amino acid transporter 1 (EAAT1) -Microglia: C-X3-C motif chemokine receptor 1 (CX3CR1), transmembrane protein 119 (TMEM119), ionized calcium-binding adaptor molecule 1 (IBA-1)

[0377] Target Gene shRNA against ApoE4 RNA to achieve downregulation in brain astrocytes and / or microglia.

[0378] FIG. 21 illustrates a construct in which the first module of the readrRNA is driven by the hSyn promoter followed by a spacer, an SES RNA specific for one of the target RNAs listed above, and a tTA2 transcription activator, whereupon ADAR editing is translated and binds to a TRE located upstream of the first module of the readrRNA, which drives expression of a short hairpin RNA complementary to ApoE4 RNA.

[0379] delivery AAV vectors were used for initial testing in the P300 tau mouse model, recapitulating the results from Wang and Holtzman Neuron 2021, i.e., demonstrating a reduction in tau-mediated neurodegeneration and synaptic phagocytosis.

[0380] In AD patients, along the progression from preclinical to early and late stages, amyloid deposition begins in the temporobasal and medial frontal regions, followed by the rest of the association neocortex, primary sensorimotor cortex, and medial temporal lobe, and finally affecting the striatum. 4, 5 AAV vectors are injected into the temporobasal and medial frontal regions of early stage patients to reduce ApoE4 production from astrocytes and microglia in these regions.

[0381] Expected Results Reducing ApoE4 production from astrocytes and microglia in the temporobasal and medial frontal regions attenuates the neuroinflammatory response and protects against tau-mediated neurodegeneration and synaptic phagocytosis by microglia. Together, these treatments attenuate or prevent the progression of AD. References [ka] [ka]

[0382] Table 6. Described herein are plasmids encoding responsive (albeit not physically linked) genes, such as (i) targeted exogenous transcripts for proof-of-principle experiments, (ii) readrRNAs, or (iii) effector genes, e.g., transactivators. [Table 6]

[0383] The UGT1A1 gene as an effector [ka] [ka]

[0384] VEGFA coding sequence as an effector [ka] [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 7-9]

Table 7-10

Table 7-11

Table 7-12

Table 7-13

Table 7-14

Table 7-15

Table 7-16

Table 7-17

Table 7-18

Table 7-19

Table 7-20

Table 7-21

Table 7-22

Claims

1. (i) a 5' region comprising a sensor domain comprising a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides in cellular RNA of a cell of a mammalian central nervous system, said sensor domain comprising a stop codon editable by ADAR; and (ii) a 3' region comprising a protein coding domain, said protein coding domain being downstream of and in frame with said sensor domain; A modular RNA molecule comprising: Upon introduction of the modular RNA into the cell containing an Adar enzyme, the stretch of contiguous nucleotides of the sensor domain and the corresponding nucleotide stretch of the cellular RNA form an RNA duplex containing the stop codon, and the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing translation of the protein. Modular RNA molecules.

2. i. a 5' region comprising a sensor domain comprising a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides of a cellular RNA of a cell of the peripheral nervous system of a mammal, said sensor domain comprising a stop codon editable by an ADAR; and ii. a 3' region comprising a protein coding domain, said protein coding domain being downstream of and in frame with said sensor domain; A modular RNA molecule comprising: Upon introduction of the modular RNA into the cell containing an Adar enzyme, the stretch of contiguous nucleotides of the sensor domain and the corresponding nucleotide stretch of the cellular RNA form an RNA duplex containing the stop codon, and the stop codon contained in the RNA duplex is edited by ADAR in the cell, thereby allowing translation of the protein. Modular RNA molecules.

3. 3. The modular RNA molecule of claim 1 or claim 2, wherein said stretch of contiguous nucleotides of said sensor domain is capable of forming an RNA duplex with at least a portion of an mRNA, said portion comprising a corresponding stretch of contiguous nucleotides.

4. 3. The modular RNA molecule of claim 1 or claim 2, wherein the protein coding region encodes an effector protein.

5. 3. The modular RNA molecule of claim 1 or claim 2, wherein the molecule further encodes a self-cleaving 2A peptide located between the sensor domain and the 3' protein coding domain.

6. 6. The modular RNA molecule of claim 5, wherein the self-cleaving 2A peptide is selected from the group consisting of one or more of a T2A peptide, a P2A peptide, an E2A peptide, and an F2A peptide.

7. 3. The modular RNA molecule of claim 1 or claim 2, wherein the 3' protein coding domain comprises a protein selected from the group of a marker, a transcriptional activator, and a transcriptional repressor.

8. i) a first nucleic acid comprising a modular RNA molecule comprising: (i) a sensor domain comprising a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA of a mammalian cell of the central nervous system, said sensor domain comprising a stop codon editable by ADAR; and (ii) a first protein coding domain encoding an effector protein, said first protein coding region downstream of and in frame with said sensor domain; and ii) a second nucleic acid comprising a second protein coding domain; A composition comprising:

9. i) a first nucleic acid comprising a modular RNA molecule comprising: (i) a sensor domain comprising a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA of a mammalian cell of the peripheral nervous system, said sensor domain comprising a stop codon editable by ADAR; and (ii) a first protein coding domain encoding an effector protein, said first protein coding region downstream of and in frame with said sensor domain; and ii) a second nucleic acid comprising a second protein coding domain; A composition comprising:

10. 10. The composition of claim 8 or claim 9, wherein the first and second nucleic acids comprise a single nucleic acid molecule.

11. 10. The composition of claim 8 or claim 9, wherein the first and second nucleic acids comprise two nucleic acid molecules.

12. 10. The composition of claim 8 or claim 9, wherein the first and second nucleic acids are covalently linked.

13. 10. The composition of claim 8 or claim 9, wherein the second protein coding domain is contained within a gene that includes a transcriptional control element, optionally a promoter.

14. The composition of claim 8 or 9, wherein the effector protein binds to the gene.

15. 10. The composition of claim 8 or claim 9, wherein expression of the second protein coding domain is modulated by the effector protein.

16. 10. The composition of claim 8 or claim 9, wherein the first protein coding domain encodes a transcriptional activator or a transcriptional repressor.

17. 10. The composition of claim 8 or claim 9, wherein the first protein coding domain encodes a DNA recombinase.

18. The composition of claim 8 , wherein the cell comprises a mammalian cortical cell.

19. The composition of claim 9 , wherein the cells comprise mammalian Schwann cells or mammalian satellite cells of the peripheral nervous system.

20. The composition of claim 8 , wherein the first protein coding domain encodes an effector protein comprising a transcriptional activator.

21. 21. The composition of claim 8 or 20, wherein the stretch of contiguous nucleotides of the sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by a Fezf2 gene.

22. 22. The composition of claim 8, 20, or 21, wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of an inducible promoter.

23. The composition of claim 9 , wherein the first protein coding domain encodes an effector protein comprising a transcriptional activator.

24. 24. The composition of claim 9 or 23, wherein the stretch of contiguous nucleotides of the sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a peripheral CNS cell.

25. 25. The composition of claim 9, 23, or 24, wherein the second nucleic acid comprises a second protein coding region under the transcriptional control of an inducible promoter.

26. The first protein coding region comprises: - a cell death protein selected from the group consisting of thymidine kinase (TK) and cytosine deaminase (CD), - programmed cell death proteins selected from the group consisting of CASP3, CASP9, BCL, GSDME, GSDMD, GZMA and GZMB, A neuroactivating protein selected from the group consisting of ChR2 and DREADD-M3Dq, - an immune enhancer protein selected from the group consisting of IFNB, IFNG, TNFA, IL2, IL12, IL15 and CD40L; - a physiological editing protein selected from the group consisting of NaChBac and Kir2.1, f) a lysine-containing protein synthesis inhibitor protein; - a neuronal inhibitory protein selected from the group consisting of DREADD-hM4D, NpHR and GtACR1; - proteins involved in neuronal cell fate, such as NEUROD, and - Proteins involved in cell regeneration, including epidermal growth factor The composition of claim 8 or claim 9, which encodes an effector protein selected from:

27. A nucleic acid delivery vehicle comprising a modular RNA molecule of claim 1 or 2, or a composition of claim 8 or claim 9, and / or a DNA encoding the modular RNA molecule of claim 1 or 2, or the composition of claim 8 or claim 9.

28. 28. The nucleic acid delivery vehicle of claim 27, selected from the group consisting of nanoparticles, liposomes, vectors, exosomes, microvesicles, gene guns, and selective endogenous encapsulation (SEND) systems for cell delivery.

29. The nucleic acid delivery vehicle of claim 28 , comprising a viral vector.

30. 30. The nucleic acid delivery vehicle of claim 29, wherein the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, retrovirus, lentivirus, herpes virus, and vesicular stomatitis virus.

31. 3. The modular RNA molecule of claim 1 or claim 2, encoded by a DNA vector.

32. The composition of claim 8 or 9, wherein the modular RNA molecule is encoded by a DNA vector.

33. The delivery vehicle of claim 27 , wherein the modular RNA molecule is encoded by a DNA vector.

34. A pharmaceutical composition comprising a modular RNA molecule according to claim 1 or claim 2, a composition according to claim 8 or claim 9, or a delivery vehicle according to claim 27, and a pharma- ceutically acceptable carrier, excipient and / or diluent.

35. 28. A cell comprising a modular RNA molecule according to claim 1 or claim 2, a composition according to claim 8 or claim 9, or a delivery vehicle according to claim 27.

36. The cell of claim 31 , which is a mammalian cell.

37. 28. A kit comprising a modular RNA molecule according to claim 1 or claim 2, a composition according to claim 8 or claim 9, or a delivery vehicle according to claim 27, and packaging therefor.

38. 28. A method for introducing a modular RNA according to claim 1 or 2, a nucleic acid composition encoding said modular RNA according to claim 8 or 9, or a delivery vehicle according to claim 27 comprising said modular RNA or a nucleic acid composition encoding said modular RNA into a selected cell of a mammal, comprising: contacting a cell of said mammal with said modular RNA molecule, said nucleic acid composition encoding said modular RNA, or said delivery vehicle comprising said modular RNA or said nucleic acid composition encoding said modular RNA under conditions that allow said cell of said mammal to contain said modular RNA, or said delivery vehicle comprising said modular RNA or said nucleic acid composition encoding said modular RNA; The modular RNA is as described in claim 1 or claim 2, the nucleic acid composition is as described in claim 8 or claim 9, and the delivery vehicle is as described in claim 27. method.

39. 1. A method for inducing ADAR editing of a stop codon in a mammalian cell containing a selected target cell RNA to allow expression of an in-frame downstream encoded protein, comprising: introducing a modular RNA molecule into said cell of said mammal under conditions in which said modular RNA is contained in said cell, said modular RNA comprising: (i) a 5' region comprising a sensor domain comprising a stretch of consecutive nucleotides that is complementary to a corresponding stretch of consecutive nucleotides of said selected cellular RNA, said sensor domain comprising a stop codon editable by ADAR; and (ii) a 3' region comprising a domain encoding an effector protein, said protein coding region being downstream of and in frame with said sensor domain; upon introduction of the modular RNA molecule into the mammal, an RNA duplex is formed in the cell between the stretch of consecutive nucleotides of the sensor domain and the corresponding stretch of consecutive nucleotides of the cellular RNA, the RNA duplex comprising the ADAR-editable stop codon, and wherein ADAR edits the stop codon contained in the RNA duplex, thereby allowing translation of the protein; The protein is produced in the mammal. A method comprising:

40. 1. A method for treating a disease or disorder in a mammal, comprising: Providing an agent, said agent comprising a modular RNA molecule according to claim 1 or claim 2, or a nucleic acid composition according to claim 8, 9, 11 or 12, or a delivery vehicle according to claim 27; and administering said agent to said mammal in a therapeutically effective amount to enable translation of said 3' encoded protein or said effector protein in selected cells of said mammal, thereby producing said protein in said cells, wherein production of said protein in said cells provides treatment of said disease or disorder in said mammal. A method comprising:

41. 37. The method of claim 36, wherein the pharmaceutical agent comprising the composition of claim 8 or claim 9 or the delivery vehicle of claim 23 is administered, and the first protein coding region encoding the effector protein contained in the pharmaceutical agent encodes a transactivator protein that activates expression of the second protein coding region, and expression of the second protein coding region in the selected cells is therapeutically effective in treating the disease or disorder.

42. 1. A method of stimulating L5b / L6 subcortical projection neuron signals in the forelimb somatosensory cortex of a mouse in response to mechanical stimulation of the forepaw, as measured by photometry, comprising:

9. Administering to the mouse the composition of claim 8, wherein the sensor domain comprises a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA encoding Ctip2 or Fezf, the first protein-coding domain encodes an effector protein comprising a transcriptional activator, and the second nucleic acid comprises a gene encoding a reporter protein under the transcriptional control of an inducible promoter; said administering provides for production of said effector protein and said reporter protein; thereby allowing stimulation of the L5b / L6 CFPN signal in the forelimb somatosensory cortex of the mouse. A method comprising:

43. 1. A method for stimulating forelimb movement in response to light stimulation of the caudal forelimb area (CFA) in a mouse, comprising:

9. Administering to the mouse the composition of claim 8, wherein the sensor domain comprises a stretch of contiguous nucleotides that is complementary to a corresponding stretch of contiguous nucleotides of a cellular RNA encoding Ctip2, the first protein-coding domain encodes an effector protein comprising a transcriptional activator, and the second nucleic acid comprises a gene encoding a light-activated reporter protein under the transcriptional control of an inducible promoter; said administering providing production of said effector protein and said light-activated reporter protein, thereby allowing light stimulation of movement of said forelimbs of said mouse. A method comprising:

44. 40. The method of claim 39, wherein a second gene is operably linked to a TRE-3G eukaryotic inducible promoter, said second gene encoding enhanced yellow fluorescent protein (eYFP), and said administering provides production of enhanced yellow fluorescent protein.

45. A pharmaceutical composition comprising a modular RNA molecule as described in claim 1 or claim 2, and / or a composition as described in claim 8 or claim 9, and / or a delivery system as described in claim 27, and a pharma- ceutically acceptable carrier, excipient and / or diluent.

46. A cell comprising a modular RNA molecule as described in claim 1 or claim 2, and / or a composition as described in claim 8 or claim 9, and / or a delivery system as described in claim 27.

47. A kit comprising a modular RNA molecule according to claim 1 or claim 2, and / or a composition according to claim 8 or claim 9, and / or a delivery system according to claim 27.

48. A method for identifying GABAergic neurons in the mammalian cortex in vivo, comprising:

9. Administering to the mammal the composition of claim 8 under conditions that allow transfection of the composition into cells of the S1 barrel cortex and hippocampus and expression of the protein coding region, said stretch of contiguous nucleotides of said sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular vGAT RNA of a cortical cell; the first protein coding domain encodes an effector protein comprising a transcriptional activator and a second effector protein comprising a first reporter protein, and the second nucleic acid comprises a coding region for a second reporter protein under the transcriptional control of an inducible promoter; the first nucleic acid comprising the modular RNA molecule is under the control of a promoter, the modular RNA molecule comprising a gene encoding a third reporter protein upstream of the sensor domain and under the control of a promoter; the protein is produced from the coding region, Identification of GABAergic neurons in the mammalian cortex that contain vGAT mRNA is possible upon detection of one or more of the first, second and third reporter proteins. A method comprising:

49. 45. The method of claim 44, wherein the sesRNA-targeted vGAT mRNA is complementary to all or a portion of exon 1 of vGAT mRNA.

50. A method for identifying GABAergic neurons in a mammalian cortex in vivo, comprising administering to a mammal a composition according to claim 8 under conditions that allow transfection of cells of the mammalian cortex with the composition and production of the protein encoded by the composition, said stretch of contiguous nucleotides of said sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular Tle4 RNA of a cortical cell; the first protein coding domain encodes an effector protein comprising a transcriptional activator and a second effector protein comprising a first reporter protein; the second nucleic acid comprises a coding region for a second reporter protein under the transcriptional control of an inducible promoter; the first nucleic acid comprising the modular RNA molecule is under the control of a promoter; the modular RNA molecule comprises a gene encoding a third reporter protein under the control of a promoter upstream of the sensor domain; detection of one or more of the first, second and third reporter proteins in cells of the mammalian cortex allows identification of TLE4 positive projection neurons, thereby identifying GABAergic neurons in the mammalian cortex. A method comprising:

51. 47. The method of claim 46, wherein the sensor domain is complementary to all or a portion of exon 15 of Tle4 mRNA.

52. 1. A method for determining the presence of cells in culture that contain Forkhead box protein P2 (FOXP2) RNA in the cortical layer of a mammalian cortex, comprising:

10. Contacting a cultured cortical layer of a mammalian cortex with the composition of claim 9, said stretch of contiguous nucleotides of said sensor domain is complementary to a stretch of contiguous nucleotides of a selected FOXP2 cellular RNA of a cortical cell; the first protein coding domain encodes an effector protein comprising a transcription activator and a second effector protein comprising a gene encoding a first reporter protein; the second nucleic acid comprises a coding region for a second reporter protein under the control of an inducible promoter; the modular RNA molecule further comprises a gene encoding a third reporter protein upstream of the sensor domain; Step, detecting one or more of said first, second and third reporter proteins, said detection in a cell body of said cortex indicating the presence of said cells. A method comprising:

53. 1. A method for inhibiting neural activity in a mammal that promotes focal epileptic seizures, comprising: administering to the mammal a therapeutically effective amount of an agent, said agent comprising a modular RNA molecule of claim 1, or a nucleic acid composition of claim 8, or a delivery vehicle of claim 27; said stretch of contiguous nucleotides of said sensor domain is complementary to a stretch of contiguous nucleotides of a selected cellular RNA of a cortical cell encoded by an SST gene; the first protein coding domain encodes a) a transcriptional activator and b) a first effector protein; the second nucleic acid comprises a coding region for a second effector protein under the control of an inducible promoter that is induced by the transcriptional activator; the modular RNA molecule further comprises a gene encoding a third effector protein upstream of the sensor domain; The composition further comprises a gene encoding a DREADD receptor or a gene encoding PSAM, In the presence of a drug effective to activate the receptor encoded by the DREADD or PSAM gene, the DREADD receptor or the PSAM receptor is activated, thereby allowing production of one or more of the effector proteins and treatment of epilepsy in the mammal. A method comprising:

54. 1. A method for inhibiting neural activity in a mammal that promotes focal epileptic seizures, comprising: administering to the mammal a therapeutically effective amount of an agent, wherein the agent comprises a modular RNA molecule of claim 1, or a nucleic acid composition of claim 11, or a delivery vehicle of claim 34, wherein the stretch of contiguous nucleotides of the sensor domain of the modular RNA is complementary to a stretch of contiguous nucleotides of a selected cfos cellular RNA of a cortical cell, and the first protein coding domain encodes a first effector protein comprising a transcriptional activator and a second effector protein comprising a gene encoding osmFlag; the second nucleic acid comprises a coding region for a first reporter protein under the control of an inducible promoter; the first nucleic acid comprising the modular RNA molecule is under the control of a promoter; the modular RNA molecule comprises a gene encoding a second reporter protein upstream of the sensor domain and under the control of the promoter; The agent further comprises a gene encoding a DREADD receptor or a gene encoding PSAM, said administering permits translation of said effector protein in selected cells of said mammal in the presence of an agent that activates said DREADD or said PSAM receptor, whereby said protein is produced in said cells, and said production of said protein in said cells is effective to suppress neural activity promoting focal epileptic seizures in said mammal. A method comprising:

55. 1. A method for treating chronic pain in a mammal, comprising: administering to the mammal a therapeutically effective amount of an agent, said agent comprising a modular RNA molecule according to claim 1 or 2, or a nucleic acid composition according to claim 12, or a delivery vehicle according to claim 34; the sensor domain of the modular RNA comprises a stretch of contiguous nucleotides complementary to a stretch of contiguous nucleotides of a selected TRPV1 or NaV1.8 cellular RNA, and the first protein coding domain encodes an effector protein comprising a transcriptional activator; the modular RNA further comprises a domain encoding an shRNA that binds to NaV1.7 or NaV1.8 RNA, the domain encoding the shRNA being under the control of an inducible promoter; producing said transcriptional activator and said shRNA in said cells of said mammal, thereby treating chronic pain in said mammal. A method comprising:

56. 1. A method of treating Alzheimer's disease in a mammal, comprising: administering to the mammal a therapeutically effective amount of an agent, said agent comprising a modular RNA molecule of claim 1, or a nucleic acid composition of claim 12, or a delivery vehicle of claim 34; wherein the sensor domain of the modular RNA comprises said stretch of contiguous nucleotides complementary to a stretch of contiguous nucleotides of a selected cellular RNA encoded by a gene selected from the following genes: a) human astrocyte marker gene for aldehyde dehydrogenase family 1 member L1 (Aldh1L1), b) glial fibrillary acidic protein (GFAP) gene, c) excitatory amino acid transporter 1 (EAAT1) gene, and d) microglial genes: C-X3-C motif chemokine receptor 1 (CX3CR1), e) transmembrane protein 119 (TMEM119), and f) ionized calcium binding adaptor molecule 1 (IBA-1); the first protein coding domain of the modular RNA encodes a transcriptional activator; the modular RNA further comprises a second coding domain encoding an inhibitor of ApoE4, the second coding domain being under the control of an inducible promoter; production of said transcriptional activator and said repressor in said cell, thereby treating and / or preventing the progression of Alzheimer's disease in said mammal. A method comprising:

57. 47. The method of claim 44 or 46, comprising administering the composition to the S1 barrel cortex and hippocampus of the mammal.

58. 45. The method of claim 44, wherein the first reporter protein comprises an antigen protein tag.

59. 55. The method of claim 54, wherein the antigen protein tag comprises smV5.

60. 50. The composition of claims 20, 23, 38, 39, 44 to 49, wherein the transcriptional activator comprises the tetracycline-dependent transcriptional activator tTA2.

61. 50. The composition of claims 22, 25, 38, 39, 44-49, wherein the second protein coding region is under the transcriptional control of a TRE-3G eukaryotic inducible promoter.

Citation Information

Cited By

  • Compositions and methods related to nucleic acid sensors

    JP2025538114A

  • Compositions and methods related to nucleic acid sensors

    JP7847274B2